Table of Contents........................................................................................................................................3
Preface .....................................................................................................................................................5
Office of Cancer Genomics (OCG) Cancer Genome Characterization Initiative (CGCI) General
Templates...................................................................................................................................................6
  OCG Template #102: Office of Cancer Genomics Suggested Language for Prospective
  Tissue Collections in Genomic-Scale Projects.......................................................................................8
  OCG Template #103: Office of Cancer Genomics Suggested Language for Retrospective
  Tissue Collections in Genomic-Scale Projects.....................................................................................13
  OCG Template #104: Institutional Material Transfer and Data Use Agreement...................................18
  OCG Template #105: Institutional Certification for Participation in Office of Cancer
  Genomics Projects..................................................................................................................................26
Burkitt Lymphoma Genome Sequencing Project (BLGSP) General Protocols........................................28
  BLGSP SOP #300: The Burkitt Lymphoma Genome Sequencing Project
  Contact Sheet .........................................................................................................................................29
  BLGSP SOP #301: Document Requirements for Sample Submission to the
  Burkitt Lymphoma Genome Sequencing Project................................................................................31
  BLGSP SOP #302: How to Complete a Study Protocol Request to an Institutional
  Review Board (IRB) for the Burkitt Lymphoma Genome Sequencing Project..................................33
  BLGSP SOP #314: Requirements for Case Inclusion in the Burkitt
  Lymphoma Genome Sequencing Project...............................................................................................35
  BLGSP SOP #303: Prospective Sample Submission Procedure for the Burkitt
  Lymphoma Genome Sequencing Project...............................................................................................36
  BLGSP SOP #304: Sample Identifier Standards for the Burkitt Lymphoma
  Genome Sequencing Project..................................................................................................................60
  BLGSP SOP #305: Processing Tissue for Molecular Characterization of
  Burkitt Lymphoma Tumors.....................................................................................................................62
  BLGSP SOP #315: Processing FFPE Samples for the Burkitt Lymphoma Genome
  Sequencing Project: Collecting FFPE tissue scrolls.............................................................................66
  BLGSP SOP #316: Use of Single FFPE block for the Dual Purposes of
  Central Pathology and Molecular Characterization.............................................................................69
  BLGSP SOP #306: Processing Non-Tumor Samples for the Burkitt Lymphoma
  Genome Sequencing Project: Blood and Buccal Cells.......................................................................71
  BLGSP SOP #307: Sample Shipping Guidelines for the Burkitt Lymphoma
  Genome Sequencing Project................................................................................................................81
  BLGSP SOP #308: Shipping Cryoports Containing Frozen Biosamples for Processing
  and Extraction of Nucleic Acids............................................................................................................82
Dear Colleague,

You are about to review the latest version of the National Cancer Institute Office of Cancer Genomics book of Standard Operating Protocols (SOPs) that should be followed when you contribute samples and data to our large-scale genomic characterization project(s).

The sample and data acquisition process is explained in comprehensive detail to ensure that all materials contributed will be of sufficient quality to be utilized in the projects. However, the actual process is simple and requires only six basic steps:

1. Creation of an IRB approved protocol and informed consent forms.
2. Institutional Certification of patient consent.
3. Acquisition and freezing of tumor samples.
4. Acquisition and freezing of patient-matched normal samples (e.g. blood).
5. Acquisition of unstained formalin-fixed paraffin-embedded sections for pathology review.
6. Shipment of tissues and data.

The book is divided into general protocols and templates that apply to all projects, as well as tissue/disease-specific ones. Although many protocols are included in this book, only a handful of them may apply to yourself, depending on your role in the acquisition process:

- Clinical Practitioners
  - IRB approved protocol and informed consent templates (OCG Templates #101-103).
  - General guidelines on the process and clinical data requirements (HTMCP SOP #201, BLGSP SOP #301).

- Institutional Officials
  - Material Transfer Agreement (MTA; OCG Template #104).
  - Institutional Certification letter (OCG Template #105).

- Laboratory or research personnel
  - General guidelines on the process and clinical data requirements (HTMCP SOP #201, BLGSP SOP #301).
  - Processing tissue for molecular characterization (HTMCP SOP #205, BLGSP SOP #305).
  - Processing normal tissue samples (HTMCP SOP #206, BLGSP SOP #306).
  - Shipping guidelines and procedures (HTMCP SOP #207 & 208, BLGSP SOP #307 & 308).

Should you require any clarification on the protocols and/or process, please do not hesitate to contact the appropriate OCG personnel listed in your SOPs.
Office of Cancer Genomics (OCG)
Cancer Genome Characterization Initiative (CGCI)
General Templates
Purpose of the Project

We would like to invite you to participate in a research project called [Project Name]. The purpose of the [Project Name] project is to discover genetic changes associated with cancer, thus potentially leading to better prevention, detection and treatment of cancer, and perhaps other diseases as well. This project is being sponsored by the National Cancer Institute (NCI), part of the government agency known as the National Institutes of Health (NIH).

Bodily tissues are made up of cells containing DNA, which is part of the unique genetic material carrying the instructions for your body’s development and function. Cancer can result from changes in this genetic material, thereby causing cells to divide in an uncontrolled way and possibly to travel to other organs. Some of the genetic changes leading to cancer are currently known, however many remain to be discovered.

The [Project Name] project is designed to identify genetic changes that can cause cancer in humans. As such, we would like to study the genetic material obtained from your tumor tissue as part of the [Project Name]. We will compare the genetic material from your cancerous tissue with the genetic material from your normal tissue to find any differences that may exist. By combining information about genetic differences between normal and disease tissues along with information contained in your medical records, it may be possible to identify the genetic changes that are associated with your particular type of cancer. This same process will be performed with normal and cancerous tissues obtained from a number of other people who have agreed to participate in this research project. In this way, we expect to identify most of the genetic changes associated with many different kinds of cancer. By comparing treatment responses of patients with various cancers (through recorded medical information), this project could also lead to more knowledge about why certain cancers respond differently to treatments. With such knowledge, future treatment options could potentially become customized to a patient’s unique genetic make-up.

Description of the Research

Collection of Samples and Medical Information

- Your scheduled surgery is part of the medical treatment that you agreed upon with your doctor. During surgery, cancerous tissue will be removed.Usually, when cancerous tissue is removed, very small amounts of nearby normal tissue are removed as well. Your surgery is not part of the...
[Project Name] research project. We will receive some of these cancerous and normal tissues following your surgery.

- We will collect a sample of blood (approximately 4 tablespoons), drawn from a vein in your arm, as a second type of normal tissue.
- Should you object to having blood drawn, we will instead swab cells from inside of your mouth through gentle sweeping of the inner cheeks to obtain a secondary source of normal tissue.
- We will also collect information from your medical records, including your age, ethnic background, diagnosis, disease history, medical treatments, and response to treatments.

Coding of Tissue Samples and Medical Information

- Your tissues, blood or buccal (cheek swab) sample, and medical information will be labeled with a confidential project-assigned ID.
- Only Dr. [Physician Name] at [Institution Name] will have the information that matches the code to traditionally-used identifying information, such as your name, address, phone number, or social security number. Dr. [Physician Name] will keep the information that matches the confidential code to this identifying information in a safeguarded database. Only authorized personnel, who have specifically agreed to protect your identity, will have access to this database. All materials conveyed to the [Project Name] will be labeled with a project-assigned ID, removing traditionally-used identifying information, such as your name, address, phone number, or social security number. All other researchers and personnel, including those who will be working with your samples and medical information, will not have access to any of the traditionally-used identifying information about you.

Storage and Release of Samples and Medical Information

- Your coded tissue samples will be sent to an NCI-sponsored storage facility. The facility will process the samples and then send portions of your samples to different types of laboratories for analysis as part of this project. One type of laboratory will analyze your DNA by a method called sequencing. Other laboratories will study your samples by different methods. The remaining tissue from your samples might be stored for an unlimited period of time for use in future research related to cancer, or perhaps in other research projects.
- Information obtained from analyses performed on your coded samples and medical information will be entered into Internet-accessible databases along with information acquired from the other research participants in this project.
  - Anonymous information from the analyses, which cannot be traced to any individual patient, will be available to anyone in a completely public Internet database.
  - Information obtained from more detailed analyses, along with your confidential coded medical information, will be put into a controlled-access database. The information in this database will be available only to researchers who have received approval from an NIH Data Access Committee. In gaining access to such information, researchers have to agree to use the data only for research projects and not to ever try to use it in order to identify the donor of the material. However, despite all of the safety measures that we will use, we cannot guarantee that your identity will never become known.

Please note that traditionally-used identifying information about you, such as your name, address,
telephone number, or social security number, will NOT be put into either the public or controlled-access databases for this project.

Recontact

- In the future, we may want to obtain additional samples or follow-up information about your health or medical care. Should this be needed, a person from [Institution Name] will contact you with an explanation of the reasons for any follow-up and to ask whether you would be interested in participating in this additional research.

Financial Compensation/Costs

You will not be paid to participate in this project. Your tissue samples and your medical information will be used for research purposes only and will not be sold. It is possible that some of the research conducted using your tissue samples or medical information will eventually lead to the development of new diagnostic tests, drugs or other commercial products. Should this occur, you will not receive any part of the profits generated from such products.

You will not incur any expenses from participating in this project. The chance that you will be physically injured as a result of participating in this project is highly unlikely. However, if you are physically injured as a result of participating in this project, emergency medical treatment for your research-related injury will be provided to you at no cost.

Potential Benefits of Participating in the Project

You should not expect to personally benefit from this research, aside from the knowledge that your participation will help researchers and health professionals around the world to better understand the causes of cancer and other diseases. Research projects such as this lead to better ways to prevent, detect, treat, and cure such illnesses.

Potential Risks of Participating in the Project

Physical Risks

- There are very few physical risks associated with this project. Possible side effects from drawing the blood sample include mild pain, bleeding, bruising, and infection at the site of the needle insertion. Fainting or light-headedness can sometimes occur, but usually lasts only a few minutes. Every precaution will be taken to minimize these effects.

Psychological or Social Risks Associated with Loss of Privacy

- Your privacy is very important to us, and we use many safety measures to protect your privacy. However, despite all of the safety measures that we will use, we cannot guarantee that your identity will never become known. Although your genetic information is unique to you, you do share some genetic information with your children, parents, brothers, sisters, and other relatives. Consequently, it may be possible that genetic information from them could be used to help identify you. Similarly, it may be possible that genetic information from you could be used to help identify them.
• While neither the public nor the controlled-access databases developed for this project will contain information that is traditionally used to identify you (your name, address, telephone number, or social security number), technology may be developed in the future that would allow someone to link your genetic or medical information in our databases back to you. For example, someone could compare information in our databases with information from you (or a relative) in another database and be able to identify you (or your relative). It is also possible that there could be violations to the security of the computer systems used to store the codes linking your genetic and medical information back to you. Because some genetic variations can help to predict the current or future health problems of you and your relatives, this information may be of interest to employers, health providers, insurance companies, and others. Patterns of genetic variation also can be used by law enforcement agencies to identify a person or his/her relatives. Therefore, your genetic information could potentially be used in ways that could cause you or your family distress, such as by revealing that you (or a relative) carry a genetic disease or by leading to the denial of employment or insurance for you (or a relative).

• There also may be other privacy risks that we have not foreseen.

While we believe that the risks to you and your family are very low, we are unable to tell you exactly what all of the risks are. There are some state laws that protect against genetic discrimination by employers or insurance companies, but there is currently no federal law that prohibits such discrimination. We believe that the benefits of learning more about cancer and other diseases outweigh these potential risks.

Confidentiality

We will make every attempt to protect your confidentiality and to ensure that your personal identity remains anonymous. This signed consent form will be stored in a locked file that will be accessible only to authorized people involved with this project. We will carefully follow the coding, storage, and release plan explained in the Description of the Research section on pages 1 and 2 of this document.

Project Results

Your individual results from this research project will not be given back to you or put into your medical records. If research from this project is published in professional journals, there will be no traditionally-used identifying information, such as your name, address, telephone number, or social security number, included in the publications. Some publications from this project will be found at the [Project Name] website.

Alternatives to Participating in the Project

The alternative option is not to participate in this project.

Voluntary Participation

The choice to participate in this research by donating your tissues and medical information is
completely up to you. **No matter what you decide, your decision will not affect your medical care.**

**Withdrawal from the Project**

Once your coded samples have been distributed to the participating research laboratories and centers, and your information transferred to the appropriate databases, you will **not** be able to withdraw your information from this research project. However, you may be able to request the return or destruction of the tissue samples if you so desire.

**Contact Information**

If you have any questions about the project or your participation, [please use specific institutional language here, but do not automatically promise ability to withdraw].

**Agreeing to Participate in the Project**

To participate in this research, you must agree to **ALL** of the following statements:

- I voluntarily agree to donate cancerous tissue and normal tissue to be used for this and for other research projects.
- I agree to release information from my medical records for this and for other research projects.
- I agree to have my coded genetic information and coded medical information placed into Internet-accessible databases as described in the *Storage and Release of Samples and Medical Information* section on page 2 of this document.
- I understand that my coded genetic information and coded medical information contained in the Internet-accessible databases will be used in this and in other research projects.
- I understand that there is a risk that someone in the future may be able to use information in these databases to identify me or possibly my relative(s).
- I agree to be contacted in the future about my willingness to provide additional samples or follow-up information about my health or medical care if it is required.

Please sign your name here if you agree to the six statements listed above.

Your signature: ________________________________

Date: ________________________________

Signature of Doctor/Nurse/Other Witness______________________________

Date: ________________________________
Purpose of the Project

We would like to invite you to participate in a research project called [Project Name]. The purpose of the [Project Name] project is to discover genetic changes associated with cancer. This should lead to better ways to prevent, detect, and treat cancer and, perhaps, other diseases as well.

This project is being sponsored by the National Cancer Institute (NCI), part of the government agency known as the National Institutes of Health (NIH).

Body tissues are made up of cells. Cells contain DNA, which is part of your unique genetic material that carries the instructions for your body’s development and function. Cancer can result from changes in a person’s genetic material that cause cells to divide in an uncontrolled way and, sometimes, to travel to other organs. Currently, researchers and doctors know some of the genetic changes that can cause cancer, but they do not know all of the genetic changes that can cause cancer.

The [Project Name] project is designed to identify most of the genetic changes that can cause cancer in people. Therefore, we would like to study the genetic material from your cancer tissue as part of the [Project Name]. We will compare the genetic material from your cancer tissue to the genetic material from your normal tissue to find the differences that exist. By combining this information with information from your medical records, it may be possible to identify the genetic changes that are associated with your particular type of cancer. We will perform this same process with many (hundreds of) other people who have agreed to participate in this research project. By studying many different kinds of cancer in this way, we expect to identify most of the genetic changes associated with different kinds of cancer. Since we also will combine genetic information with information from medical records, such as the responses of different kinds cancers to different treatments, this project could lead to more knowledge about why certain cancers respond differently to treatments. With such knowledge, future treatments potentially could become customized to a patient’s unique genetic make-up.

Description of the Research

Collection of Samples and Medical Information

- You already have had surgery as a part of the medical treatment that you agreed upon with your doctor. During your surgery, cancerous/tumor tissue was removed. As usually happens, when your cancerous tissue was removed, very small amounts of nearby normal tissue were
removed along with it. Your surgery was not part of the [Project Name] project. For this research project, we seek permission to receive some of these cancerous and normal tissues.

- If a second type of normal tissue (e.g., blood) was collected from you before or after your surgery, we request permission to obtain some of this tissue and genetic material that already may have already been extracted from this tissue.
- If an adequate blood sample is not available for this project, we will collect a sample from you by drawing approximately 4 tablespoons of blood from a vein in your arm. If you object to having blood drawn, we will collect normal tissue from you by swabbing cells from the inside of your cheeks.
- We will also collect information from your medical records, including your age, ethnic background, diagnosis, disease history, medical treatments, and response to treatments.

Coding of Tissue Samples and Medical Information

- Your tissues, blood or buccal (cheek swab) sample, and medical information will be labeled with a project-assigned ID.
- Only Dr. [Physician Name] at [Institution Name] will have the information that matches the code to traditionally-used identifying information, such as your name, address, phone number, or social security number. Dr. [Physician Name] will keep the information that matches the code to this traditionally-used identifying information in a safeguarded database. Only authorized people, who have specifically agreed to protect your identity, will have access to this database. All materials conveyed to the [Project Name] will be labeled with a project-assigned ID, removing traditionally-used identifying information, such as your name, address, phone number, or social security number. All other researchers and personnel, including those who will be working with your samples and medical information, will not have access to any of the traditionally-used identifying information about you.

Storage and Release of Samples and Medical Information

- Your coded tissue samples will be sent to an NCI-sponsored storage facility that will process the samples and then send portions of your samples to different types of laboratories as part of this project. One type of laboratory will analyze your DNA by a method called sequencing. Other laboratories will study your samples by different methods. The remaining portions of your samples will be stored for an unlimited period of time for future use in research related to cancer, or perhaps in other research projects.
- Information obtained from analyses performed on your coded samples and your coded medical information will be put into databases along with information from the other research participants. These databases will be accessible by the Internet.
  - Anonymous information from the analyses will be put into a completely public database, available to anyone on the Internet.
  - Your coded medical information and information from more detailed analyses of your coded samples will be put into a controlled-access database. The information in this database will be available only to researchers who have received approval from an NIH Data Access Committee. In gaining access to such information, researchers have to agree to use the data only for research projects and not to ever try to use it in order to
identify the donor of the material. However, despite all of the safety measures that we will use, we cannot guarantee that your identity will never become known.

Please note that traditionally-used identifying information about you, such as your name, address, telephone number, or social security number, will NOT be put into either the public or controlled-access databases for this project.

Recontact

- In the future, we may want to obtain additional samples or follow-up information about your health or medical care. Should this be needed, a person from [Institution Name] will contact you to ask whether you would be interested in participating in this additional research.

Financial Compensation/Costs

You will not be paid to participate in this project. Your tissue samples and your medical information will be used only for research purposes and will not be sold. It is possible that some of the research conducted using your samples or information will eventually lead to the development of new diagnostic tests, new drugs or other commercial products. Should this occur, you will not receive any part of the profits generated from such products.

You will not incur any expenses from participating in this project. It is unlikely that you will be physically injured as a result of participating in this project. However, if you are physically injured as a result of participating in this project, emergency medical treatment for your research-related injury will be provided to you at no cost.

Potential Benefits of Participating in the Project

You should not expect to personally benefit from this research. The main reason you may want to participate is to help researchers and health professionals around the world to better understand the causes of cancer, and other diseases, and potentially to find better ways to prevent, detect, treat, and cure such illnesses. We hope that you will feel good knowing that you may be helping future cancer patients, as well as patients with other diseases.

Potential Risks of Participating in the Project

Physical Risks

- If no blood sample is taken from you, there are no physical risks associated with this project.
- There are very few physical risks if a blood sample is taken from you. Possible side effects from drawing the blood sample include mild pain, bleeding, bruising, and infection at the site of needle insertion. Fainting or light-headedness can sometimes occur, but usually last only a few minutes.

Psychological or Social Risks Associated with Loss of Privacy

- Your privacy is very important to us, and we use many safety measures to protect your privacy. However, despite all of the safety measures that we will use, we cannot guarantee that your identity will never become known. Although your genetic information is unique to you, you do
share some genetic information with your children, parents, brothers, sisters, and other relatives. Consequently, it may be possible that genetic information from them could be used to help identify you. Similarly, it may be possible that genetic information from you could be used to help identify them.

- While neither the public nor the controlled-access databases developed for this project will contain information that is traditionally used to identify you (your name, address, telephone number, or social security number), technology may be developed in the future that would allow someone to link your genetic or medical information in our databases back to you. For example, someone could compare information in our databases with information from you (or a relative) in another database and be able to identify you (or your relative). It is also possible that there could be violations to the security of the computer systems used to store the codes linking your genetic and medical information back to you. Because some genetic variations can help to predict the current or future health problems of you and your relatives, this information may be of interest to employers, health providers, insurance companies, and others. Patterns of genetic variation also can be used by law enforcement agencies to identify a person or his/her relatives. Therefore, your genetic information could potentially be used in ways that could cause you or your family distress, such as by revealing that you (or a relative) carry a genetic disease or by leading to the denial of employment or insurance for you (or a relative).

- There also may be other privacy risks that we have not foreseen.

While we believe that the risks to you and your family are very low, we are unable to tell you exactly what all of the risks are. There are some state laws that protect against genetic discrimination by employers or insurance companies, but there is currently no federal law that prohibits such discrimination. We believe that the benefits of learning more about cancer and other diseases outweigh these potential risks.

Confidentiality

We will make every attempt to protect your confidentiality and to make sure that your personal identity remains anonymous. This signed consent form will be stored in a locked file that will be accessible only to a very small number of authorized personnel involved in this project. We will carefully follow the coding, storage, and release plan explained in the Description of the Research section on pages 1-3 of this document.

Project Results

Your individual results from this research project will not be given back to you or put into your medical records. If research from this project is published in professional journals, there will be no traditionally-used identifying information, such as your name, address, telephone number, or social security number, included in the publications. Some publications from this project will be found at the [Project Name] website.

Alternatives to Participating in the Project

The alternative option is not to participate in this project.
Voluntary Participation

The choice to participate in this research by donating your tissues and medical information is completely up to you. **No matter what you decide to do, your decision will not affect your medical care.**

Withdrawal from the Project

Once your coded samples have been distributed to the participating research laboratories and centers, and your information transferred to the appropriate databases, you will **not** be able to withdraw your information from this research project. However, you may be able to request the return or destruction of the tissue samples if you so desire.

Contact Information

If you have any questions about the project or your participation, *please use specific institutional language here, but do not automatically promise ability to withdraw*.

Agreeing to Participate in the Project

To participate in this research, you must agree to **ALL** of the following statements:

- I voluntarily agree to donate cancerous tissue and normal tissue to be used for this and for other research projects.
- I agree to release information from my medical records for this and for other research projects.
- I agree to have my coded genetic information and coded medical information placed into databases accessible by the Internet, as described in the *Storage and Release of Samples and Medical Information* section on page 2 of this document.
- I understand that my coded genetic information and coded medical information in the Internet-accessible databases will be used in this and in other research projects.
- I understand that there is a risk that someone in the future might be able to use information in these databases to identify me or possibly my relative(s).
- I agree to be contacted in the future to see if I am willing to provide additional samples or follow-up information about my health or medical care if they are needed.

Please sign your name here if you agree to the six statements listed above.

Your signature: ____________________________
Date: ________________________________

Signature of Doctor/Nurse/Other Witness: ____________________________
Date: ________________________________
This Material Transfer and Data Use Agreement (the “Agreement”) is entered into by and between _____________________________ (“Provider”) and _____________________________ (“Recipient”), regarding the transfer of human specimens and associated data to the Recipient as part of tumor characterization projects and associated research coordinated by the National Cancer Institute’s Office of Cancer Genomics (“the Projects”), including [Project Name]. Throughout this Agreement, Provider and Recipient are collectively referred to as the “Parties” and individually as “Party.” This Agreement will become effective upon the date of the last signature affixed below (the “Effective Date”).

WHEREAS, in order to improve the ability to diagnose, treat, and prevent cancer, the National Cancer Institute (“NCI”), a member institute of the National Institutes of Health, an agency of the federal government, has undertaken the Projects as a comprehensive and coordinated research effort to accelerate the understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing;

WHEREAS, the Projects are managed by the NCI Office of Cancer Genomics;

WHEREAS, under the Projects, clinically annotated tissue samples will originate from several clinical Tissue Source Sites, and the tissue samples and associated data will be processed by centralized core facility(ies);

WHEREAS, Recipient has been selected to act as a centralized core facility, pursuant to a subcontract with NCI’s Operations and Technical Support (“OTS”) contractor, Leidos Biomedical Research, Inc. or directly with the NCI (either, the “OTS Contractor”), and the tasks with which it is charged include receiving and processing human biospecimens, derivative materials and associated data and distributing all of the foregoing to NCI approved characterization centers (“the Centers”) and distributing only the associated data to a data coordinating center that is operated by NCI (“DCC”);

WHEREAS, Recipient, as a subcontractor of NCI’s OTS Contractor, desires to receive and, in conjunction with subcontractors of Recipient and the NCI and/or Leidos Biomedical Research, Inc. (collectively, “the Project Subcontractors”), process biospecimens, derivative materials and associated data from the Provider and distribute the same to the Centers and a DCC, as appropriate;

WHEREAS, Provider, acting as a Tissue Source Site under the Projects, desires to transfer certain human biospecimens, derivative materials, and associated data to Recipient for further distribution to the Centers and a DCC, as appropriate;
WHEREAS, the Centers and the DCC, pursuant to policies and practices established as part of the Projects, may not make a claim for intellectual property rights in the MATERIAL (as defined below), nor may they make a claim for intellectual property rights in DATA (as defined below) prior to its public availability;

WHEREAS, Provider and Recipient desire to protect the privacy and provide for the security of certain information disclosed to Recipient in compliance with applicable laws and regulations; and

WHEREAS, Provider, if an entity of the United States of America (“U.S.”), may be a covered entity subject to the Health Insurance Portability and Accountability Act of 1996, as amended (“HIPAA”), and, if not a U.S. entity, desires to protect the privacy of certain information disclosed to the Recipient in a manner consistent with HIPAA and the applicable laws of its jurisdiction that are similar in nature.

NOW, THEREFORE, in consideration of the mutual promises in this Agreement and for other good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

1. DEFINITIONS. Within this Agreement, the following terms will have the same meaning and effect as those used in the Standards for Privacy of Individually Identifiable Health Information set forth in 45 CFR Parts 160 and 164 (“HIPAA Privacy Rule”). These terms are repeated here for convenience.

   (a) Under 45 CFR 160.103 (“Definitions”), a “covered entity” is an organization, individual, institution, or other entity that is subject to the standards, requirements, and implementation specifications of the HIPAA Privacy Rule with respect to protected health information.

   (b) Under 45 CFR 164.514 (“Other requirements relating to uses and disclosures of protected health information”), “De-identified” information is information that formerly contained individually identifiable health information but which has had all unique identifying information, numbers, characteristics, and codes removed such that the information a record contains cannot be used alone or in combination with other information to identify the individual who is the subject of the information. Identifying information includes, but is not limited to, the 18 categories of identifiers described in 45 CFR 164.514(b)(2).

   (c) Under 45 CFR 164.103 (“Definitions”), “Protected Health Information” or “PHI” means any information, whether oral or recorded in any form or medium: (i) that relates to the past, present, or future physical or mental condition of an individual; the provision of health care to an individual; or the past, present, or future payment for the provision of health care to an individual, and (ii) that identifies the individual or with respect to which there is a reasonable basis to believe the information can be used to identify the individual.

   (d) Under 45 CFR 164.514(e)(2) (“Implementation Specification: Limited data set”), a “limited data set” (herein “LDS”) is protected health information that excludes the 16 direct identifiers listed in that
section. Any such information that identifies the individual who is the subject of the PHI, his or her relatives, employers, or household members must be removed for the PHI to constitute an LDS.

2. DESCRIPTION OF MATERIAL AND DATA.

(a) The material to be transferred (“ORIGINAL MATERIAL”) is a set of human biospecimens described specifically as: Human Tumors, Matching Normal Specimens or Blood, and Formalin Fixed Paraffin Embedded Tissues.

(b) The data to be transferred to Recipient are clinical, biological, technical and/or other information describing the ORIGINAL MATERIAL (“DATA”). Some of the DATA may be Protected Health Information and will be transferred in the form of an LDS.

3. COLLECTION OF MATERIAL AND DATA. The Provider represents and warrants to Recipient that:
(a) as necessary, all ORIGINAL MATERIAL and DATA provided to Recipient by Provider were collected pursuant to and in accordance with a protocol approved by an Institutional Review Board (“IRB”); (b) the IRB’s oversight of the collection of any ORIGINAL MATERIAL and DATA included a review of all necessary informed consents and authorizations, which consents do not prohibit redistribution of the ORIGINAL MATERIAL or materials derived from the ORIGINAL MATERIAL, e.g., DNA and RNA products (“DERIVATIVE MATERIAL,” together with the ORIGINAL MATERIAL, the “MATERIAL”) or DATA in the manner described in Section 4 of this Agreement; (c) the transfer, processing and analysis of the ORIGINAL MATERIAL and DATA, as part of the Projects and for the Purpose (as defined below), is authorized by or consistent with the general principles of the informed consent of the patient supplying such ORIGINAL MATERIAL and DATA, as determined by an IRB; and (d) the collection of the ORIGINAL MATERIAL and DATA was conducted in compliance with all applicable laws, regulations and policies for the protection of human subjects, including, in the case where Provider is a covered entity, 45 CFR Part 46, “Protection of Human Subjects” (the “Common Rule”) and the HIPAA Privacy Rule, and any necessary approvals, authorizations, human subjects assurances, informed consent documents, and IRB approvals were obtained.

4. TRANSFER OF ORIGINAL MATERIAL AND DATA; PURPOSE. (a) Provider agrees to provide to Recipient the ORIGINAL MATERIAL and DATA, in the form of an LDS pursuant to Case Report Forms provided by the Recipient to the Provider, in accordance with applicable laws, regulations and policies, including but not limited to the Common Rule, the HIPAA Privacy Rule, and any necessary authorizations, human subjects assurances, informed consent documents, and IRB approvals. The sole and limited purpose of the Provider’s transfer to Recipient of the ORIGINAL MATERIAL and the DATA is to enable Recipient to receive, process and distribute the MATERIAL and the DATA, in the appropriate form as indicated below, to the Centers, a DCC, and the Project subcontractors in fulfillm ent of its contractual obligations to NCI’s OTS Contractor (the “Purpose”). If Provider is a HIPAA Covered Entity, the Parties expressly intend for this Agreement to constitute a Data Use Agreement, authorizing use and disclosure only in furtherance of the Purpose, in accordance with 45 CFR 164.514(e)(4). Provider is responsible for removing all of the prohibited direct identifiers from the DATA, such that the DATA will be in the form of an LDS, before transfer to Recipient.
(b) Provider has the authority and hereby grants Recipient explicit permission to further distribute the MATERIAL and De-identified DATA to the Centers and the Project Subcontractors.

(c) Provider has the authority and hereby also grants Recipient explicit permission to further distribute the DATA, in the form of an LDS, to a DCC upon execution by both Recipient and NCI of a Data Use Agreement that is consistent with the requirements of the HIPAA Privacy Rule. Furthermore, Provider acknowledges and agrees that Recipient may allow the DCC to provide all or part of the LDS to third parties pursuant to separate Data Use Agreements that are no less restrictive than this Agreement and that prohibit such third parties from further distributing the LDS.

(d) The Agreement does not restrict the Provider’s right to distribute the MATERIAL and DATA to third parties.

5. RESPONSIBILITIES AND AUTHORIZATIONS OF RECIPIENT

(a) Recipient’s IRB has approved the Recipient’s participation in the Projects (IRB approval number: IRB 12-00222). Recipient agrees to handle and distribute the MATERIAL in accordance with all applicable laws, regulations and policies, including, as applicable, the Common Rule, the HIPAA Privacy Rule, and any necessary human subject’s assurances, informed consents and IRB approvals.

(b) Recipient further agrees that it will only use and/or disclose the DATA for the Purpose described herein and shall not use or disclose the DATA in a manner inconsistent with the HIPAA Privacy Rule.

(c) Recipient is not authorized and shall not further disclose the DATA other than as permitted by this Agreement or as otherwise required by law. Recipient shall not distribute the DATA to other third parties without written consent from Provider and the NCI Program Director or designee for the particular Project in question.

(d) Recipient shall use appropriate administrative, technical, and physical safeguards to prevent use or disclosure of the DATA other than as provided for in this Agreement.

(e) Recipient shall notify Provider in writing within five (5) working days of its discovery of any use or disclosure of the DATA not permitted by this Agreement of which Recipient, its officers, employees, or agents become aware. Recipient shall take (i) prompt corrective action to cure any deficiencies or (ii) any action pertaining to such unauthorized disclosure required by applicable federal law.

(f) Recipient shall ensure that any of its agents or subcontractors agree with Recipient in writing that such agent or subcontractor will hold any DATA transmitted from the Recipient to such agent or subcontractor confidential and will use or disclose the information only for the purpose for which it was used or disclosed to the agent or subcontractor, or as required by law. Additionally, the agent or subcontractor shall notify Recipient of any instances, of which it is aware, in which the DATA has been used or disclosed inconsistent with this Agreement.
(g) Recipient agrees to not identify or contact any donor, or living relative of a donor, who provided the MATERIAL or any DATA received by Recipient under this Agreement from Provider. Furthermore, Recipient will not attempt to obtain or otherwise acquire any PHI associated with the MATERIAL beyond that which is provided in the DATA by the Provider.

(h) Recipient will retain and abide by this Agreement for as long as it retains the DATA or other PHI received from the Provider, plus six (6) years after the date it returns or destroys all such information.

6. BREACH OR VIOLATION. Provider is not responsible for Recipient’s violations of this Agreement, unless Provider knows of a pattern of activity or practice that constitutes a material breach or violation of this Agreement, in which case it must take reasonable steps to cure the breach, end the violation or withhold the LDS or other PHI delivered to Recipient. If this is not possible, the breach will be reported to the Secretary of the Department of Health and Human Services (“DHHS”).

7. THE MATERIAL AND DATA ARE NOT FOR USE IN HUMAN SUBJECTS OR FOR THE TREATMENT OR DIAGNOSIS OF HUMAN SUBJECTS.

8. DISCLAIMER. Any MATERIAL delivered pursuant to this Agreement is understood to be experimental in nature and may have hazardous properties. SUBJECT TO THE REPRESENTATIONS IN SECTION 3 ABOVE WITH RESPECT TO THE MATERIAL OR DATA, PROVIDER MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL OR DATA WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS.

9. DISPOSAL OF MATERIAL AND DATA. At the end of its subcontract with the NCI’s OTS Contractor or upon the termination of this Agreement by either Party, Recipient will dispose of the MATERIAL and DATA in its possession in the manner decided at the sole discretion of the NCI Office of Cancer Genomics or designee for the particular Project in question and consistent with law and the informed consent of the individual providing the ORIGINAL MATERIAL. Such disposition may include, but is not limited to, continued storage on behalf of Provider for future research, transfer to the Provider, use in an expansion of the Projects, transfer to another organization acting on NCI’s behalf, or destruction. NCI shall be responsible for ensuring that any directive given to the Recipient regarding the disposition of the MATERIAL and DATA is consistent with the informed consent of the patient who provided the ORIGINAL MATERIAL. Provider acknowledges that any ORIGINAL MATERIAL transferred by Recipient to the Centers may be destroyed as a consequence of the analyses conducted in accordance with the Projects.

10. INTELLECTUAL PROPERTY. Provider explicitly retains ownership of ORIGINAL MATERIAL and DATA. Provider acknowledges and agrees that it does not by virtue of this Agreement acquire any intellectual property rights in the future inventions or discoveries made by third parties using the MATERIAL or DATA distributed by Recipient. Recipient acknowledges that it serves only as the custodian of the MATERIAL and DATA, and therefore agrees that it does not by virtue of this
Agreement acquire any intellectual property rights in the MATERIAL or DATA, nor any future intellectual property rights in any research conducted by third-parties using the MATERIAL or DATA.

11. ASSIGNMENT; SUCCESSORS AND ASSIGNS; NO THIRD-PARTY RIGHTS. Recipient may not assign its rights or cause to be assumed its obligations hereunder without the prior written consent of Provider, which consent shall not be unreasonably withheld or delayed. Subject to the foregoing, this Agreement shall apply to, be binding in all respects upon and inure to the benefit of the Parties hereto and their respective successors and assigns. Nothing expressed or referred to in this Agreement shall be construed to give any person or entity other than the Parties hereto any legal or equitable right, remedy or claim under or with respect to this Agreement or any provision of this Agreement.

12. COST. The MATERIAL and DATA are provided at no cost to Recipient.

13. SHIPPING. Provider will notify Recipient when the ORIGINAL MATERIAL and DATA are ready for shipment. Recipient will be responsible for the pick-up and shipment, including shipping costs, of the ORIGINAL MATERIAL and DATA.

14. ENTIRE AGREEMENT. This Agreement constitutes the entire agreement between the Parties with respect to the subject matter hereof, and supersedes and replaces all prior agreements, understandings, commitments, communications and representations made between the Parties, whether written or oral, with respect to the subject matter hereof. This Agreement may not be amended, supplemented, or otherwise modified except by a written agreement executed by each of the Parties.

15. TERMINATION. Either Party has the right to terminate this Agreement at any time upon sixty (60) days prior written notice to the other Party.

16. INDEMNIFICATION. Each party shall indemnify, defend and hold the other party and its parent and affiliates and their officers, directors, employees, and agents, harmless from and against any claims, charges, judgments, costs, liabilities, damages, losses, or expenses (including reasonable attorneys’ fees and expenses of litigation) resulting from any third party claims, allegations, suits, actions, or demands (collectively “Claims”) that arise out of or result from the indemnifying party’s acts or omissions relating to this Agreement or the indemnifying party’s failure to perform any obligation undertaken or covenant made in this Agreement. The indemnified party shall promptly notify and provide reasonable cooperation to the indemnifying party in the defense of any Claim for which indemnification is sought at the indemnifying party’s expense. The indemnifying party shall have the right to settle Claims; provided, however, that the indemnifying party shall make no admission of fault or wrongdoing or other statement reflecting negatively on the indemnified party, without the indemnified party’s prior express written consent.

17. INSURANCE. Each party shall maintain liability coverage of the types and at the levels that are usual and customary to insure its obligations and activities under this Agreement.
18. NOTICE. All notices, requests, demands, and other documentation required or permitted to be given under this Agreement shall be provided in writing and will be deemed to have been fully given and received (i) when delivered in writing personally; (ii) when sent by confirmed electronic message or facsimile; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) day after deposit with a commercial overnight carrier, with written verification of such receipt, to the addresses provided below.

19. WAIVER. No waiver by either Party of any term or condition of this Agreement, no matter how long continuing or how often repeated, shall be deemed a waiver of any subsequent act or omission, nor shall any delay or omission on the part of either Party to exercise any right, power, or privilege or to insist upon compliance with any term or condition of this Agreement be deemed a waiver of such right, power or privilege or excuse a similar subsequent failure to perform any such term or condition. All waivers must be in writing and signed by the Party granting such waiver.

20. EXECUTION OF AGREEMENT. This Agreement may be executed in two or more counterparts, each of which will be deemed to be an original copy and all of which, when taken together, will be deemed to constitute one and the same agreement. The exchange of copies of the Agreement and of signature pages by facsimile or electronic transmission will constitute effective execution and delivery of this Agreement as to the Parties hereto and may be used in lieu of the original Agreement for all purposes. Signatures of the Parties transmitted by facsimile or electronic transmission will be deemed to be their original signatures for all purposes.

[The rest of this page was left blank intentionally. Signature page follows.]
IN WITNESS WHEREOF, the Parties have executed this Agreement through their duly authorized representatives as of the Effective Date.

Signature for Provider

Provider Scientist:  
Provider Organization:  
Address:  

Name of Authorized Official:  
Title of Authorized Official:  

__________________________________________  ______________________________
Signature of Authorized Official Date

Certification of Provider Authorized Official: This Agreement __has / __has not been modified from the original template.

Signature for Recipient

Recipient Scientist  
Recipient Organization:  
Address:

Name of Authorized Official:  
Title of Authorized Official:  

__________________________________________  ______________________________
Signature of Authorized Official Date
OCG Template #105: 
Institutional Certification for Participation in Office of Cancer Genomics Projects

Institutions are responsible for assuring, through an Institutional Certification, that plans for the submission of large-scale human genomic data to the NIH meet the expectations of the Genomic Data Sharing Policy. An Institutional Certification must accompany the submission of all large-scale human data to the NIH Database of Genotypes and Phenotypes (dbGaP).


Burkitt Lymphoma Genome Sequencing Project (BLGSP)
General Protocols
BLGSP SOP #300:
The Burkitt Lymphoma Genome Sequencing Project Contact Sheet

Project Team (PT) Manager

Nicholas B. Griner
Office of Cancer Genomics
National Cancer Institute
31 Center Drive, Suite 10A07
Bethesda, MD 20892
Phone: 339-502-8280
Fax: 301-480-4368
E-mail: nicholas.griner@mail.nih.gov

Data Coordinating Center

Patee Gesuwan
Center for Biomedical Informatics and Information Technology
National Cancer Institute
9609 Medical Center Drive 1W434
Bethesda, MD 20892-9719
Phone: 240-276-5311
E-mail: gesuwanp@mail.nih.gov

NCH Coordinator

Jay Bowen
Biospecimen Processing Core
The Research Institute at Nationwide Children's Hospital
700 Children's Drive WA 1100A
Columbus, OH 43205
Phone: 614-722-5302
Fax: 614-355-2906
E-mail: jay.bowen@nationwidechildrens.org
BLGSP Pathology Coordinator

Dr. Timothy C. Greiner, MD
Department of Pathology
MSB 3530
University of Nebraska Medical Center
LTC 11723
Phone: 402-559-8707
Fax: 402-559-6018
E-mail: tgreiner@unmc.edu

GSC-BC Coordinator

Andy Mungall, Room 508
Biospecimen Core
Genome Sciences Centre
BC Cancer Agency
Suite 100, 570 West 7th Avenue
Vancouver, BC V5Z 4S6
Canada
Email: amungall@bcgsc.ca
Tel: 604-707-5900 ext 673251
Introduction

The National Cancer Institute’s Office of Cancer Genomics (OCG) has developed an initiative to generate a database of comprehensive molecular changes in Burkitt lymphomas. The Burkitt Lymphoma Genome Sequencing Project (BLGSP) aims to generate large scale, high-quality data on the cancers’ genomes and transcriptomes using 2nd and 3rd generation sequencing technology. The data collected will allow scientists to identify genetic alterations in individuals with the various subtypes of Burkitt lymphoma.

It is imperative that all personnel involved in the project read all the protocols and adhere to them at all times. It is your responsibility as a contributor to the BLGSP to familiarize yourself with all aspects of the procedures and assure their compliance.

Scope and Purpose

1. To list all the documents needed in order to start collection of samples for the Burkitt Lymphoma Genome Sequencing Project (BLGSP).
2. This protocol applies to all Tissue Source Sites (TSSs) providing tissues prospectively.
3. Any deviation from this protocol should be noted in the lab notebook, indicating the nature of the deviation, times, and which samples were affected. This information should be given within 48 hours of the occurrence to the Project Team (PT) representative by sending an email (see BLGSP SOP #300) with the details.

Requirements

1. Every TSS must have an Institutional Review Board (IRB)-approved protocol in place that allows collection of tumor tissue, matched normal tissue (blood, whenever possible) and clinical data that can be used in a characterization project. The protocol must have explicit language permitting the molecular characterization of the samples by genomic-scale methodologies, and subsequent deposition of the data into a public, but protected database. BLGSP SOP #302 provides advice for writing a study protocol to submit to an IRB. A sample protocol with the suggested language is provided as OCG Template #101.
2. Every patient accrued to the project must be enrolled in the protocol and agree to participate by signing an informed consent. A sample informed consent document which contains the required language is provided as OCG Template #102.

3. If you require additional assistance drafting such a protocol or informed consent form, please contact the PT representative (see BLGSP SOP #300).

4. TSSs must have in place a materials transfer agreement (MTA) with The Research Institute at Nationwide Children’s Hospital (NCH; see BLGSP SOP #300) to allow transfer of tissues and clinical data. The TSS must also have in place an MTA with the Pathology Coordinator (see BLGSP SOP #300) to allow transfer of tissues. A sample MTA is provided as OCG Template #104. Contact the PT representative if you need assistance.

5. OCG will store a copy of the IRB-approved protocol and a blank informed consent form. Additionally, certification that such a protocol exists, and that patients have been consented, must be provided to the NCH and OCG by the TSS institution before the samples can be accepted and costs can be reimbursed. A template of such a certification document is provided as OCG Template #105.

6. The completed Institutional Certification must be sent to the PT and the NCH before any sample can be shipped.
BLGSP SOP #302:  
*How to Complete a Study Protocol Request to an Institutional Review Board (IRB) for the Burkitt Lymphoma Genome Sequencing Project*

**Introduction**

A goal of the Burkitt Lymphoma Genome Sequencing Project (BLGSP) is to develop a genomic databank of the molecular changes in Burkitt Lymphoma that will be available to the research community worldwide. The data collected will allow scientists to identify genetic alterations in individuals with the various subtypes of Burkitt Lymphoma. The project aims to generate large scale, high-quality data on the cancers’ genomes and transcriptomes using 2nd and 3rd generation sequencing technology. The changes identified will include genomic rearrangements such as translocations, deletions, and amplifications, expression alterations, and sequence mutations such as single nucleotide variants, insertions, and deletions.

In order for cases to be included in the project, the patients must provide consent of participation in an IRB-approved study protocol specifying that the samples can be used for genomic characterization and that the data will be deposited in a publicly available, yet patient privacy protected database. The Office of Cancer Genomics (OCG) of the National Cancer Institute has created a generic template that contains the appropriate language to help the Tissue Source Site (TSS) produce the study protocol to submit to their IRB. This template lacks details that are Institution-specific and should not be considered complete.

**Scope and Purpose**

1. To establish a set of guidelines for TSSs to create their own study protocol to submit to their IRB in order to contribute samples to the BLGSP.
2. This SOP is meant to be useful to TSSs contributing samples to the BLGSP, but if an Institution has their own process, as long the study protocol includes the specifics provided below, that is also acceptable.

**Instructions**
A. Obtain the IRB-approved study protocol template (OCG Template #101) from the OCG SOP Manual or request a copy from the Project Team representative (see BLGSP SOP #300).

B. Fill in your organization name, PI's name and other pertinent information in the form. The Project name is “Burkitt Lymphoma Genome Sequencing Project” and its acronym is BLGSP.

C. The project rationale can be found in the introductory section above.

D. The total number of samples that will be collected as part of the discovery set is 240. Additional samples will be collected for the validation set.

E. Details on amount of tissue requested are given in BLGSP SOP #303 in Appendix A (Sample Requirements).

F. Details on the blood collection for germline DNA extraction can be found in BLGSP SOP #306.

G. All the operational details of the project are specified in the OCG SOP Manual sent to the TSSs. It is expected that all participating personnel will read the SOPs, be familiar with the project procedures and requirements and follow them in all instances.

Questions regarding this protocol should be directed to the Project Team representative (see BLGSP SOP #300).
Institutional Requirements

Participating institutions (BLGSP Tissue Source Sites) will use standard operating procedures (SOPs) developed by the NCI Office of Cancer Genomics (OCG) to prospectively collect tissue from BL patients. Retrospective samples will be considered if those tissues meet the project requirements. BLGSP Tissue Source Sites must:

- Obtain IRB approval for the BLGSP study protocol and patient consent forms
- Follow BLGSP SOPs for tissue collection, storage, and pathology requirements
- Provide BLGSP-required clinical data

Tissue Source Site investigators will have the opportunity to participate in working group meetings as well as co-author the first manuscript generated from BLGSP data.

Tissue Requirements

The detailed tissue requirements for the BLGSP are included in the SOPs. Briefly, the BLGSP requires:

- Tumors from untreated patients diagnosed and confirmed by pathology as Burkitt Lymphoma (minimum tumor tissue biopsy size of 10 x 10 x 2 mm)
- In lieu of frozen tissue, FFPEs may be used if it meets the following requirements:
  - At least 10-20 mg of tissue
  - Fixative buffer pH should be noted
  - No age requirement, but age of FFPEs should be noted
- Case-matched normal tissue or DNA in sufficient quantities such as 10 mL blood, 3 buccal swabs, or ~100 mg of normal tissue
- Tumors with a minimum of 50% tumor nuclei and ~80% viable cells
- No prior neo-adjuvant therapy for the submitted tumor type
- No prior diagnosis of a malignant neoplasm
BLGSP SOP #303: Prospective Sample Submission Procedure for the Burkitt Lymphoma Genome Sequencing Project

Introduction

The National Cancer Institute’s Office of Cancer Genomics (OCG) has developed an initiative to generate a database of comprehensive molecular changes in Burkitt Lymphomas. The Burkitt Lymphoma Genome Sequencing Project (BLGSP) aims to generate large scale, high-quality data on the cancers’ genomes and transcriptomes using 2nd and 3rd generation sequencing technology. The data collected will allow scientists to identify genetic alterations in individuals with the various subtypes of Burkitt Lymphoma.

Scope and Purpose

1. To establish a general procedure to inform personnel of all the steps necessary for a successful submission of a sample to the BLGSP.
2. This protocol applies to all Tissue Source Sites (TSSs) providing tissues prospectively.
3. Any deviation from this protocol should be noted in the lab notebook, indicating the nature of the deviation, times, and which samples were affected. This information should be given within 48 hours of the occurrence to the Project Team (PT) manager by sending an email (see BLGSP SOP #300) with the details.

Procedures

A. Before patient accrual begins:

1. All regulatory documents must be in place, including an executed IRB before any tissue accrualment begins.
2. Make sure all the documents required for sample shipment as spelled out in BLGSP SOP #301 are in place before you start case accruals.
3. You may request project-assigned IDs in advance. Contact the Office of Cancer Genomics (OCG, see BLGSP SOP #300) with your TSS-assigned ID to obtain project-assigned IDs (see BLGSP SOP #304) which you must use in all documents regarding the case and all materials shipped. The TSS is responsible for maintaining the link between project-assigned ID and TSS-assigned ID in order to retrieve clinical information when required.
4. You may request freezer-resistant labels with the project-assigned IDs in advance. Contact the OCG PT manager (see BLGSP SOP #300) to obtain freezer-resistant labels that you will use to mark all containers/slides carrying materials for the project.

B. Before patient surgery:
   1. Create a TSS-assigned ID for your patient. Your institution will be the keeper of the key as described in your approved IRB protocol.
   2. If you have not done so already, contact the Office of Cancer Genomics (OCG) with your TSS-assigned ID to obtain a project-assigned ID to use in all documents regarding the case and all materials shipped. **The TSS is responsible for maintaining the link between project-assigned ID and TSS-assigned ID in order to retrieve clinical information when required.** It is the TSSs responsibility to be able to track the patient’s records back in the event that the original researcher(s) at the institution lose their affiliation.
   3. If you have not done so already, contact the OCG PT representative and obtain freezer-resistant labels that you will use to mark all containers/slides carrying materials for the project.
   4. Prepare the tissue freezing station and have ready all the materials needed for tissue processing (BLGSP SOP #305).
   5. If a blood sample will be used as a non-tumoral control, inform the research nurse that a 10 mL peripheral blood sample must be obtained from the patient (see Appendix A). The white blood cells and granulocytes (if there is a chance of blood contamination from the tumor) must be separated from the plasma within 2 hours of the blood draw from the patient (see BLGSP SOP #306). Store the blood sample in the refrigerator until processing.

C. During patient surgery:
   1. Inform the surgical staff of the tissue requirements for the project (see Appendix A).
   2. Have a person ready to transport the ablated tissue to the processing station. It is generally accepted that for the best tissue preservation snap freezing should take place within 20 minutes after tissue is obtained from the patient.
   3. Note the time between surgery and freezing in a notebook and send to the PT representative.

D. After patient surgery:
   1. Process solid tissue as described in the tissue processing protocol (BLGSP SOP #305). Timely processing is crucial, it is generally accepted that for the best tissue preservation snap freezing should take place within 20 minutes after tissue is obtained from the patient.
   2. Process the blood or buccal cell sample according to BLGSP SOP #306. Store isolated cells in liquid nitrogen storage until shipment.
   3. Obtain a formalin-fixed, paraffin-embedded (FFPE) tissue block or, if not possible, **sixteen (16)** unstained 4 μm sections from the formalin-fixed block mounted on adhesive (e.g. poly-L-lysine or APTS) coated glass slides. Affix one of the provided freezer-resistant labels to each slide or block.

E. Preparing samples and shipment:
1. Send a formalin-fixed, paraffin-embedded tissue block or, if not possible, **sixteen (16)** unstained 4 µm sections obtained from the formalin fixed block mounted on adhesive (e.g. poly-L-lysine or APTS) coated glass slides, to the Pathology Coordinator at University of Nebraska (see BLGSP SOP #300). A shipping manifest must be sent that includes the project-assigned IDs with information pertaining to the gender and age of the patient from whom the tissue was obtained from as well as the anatomic site of origin (use terminology found in the Clinical Report Form and Appendix A). Provide both the Pathology Coordinator and PT manager with the tracking number and shipping manifest the day of the shipment. If slides are sent, ship in a box designed to hold slides securely to prevent breakage (such as Thermo Scientific® Plastic Slide Box, capacity 25 slides, catalog# B1780).

2. OCG will contact the TSS once a case qualifies by passing central pathology review. When tissue from at least three cases are accrued, or every four months (see BLGSP SOP #307), and qualified by central pathology review, contact The Research Institute at Nationwide Children’s Hospital (NCH) coordinator (see BLGSP SOP #300) to schedule a shipment of a cryoport transport vessel to send the cryovials containing frozen tumor sample sections and frozen blood cells. **The TSS will not ship frozen tissues until notification from OCG that cases have qualified by central pathology review.**

3. When the cryoport arrives follow the frozen sample shipment protocol (BLGSP SOP #308) and send the frozen samples to NCH (Any exception needs to be negotiated with OCG). It is expected that most sites will send tissues within to NCH within 24 hours of receiving the cryoport. The timing of shipment should be discussed prior to tissue collection, especially if exceptions are required. Upon shipping, provide both the NCH and PT with tracking number.

4. Collect all the **de-identified** clinical data requested (see Appendix A). OCG will notify the TSS to send the de-identified clinical data electronically to NCH once the frozen samples passes molecular QC.

**Notes**

- A checklist is provided to help you track all the steps required in this process (Appendix B). Please use it!
- If any one of the required items (institutional certification, confirmation of informed consent, frozen tissue, frozen non-tumoral cells, unstained tissue blocks or slides, and clinical data) is not present, the submission is incomplete, the sample cannot be accepted for BLGSP, and reimbursement of costs cannot proceed.
- **At no point in the process can traditionally-used identifying information (such as the patient name, address, phone number, medical record number, or social security number) be used to label samples. Only use the project-assigned ID and labels provided by the Project Team.**
APPENDIX A: Sample Requirements

Tissue Requirements

To be accepted to the project, the following conditions have to be met at the tissue level.

- Tissue must come from a patient who has not received neoadjuvant therapy for Burkitt Lymphoma or systemic treatment for any tumor.
- Paired tumor and normal (blood or buccal cells) must be available in sufficient quantities (~100 mg of frozen tumor tissue, plus 10 ml of blood or at least three buccal swabs).
- Tissues (both normal and tumor) need to be snap frozen. Time between tissue excision and freezing must be recorded.
- Optimal storage of the tissues is in liquid nitrogen, but -80°C or lower is acceptable. The form of tissue storage must be recorded.
- There must be enough frozen tissue to produce 2-3 sections which are each 200 µm thick.
- Tumors need to have a minimum percent of tumor nuclei of 50% as assessed by H&E on top and bottom of a tissue section physically adjacent to the specimen used for generating the RNA and DNA.
- A formalin-fixed paraffin embedded block for pathology consensus review (or at least sixteen [16] unstained 4 µm sections mounted on adhesive (e.g. poly-L-lysine or APTS) coated glass slides) must exist for the tumor.
- For samples that have been sorted by flow cytometry, tumor samples should be CD45+, CD20+, CD10+ and CD19+. Normal T-lymphocytes should be CD45+, SSC-A low, CD3+ and CD19-.

Clinical Data Requirements

To be accepted to the project, the following conditions must be met at the clinical data level. The samples must meet ALL the clinical data elements (CDEs) listed on the following pages. Should some of the data fields be missing, please contact the OCG PT representative to get approval for submission. All patient information must be de-identified.

These clinical data elements must be reported to the NCH as an initial report when indicated by OCG that the sample has passed molecular QC. At 12 months and 24 months after the patient’s enrollment in the BLGSP, an update of the status and clinical condition of each patient needs to be submitted to the NCH. If the patient dies prior to the first year update, the second year update would only serve to confirm the status.

Patients need to be consented in such a way that allows for the use of their tissues for genomic-scale molecular characterization.
**Enrollment Form**  
Burkitt Lymphoma Genome Sequencing Project (BLGSP)

**Instructions:** The Clinical Data needed to complete this Enrollment Form should be collected for each patient in the Burkitt Lymphoma Genome Sequencing Project (BLGSP) prior to acquisition of tissues. Upon qualification notice from the Office of Cancer Genomics (OCG), the Tissue Source Site (TSS) should complete this Enrollment form for each qualified case within 60 days.

Questions regarding this form should be directed to the Nationwide Children’s Hospital (NCH) or OCG.

---

Please note the following definitions for the “Unknown” and “Not Evaluated” answer options on this form.

**Unknown:** This answer option should only be selected if the TSS does not know this information after all efforts to obtain the data have been exhausted. If this answer option is selected for a question that is part of the BLGSP required data set, the TSS must complete a discrepancy note providing a reason why the answer is unknown.

**Not Evaluated:** This answer option should only be selected by the TSS if it is known that the information being requested cannot be obtained. This could be because the test in question was never performed on the patient or the TSS knows that the information requested was never disclosed.

---

Tissue Source Site (TSS): ____________________________  
TSS Identifier: _____________  
TSS Unique Patient Identifier: _____________________

Completed By (Interviewer Name in OpenClinica): ___________________________  
Completed Date: _____________________________

---

<table>
<thead>
<tr>
<th>#</th>
<th>Data Element</th>
<th>Entry Alternatives</th>
<th>Working Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General Information</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BLGSP Project ID:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 1 | Is this a prospective tissue collection? | □ Yes  
□ No | Indicate whether the TSS providing tissue is contracted for prospective tissue collection. If the submitted tissue was collected after the date the BLGSP contract was executed, the tissue has been collected prospectively.  
3088492 |
| 2 | Is this a retrospective tissue collection? | □ Yes  
□ No | Indicate whether the TSS providing tissue is contracted for retrospective tissue collection. If the submitted tissue was collected prior to the date the BLGSP contract was executed, the tissue has been collected retrospectively.  
3088528 |
| **Patient Information** | | | |
| **Demographic Information** | | | |
| 3 | Date of Birth | _____ / _____ / _____  
(month)  
(day)  
(year) | Provide the date the patient was born.  
2896950 (month), 2896952 (day), 2896954 (year)  
*Note: The day of Birth is not required.* |
| 4 | Gender | □ Female  
□ Male | Provide the patient’s gender using the provided categories.  
2200604 |
| 5 | Race (check all that apply) | □ American Indian or Alaska Native  
□ Asian/East Indian  
□ White  
□ Black/African American  
□ Native Hawaiian or other Pacific Islander  
□ Unknown | Provide the patient’s race using the defined categories.  
2192199  
American Indian or Alaska Native: A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment.  
Asian: A person having origins in any of the original peoples of the far East, Southeast Asia, or in the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippines, Thailand, and Vietnam.  
White: A person having origins in any of the original peoples of the four European, the Middle East, or North Africa.  
Black or African American: A person having origins in any of the black racial groups of Africa. Terms such as “Haitian” or “Negro” can be used in addition to “Black or African American.”  
Native Hawaiian or other Pacific Islander: A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands.  
Unknown: Could not be determined or unsure |
| 6 | Ethnicity | □ Not Hispanic or Latino  
□ Hispanic or Latino  
□ Not Reported  
□ Unknown | Provide the patient’s ethnicity using the defined categories.  
2192217  
Not Hispanic or Latino: A person not meeting the definition of Hispanic or Latino.  
Hispanic or Latino: A person of Mexican, Puerto Rican, Cuban, Central or South American, or other Spanish culture or origin, regardless of race.  
Not Reported: Not provided or available  
Unknown: Could not be determined or unsure |
| 7 | Height (at time of diagnosis) | ________________(cm) | Provide the patient’s height (centimeters) at the time the patient was diagnosed with the tumor submitted for BLGSP.  
649 |
| 8 | Weight (at time of diagnosis) | ________________(kg) | Provide the patient’s weight (kilograms) at the time the patient was diagnosed with the tumor submitted for BLGSP.  
651 |
| **Survival Information** | | | |
| 9 | Vital Status (at date of last contact) | □ Living  
□ Deceased | The survival state of the person registered on the protocol.  
2 |
<table>
<thead>
<tr>
<th>#</th>
<th>Data Element</th>
<th>Entry Alternatives</th>
<th>Working Instructions</th>
</tr>
</thead>
</table>
| 11 | Date of Last Known Alive                 | ___________/ _______/ _______ (month) / (day) / (year) | Indicate the last date the patient was known to be alive, regardless of whether the patient, medical provider, family member or caregiver was contacted.  
2897022 (month), 2897024 (day), 2897026 (year)  
Note: The day of Last Known Alive is not required. |
| 10 | Date of Last Contact                      | ___________/ _______/ _______ (month) / (day) / (year) | If the patient is living, provide the date of last contact with the patient (as reported by the patient, medical provider, family member, or caregiver).  
2897020 (month), 2897022 (day), 2897024 (year)  
Note: The day of Last Contact is not required.  
Do not answer if patient is deceased. |
| 12 | Date of Death                             | ___________/ _______/ _______ (month) / (day) / (year) | If the patient is deceased, provide the month of death.  
2897026, (month) 2897028 (day), 2897030 (year)  
Note: The day of Death is not required. |
| 13 | Cause of Death                           | Cancer Related, Non-Cancer Related, Unknown, Other (please specify) | Indicate the patient’s cause of death.  
2554674 |
| 14 | Other Cause of Death                      | ___________________________ | If the patient’s cause of death was not included in the provided list, specify the patient's cause of death.  
2004150 |
| 15 | Did the patient receive neo-adjuvant therapy for the tumor submitted for BLGSP? | Yes (exclusion criterion), No | Indicate whether the patient received treatment (radiation, pharmaceutical, or both) prior to the procurement of the sample submitted for BLGSP.  
3382737  
If the answer to this question is “yes”, the submitted case is excluded. |
| 16 | Tumor Status (at time of last contact or death) | Tumor free, With tumor, Unknown | Indicate whether the patient was tumor/disease free (i.e. free of the malignancy that yielded the sample submitted for the BLGSP study) at the date of last contact or death.  
2759550 |
| 17 | Performance Status: Eastern Cooperative Oncology Group (at diagnosis) | 0: Fully active, able to carry on all pre-disease performance without restriction.  
1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work.  
2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.  
3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.  
4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.  
Unknown, Not Evaluated | Provide the Eastern Cooperative Oncology Group (ECOG) performance status of the patient at the time selected in the “timing” question below.  
88 |
| 18 | Performance Status: Karnofsky Score (at diagnosis) | 0: Normal, no complaints, no evidence of disease  
90: Able to carry on normal activity; minor signs or symptoms of disease  
80: Normal activity with effort; some signs or symptoms of disease  
70: Cares for self, unable to carry on normal activity or to do active work  
60: Requires occasional assistance, but is able to care for most of his/her needs  
50: Requires considerable assistance and frequent medical care  
40: Disabled, requires special care and assistance  
30: Severely disabled, hospitalization indicated. Death not imminent.  
20: Very sick, hospitalization indicated. Death not imminent.  
10: Moribund, fatal processes progressing rapidly  
0: Dead  
Unknown, Not Evaluated | Provide the Karnofsky score for the patient at the time selected in the “timing” question below.  
2003853 |
| 19 | Tumor Response                           | Progressive Disease, Stable Disease, Partial Response, Complete Response | Indicate the patient’s measure of success after their primary treatment for the tumor submitted. Treatment includes surgery and adjuvant therapies.  
2786727 |
## Enrollment Form
Burkitt Lymphoma Genome Sequencing Project (BLGSP)

<table>
<thead>
<tr>
<th>#</th>
<th>Data Element</th>
<th>Entry Alternatives</th>
<th>Working Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>Adjuvant (Post-Operative) Radiation Therapy</td>
<td>Yes, No, Unknown</td>
<td>Indicate whether the patient had adjuvant/post-operative radiation therapy &lt;br&gt;for the tumor submitted.</td>
</tr>
<tr>
<td>21</td>
<td>Adjuvant (Post-Operative) Pharmaceutical Therapy</td>
<td>Yes, No, Unknown</td>
<td>Indicate whether the patient had adjuvant/post-operative pharmaceutical therapy &lt;br&gt;for the tumor submitted.</td>
</tr>
</tbody>
</table>

### Patient History of Disease

#### HIV Status

*22 Is this patient HIV positive?  
☐ Yes  
☐ No  
☐ Unknown  

Indicate whether the patient is HIV positive.  
[2180464]

**23 Date of HIV Diagnosis (if known)**  
Only complete if "Yes" is selected above.  

Provide the month the patient was diagnosed with HIV.  
[3579640 (month), 3579644 (day), 3579643 (year)]  
Note: The day of HIV Diagnosis is not required.  

**24 Nadir CD4 Counts (at time of last contact)**  

Provide the patient’s Nadir CD4 counts, which are the lowest CD4 counts the patient has had.  
[2684395]

**25 CD4 Counts at Diagnosis of the Submitted Malignancy**  

Provide the patient’s CD4 Counts at the time the patient was diagnosed with the malignancy submitted for the BLGSP study.  
[2922654]

**26 HIV RNA load at Diagnosis of Submitted Malignancy**  

Provide the HIV RNA load (also known as the "viral load") at the time the patient was diagnosed with the malignancy submitted for the BLGSP study.  
[2922674]

**27 Prior AIDS Defining Conditions**  

- Candidiasis of bronchi, trachea or lungs  
- Candidiasis, esophageal  
- CMV other than liver, spleen or nodes, onset at age >1month  
- CMV retinitis  
- Coccidioidomycosis, disseminated or extrapulmonary  
- Cryptococcosis, extrapulmonary  
- Cryptosporidiosis, chronic intestinal  
- Encephalopathy, HIV-related  
- Herpes simplex: chronic ulcers (> 1 month’s duration) or bronchitis, pneumonitis or esophagitis (onset at age > 1 month)  
- Histoplasmosis, disseminated or extrapulmonary  
- Isosporiasis, chronic intestinal (> 1 mon)  
- Mycobacterium avium complex or Mycobacterium kansasii disseminated or extrapulmonary  
- Mycobacterium tuberculosis of any site, pulmonary, disseminated or extrapulmonary  
- Mycobacterium; other species or unidentified species, disseminated or extrapulmonary  
- Nocardiosis  
- Pneumocystis jirovecii pneumonia  
- Pneumonia, recurrent  
- Progressive multifocal leukoencephalopathy  
- Salmonella septicemia, recurrent  
- Toxoplasmosis of the brain, onset at age >1month  
- Wasting syndrome, due to HIV

**28 Co-Infections**  

<table>
<thead>
<tr>
<th>Test</th>
<th>(+)</th>
<th>(-)</th>
<th>Inconclusive</th>
<th>Not Tested</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBV</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>HCV</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>HPV</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>KSHV/HHV8</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

Using the list provided, indicate whether the patient had any co-infections by providing the results of each of the tests listed.  
[2180456, 2695021, 2230033, 3335773]

**29 HAART Treatment Prior to Diagnosis of Submitted Malignancy**  

- Yes  
- No  
- Unknown

Indicate whether the patient received Highly Active Antiretroviral Therapy (HAART) treatment prior to the diagnosis of the malignancy submitted for the BLGSP study.  
[3335156]
<table>
<thead>
<tr>
<th>#</th>
<th>Data Element</th>
<th>Entry Alternatives</th>
<th>Working Instructions</th>
</tr>
</thead>
</table>
|    | HAART Treatment at Time of Diagnosis of              | □ Yes  
                     | Submitted Malignancy                                      | □ No  
<pre><code>                 | □ Unknown                                                                  | Indicate whether the patient received Highly Active Antiretroviral Therapy (HAART) treatment at the time of the diagnosis of the malignancy submitted for the BLGSP study. 2892679 |
</code></pre>
<p>| 30 |                                                        |                                                         |                                                                                                                                                      |
|    | CDC HIV Risk Group                                    | □ Homosexual or bisexual contact                        | □ Heterosexual contact                                                                                                                                  | Indicate whether the patient has a history of any of the listed HIV Risk Groups as defined by the Center for Disease Control (CDC). 2542215 |
| 31 |                                                        | □ IV drug user                                          | □ Transfusion recipient                                                                                                                                  |                                                                                                                                                      |
|    |                                                        | □ Hemophilic                                           | □ Unknown                                                                                                                                           |                                                                                                                                                      |
|    | Prior Malignancies                                    |                                                        |                                                                                                                                                      | Indicate whether the patient has a history of malignancies, including synchronous or bilateral malignancies. 3382736 |
|    |                                                        |                                                         |                                                                                                                                                      | If the answer to this question is “yes”, the submitted case is excluded. This exclusion does not apply if the patient only has a history of non-melanoma skin cancer OR cervical in situ carcinoma. |
| 32 | History of other malignancy                           | □ Yes (exclusion criterion)                            | □ No                                                                                                                                                |                                                                                                                                                      |
|    |                                                        |                                                         |                                                                                                                                                      |                                                                                                                                                      |
|    | Prior Immunological Disease                           |                                                        |                                                                                                                                                      | Indicate whether the patient has a history of any of the listed immunological diseases. 3233628 |
| 33 | Patient History of Prior Immunological Disease        | □ Rheumatoid Arthritis                                 | □ Sjogren’s Syndrome                                                                                                                                    |                                                                                                                                                      |
|    |                                                        | □ Systemic Lupus Erythematosus                        | □ Crohn’s Disease                                                                                                                                       |                                                                                                                                                      |
|    |                                                        | □ Ulcerative Colitis                                   | □ Hashimoto’s Thyroiditis                                                                                |                                                                                                                                                      |
|    |                                                        | □ None                                                 | □ Other                                                                                                                                             |                                                                                                                                                      |
|    |                                                        | □ Unknown                                               | □ Unknown                                                                                                                                           |                                                                                                                                                      |
|    |                                                        |                                                         |                                                                                                                                                      |                                                                                                                                                      |
| 34 | Patient History of Other Immunological Disease        |                                                        |                                                                                                                                                      | Indicate whether the patient has a history of any of the listed immunological diseases. 3233629 |
|    | Only complete if “other” is selected above.           |                                                         |                                                                                                                                                      |                                                                                                                                                      |
| 35 | Patient History of Prior Immunosuppressive Therapy for| □ Methotrexate                                          | □ None                                                                                                                                             | If the patient received immunosuppressive therapy for the immunological disease selected in the previous question, provide the type of immunosuppressive therapy given. 3233638 |
|    | Immunological Disease                                 | □ Cyclophosphamide                                     | □ Other                                                                                                                                             |                                                                                                                                                      |
|    |                                                        | □ Azathioprine                                         | □ Unknown                                                                                                                                           |                                                                                                                                                      |
|    |                                                        | □ Anti-TNF therapy                                     |                                                                                                                                                      |                                                                                                                                                      |
|    | Other History of Prior Immunosuppressive Therapy      |                                                        |                                                                                                                                                      | What was the other immunosuppressive therapy administered? 2873928 |
|    | Only complete if “other” is selected above.           |                                                         |                                                                                                                                                      |                                                                                                                                                      |
| 36 |                                                        |                                                         |                                                                                                                                                      |                                                                                                                                                      |
|    | Prior Infectious Disease                              |                                                        |                                                                                                                                                      |                                                                                                                                                      |
| 37 | Patient History of Relevant Prior Infectious Disease  | □ Hepatitis B                                          | □ Malaria                                                                                                                                           | Indicate whether the patient has a history of any of the listed infectious disease. 3233642 |
|    |                                                        | □ Hepatitis C                                          | □ None                                                                                                                                             |                                                                                                                                                      |
|    |                                                        | □ H. Pylori                                            | □ Other                                                                                                                                             |                                                                                                                                                      |
|    |                                                        |                                                         | □ Unknown                                                                                                                                           |                                                                                                                                                      |
| 38 | Patient History of Other Relevant Infectious Disease  |                                                        |                                                                                                                                                      | If the patient has a history of relevant prior disease that was not included in the list, provide the infectious disease. 3233643 |
|    | Only complete if “other” is selected above.           |                                                         |                                                                                                                                                      |                                                                                                                                                      |
|    |                                                        |                                                         |                                                                                                                                                      |                                                                                                                                                      |
|    | Pathologic Information                                |                                                        |                                                                                                                                                      | Using the patient’s final diagnostic pathology report, provide the most detailed histological subtype available. 3081934 |
|    |                                                        | □ Burkitt Lymphoma (BL), classic morphology           | □ Burkitt Lymphoma (BL), atypical morphology                                                                                                            |                                                                                                                                                      |
|    |                                                        | □ B-cell lymphoma, unclassifiable, with features      | □ B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma |                                                                                                                                                      |
|    |                                                        | intermediate between diffuse large B-cell lymphoma and | □ Diffuse large B-cell lymphoma (DLBCL), specify subtype (e.g. NOS, plasmablastic)                                                                  |                                                                                                                                                      |
|    |                                                        | Burkitt lymphoma                                       | □ Unclassifiable B-cell lymphoma                                                                                                                      |                                                                                                                                                      |
|    |                                                        | □ Other, specify                                        | □ Unknown                                                                                                                                           |                                                                                                                                                      |
|    |                                                        |                                                         |                                                                                                                                                      |                                                                                                                                                      |
| 39 | Histological Subtype                                  |                                                        |                                                                                                                                                      | Free text field to specify the structural pattern of cancer cells used to define a microscopic diagnosis that is not already specified or mentioned. 3294805 |
|    |                                                        |                                                         |                                                                                                                                                      |                                                                                                                                                      |
| 40 | Other Neoplasm Histologic Type, Specify                |                                                        |                                                                                                                                                      |                                                                                                                                                      |
|    | Only complete if “other” is selected above.           |                                                         |                                                                                                                                                      |                                                                                                                                                      |</p>
<table>
<thead>
<tr>
<th>#</th>
<th>Data Element</th>
<th>Entry Alternatives</th>
<th>Working Instructions</th>
</tr>
</thead>
</table>
| *41| Site(s) of Nodal Involvement at Diagnosis        | □ Axillary  □ Cervical  □ Epitrochlear  □ Femoral  □ Hilar  □ Hilar-common  □ Hilar-external  □ Inginal  □ Mediastinal  □ Mesenteric  □ Occipital  □ Paraaortic  □ Parotid  □ Popliteal  □ Retroperitoneal  □ Splenic  □ Supravacuicular  □ Submandibular  □ No known nodal involvement | Using the patient’s medical record check all applicable boxes to identify the lymph node chain(s) that were involved by Burkitt lymphoma at the time of initial diagnosis. 2180591  
To select multiple sites of involvement, press the control button and select the sites of involvement. Your selections should be highlighted after you’ve selected. |
| 42 | Extranodal Involvement At Diagnosis              | □ Yes  □ No  □ Unknown                                      | Provide the total number of extranodal sites with lymphoma involvement. Use the previous three questions to determine this number. This information, along with other data provided, will be used by the Analysis Working Group (AWG) to calculate the International Prognostic Index (IPI). 3233242 |
| 43 | Number of Extranodal Sites of Involvement Above  |                                                              |                                                                                           | 2952463                                                                                                                                                                                                             |
|    | (to calculate the IPI)                           |                                                              |                                                                                           |                                                                                           | 3288482                                                                                                                                                                                                             |
| 44 | Site(s) of Extranodal Involvement At Diagnosis   | □ Adrenal Gland  □ Bone  □ Bone Marrow  □ Breast  □ Neck  □ Peripheral Blood  □ Skin  □ Soft Tissue (muscle, ligaments, subcutaneous)  □ ENT & Eye  □ Eye  □ Larynx  □ Mandible  □ Maxilla  □ Nasal Soft Tissue  □ Nasopharynx  □ Ocular orbits  □ Oropharynx  □ Parotid Gland  □ Peri-orbital Soft Tissue  □ Salivary Gland  □ Sinus(es)  □ Thyroid gland  □ Central Nervous system  □ Brain  □ Cerebrospinal Fluid  □ Epidural space  □ Leptomeninges  □ Gastrointestinal/Abdominal  □ Ascites  □ Appendix  □ Colon  □ Esophagus  □ Gallbladder  □ Liver  □ Pancreas  □ Rectum  □ Small Intestine  □ Stomach  □ Genito-urinary Tract  □ Bladder  □ Epididymis  □ Kidney  □ Ovary  □ Prostate  □ Testicle  □ Uterus  □ Mediastinal/Intra-thoracic  □ Heart  □ Lung  □ Mediastinal Soft Tissue  □ Pericardium  □ Pleura  □ Not applicable  □ Other, please specify | Using the patient’s medical record check all applicable boxes to identify the anatomic location of all site(s) of extranodal involvement by Burkitt lymphoma at the time of initial diagnosis. 3288492  
To select multiple sites of involvement, press the control button and select the sites of involvement. Your selections should be highlighted after you’ve selected. |
<p>| *45| Other Specified Site of Extranodal Involvement at Diagnosis |                                                              | If all extranodal sites of involvement are not included in the list provided, please indicate any sites of extranodal involvement. 3234303                                                                 |
| 46 | Maximum Tumor Bulk (Dimension)                   |                                                              | After review of the entire medical record, record the length of the largest dimension/diameter of a tumor, regardless of anatomical plane. 364215                                                                 |
| 47 | Anatomic Site of Maximum Tumor Bulk             | □ Adrenal  □ Bone  □ Bone Marrow  □ Breast  □ Neck  □ Gastrointestinal/Abdominal  □ Ascites  □ Appendix  □ Colon  □ Esophagus | Using the list of sites in the nodal and extranodal questions above, provide the anatomic site of the maximum tumor bulk. 3639616                                                                 |</p>
<table>
<thead>
<tr>
<th>#</th>
<th>Data Element</th>
<th>Entry Alternatives</th>
<th>Working Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>#</td>
<td>Data Element</td>
<td>Entry Alternatives</td>
<td>Working Instructions</td>
</tr>
<tr>
<td>----</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>54</td>
<td>Number of Lymph Nodes Positive by H&amp;E light microscopy</td>
<td></td>
<td>Provide the number of lymph nodes positive through hematoxylin and eosin (H&amp;E) staining and light microscopy.</td>
</tr>
<tr>
<td></td>
<td>Only complete if “yes” is selected above.</td>
<td></td>
<td>3086388</td>
</tr>
<tr>
<td>55</td>
<td>Number of Lymph Nodes Positive by IHC Keratin Staining only</td>
<td></td>
<td>Provide the number of lymph nodes positive through keratin immunohistochemistry (IHC) staining.</td>
</tr>
<tr>
<td></td>
<td>Only complete if “yes” is selected above.</td>
<td></td>
<td>3086383</td>
</tr>
<tr>
<td>56</td>
<td>Pathologic Positive Lymph Node Location(s) (Check all that apply)</td>
<td>□ Pelvic (external iliac, internal iliac, obturator) □ Common iliac □ Paraaortic □ Supraclavicular □ Unknown □ Other, specify</td>
<td>Using the patient's pathology/laboratory report, provide the location(s) of any positive lymph nodes.</td>
</tr>
<tr>
<td></td>
<td>Only complete if “yes” is selected above.</td>
<td></td>
<td>3151519</td>
</tr>
<tr>
<td>57</td>
<td>Other Positive Lymph Node</td>
<td></td>
<td>If the location of positive lymph nodes was not included in the list provide, please provide the location of positive lymph nodes.</td>
</tr>
<tr>
<td></td>
<td>Only complete if “other” is selected above.</td>
<td></td>
<td>3151522</td>
</tr>
</tbody>
</table>

**Staging and Histology of Bone Marrow**

| *58 | Tumor Stage (Follow Ann Arbor Criteria)                                      | □ Stage I □ Stage II □ Stage III □ Stage IV             | Using the patient's pathology/laboratory report in conjunction with the patient's medical record, select the clinical or pathological stage as defined by the American Joint Committee on Cancer (AJCC). |
| *59 | Are "B" Symptoms Present?                                                     | □ Yes □ No                                            | Using the patient’s medical record, indicate whether there is documentation of “B” symptoms. Note: “B” symptoms are defined as unexplained fevers, drenching night sweats, or unexplained weight loss of more than 10% of usual body weight in the six months prior to lymphoma diagnosis. |
| *60 | Lymphomatous Involvement of Extranodal “E” Site?                             | □ Yes □ No                                            | Using the patient’s medical record, indicate whether there is documentation of extranodal site involvement. Note: If the answer is “Yes”, the anatomic site(s) of extranodal involvement should be included inextranodal site question above. |
| 61  | Presence of Malignant Cells in Bone Marrow by Histology                      | □ Yes □ No □ Unknown                                  | Indicate if malignant cells are histologically confirmed in the patient's bone marrow.                                                            |
| 62  | Histology of Bone Marrow Samples                                             | □ Concordant Histology □ Discordant Histology □ Unknown | If malignant cells are present in the bone marrow at the time of initial staging workup, determine if the histologic diagnosis of the bone marrow is concordant with the diagnosis of BL. |

**Tests Performed**

**LDH Level (at the time of staging)**

| *63 | LDH Level                                                                    | ______________________ (IU)                          | Record the result of the LDH lab test performed during the staging workup.                                                                      |
|     |                                                                             |                                                        | 2798766                                                                                                                                            |
| *64 | LDH Level Upper Limit for Normal at Facility                                | ______________________ (IU)                          | Record the upper limit of the normal range of the LDH lab test performed at the reporting facility.                                              |
|     |                                                                             |                                                        | 2953115                                                                                                                                            |

**Genetic Testing**

<p>| 65  | Tests Performed for Immunophenotyping                                       | (+) (+) (+) Indeterminate                             | Indicate all tests performed for immunophenotypic analysis in order to classify clonal subgroups.                                                   |
|     | Ki-67 &gt; 90%                                                                 | □ □ □                                               | 3234614 (test performed), 3234626 (Result)                                                                                                    |
|     | CD10 &gt; 30%                                                                  | □ □ □                                               |                                                                                                                                               |
|     | BCL2                                                                        | □ □ □                                               |                                                                                                                                               |
|     | CD20                                                                        | □ □ □                                               |                                                                                                                                               |
|     | BCL6 &gt; 30%                                                                  | □ □ □                                               |                                                                                                                                               |
|     | CD3                                                                        | □ □ □                                               |                                                                                                                                               |</p>
<table>
<thead>
<tr>
<th>#</th>
<th>Data Element</th>
<th>Entry Alternatives</th>
<th>Working Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>66</td>
<td>Other Tests Performed for Immunophenotyping (please specify)</td>
<td><img src="options.png" alt="Options" /></td>
<td>Indicate all tests performed for immunophenotypic analysis in order to classify clonal subgroups. 2516429</td>
</tr>
<tr>
<td>67</td>
<td>B-cell Immunophenotype Methodology</td>
<td><img src="options.png" alt="Options" /></td>
<td>If B-cell genotype was performed, indicate the testing method used. 64540</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Genetic Abnormalities</td>
<td><img src="options.png" alt="Options" /></td>
<td>Specify any other genetic abnormalities not in the provided list for which the patient was tested. 3234675, 3234680</td>
</tr>
<tr>
<td>68</td>
<td>C-MYC</td>
<td><img src="options.png" alt="Options" /></td>
<td>N = Normal</td>
</tr>
<tr>
<td></td>
<td>BCL2</td>
<td><img src="options.png" alt="Options" /></td>
<td>T = Translocation</td>
</tr>
<tr>
<td></td>
<td>BCL6</td>
<td><img src="options.png" alt="Options" /></td>
<td>G = Gain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>L = Loss</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>A = Amplification</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>O = Other</td>
</tr>
<tr>
<td>69</td>
<td>Other Genetic Abnormalities (please specify)</td>
<td><img src="options.png" alt="Options" /></td>
<td>Specify any other genetic abnormalities not in the provided list for which the patient was tested. 3234685, 3234680</td>
</tr>
<tr>
<td>70</td>
<td>Other Results of Testing for Genetic Abnormality</td>
<td><img src="options.png" alt="Options" /></td>
<td>Specify any other results of testing for genetic abnormalities not in the provided list. 4459354</td>
</tr>
<tr>
<td>71</td>
<td>Methodology Used in Testing for Genetic Abnormality</td>
<td><img src="options.png" alt="Options" /></td>
<td>If the patient was tested for a specific genetic abnormality, indicate the testing method used to perform each analysis. 3234684</td>
</tr>
<tr>
<td></td>
<td>Only complete if patient had a genetic abnormality.</td>
<td></td>
<td>Methodology Code:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 = PCR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2 = Southern Blot</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3 = FISH</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4 = Cytogenetic</td>
</tr>
<tr>
<td>72</td>
<td>Methodology Used to Determine EBV Status of Malignant Cells</td>
<td><img src="options.png" alt="Options" /></td>
<td>If the patient’s EBV status was positive, provide the testing method used to determine the EBV status of the malignant cells. 3233656</td>
</tr>
<tr>
<td></td>
<td>Only complete if patient had a genetic abnormality.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>73</td>
<td>EBV Status of Malignant Cells</td>
<td><img src="options.png" alt="Options" /></td>
<td>Provide the result of the lab test to detect the presence of Epstein/Barr Virus antibody in the patient. 2003961</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>74</td>
<td>If EBV status is positive, provide the percent positive. (does not include background positives) Only complete if “positive” is selected above.</td>
<td><img src="options.png" alt="Options" /></td>
<td>If the patient’s EBV status was positive, provide the percentage of EBV positive malignant cells. Do not include the number of background positives. 3233649</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**New Tumor Event Information** Complete this section if the patient had a new tumor event. If the patient did not have a new tumor event (or if the TSS does not know) indicate this in the question below, and the remainder of this section can be skipped.

| !*  | New Tumor Event After Initial Treatment?                                    | ![Options](options.png)                     | Indicate whether the patient had a new tumor event (e.g. metastatic, recurrent, or new primary tumor) after initial treatment. 3121376 |
|     |                                                                             |                                             | If the patient did not have a new tumor event or if this is unknown, the remaining questions can be skipped. |
### Enrollment Form

**Burkitt Lymphoma Genome Sequencing Project (BLGSP)**

<table>
<thead>
<tr>
<th>#</th>
<th>Data Element</th>
<th>Entry Alternatives</th>
<th>Working Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>ii</td>
<td>Date of New Tumor Event</td>
<td>⬇️ Month ⬇️ Day ⬇️ Year</td>
<td>If the patient had a new tumor event, provide the date of diagnosis for this new tumor event. 3104044 (Month), 3104042 (Day), 3104046 (Year)</td>
</tr>
<tr>
<td>iii</td>
<td>Type of New Tumor Event</td>
<td>□ Locoregional Recurrence □ Distant Metastasis □ New Primary Tumor</td>
<td>Indicate whether the patient's new tumor event was a locoregional recurrence or a distant metastasis of the tissue submitted for TCGA; or a new primary tumor. 3119721</td>
</tr>
<tr>
<td>iv</td>
<td>Anatomic Site of New Tumor Event</td>
<td>□ Bone □ Lung □ Liver □ Retroperitoneum □ Lymph Node(s) □ Other, specify</td>
<td>Indicate the site of this new tumor event. 3108271</td>
</tr>
<tr>
<td>v</td>
<td>Other Site of New Tumor Event</td>
<td></td>
<td>If the site of the new tumor event is not included in the provided list, describe the site of this new tumor event. 3128033</td>
</tr>
<tr>
<td>vi</td>
<td>Diagnostic Evidence of Recurrence / Relapse (check all that apply)</td>
<td>□ Biopsy w/Histologic Confirmation □ Convincing Imaging (i.e. CT, PET, MRI) □ Positive Biomarker(s)</td>
<td>Indicate the procedure or testing method used to diagnose tumor recurrence or relapse. 2786205</td>
</tr>
<tr>
<td>vii</td>
<td>Additional Surgery for New Tumor Event</td>
<td>□ Yes □ No □ Unknown</td>
<td>Using the patient's medical records, indicate whether the patient had surgery for the new metastatic tumor event in question. 3427611</td>
</tr>
<tr>
<td>vii</td>
<td>Additional Treatment of New Tumor Event Radiation Therapy</td>
<td>□ Yes □ No □ Unknown</td>
<td>Indicate whether the patient received radiation treatment for this new tumor event. 3427615</td>
</tr>
<tr>
<td>vii</td>
<td>Additional Treatment of New Tumor Event Pharmaceutical Therapy</td>
<td>□ Yes □ No □ Unknown</td>
<td>Indicate whether the patient received pharmaceutical treatment for this new tumor event. 3427616</td>
</tr>
</tbody>
</table>

### Patient Status

| *75 | Is This Patient Lost to Follow-up?         | □ Yes □ No                                                                         | Indicate whether the patient is lost to follow-up as defined by the ACoS Commission on Cancer. This only includes cases where updated information has not been collected within the last 15 months. If the patient is lost to follow-up, the remaining questions may be left unanswered. 61333 |

If the patient is lost to follow-up or deceased at the time of enrollment, follow-up forms are not required.

---

Principal Investigator (*Printed Name*)

---

Principal Investigator (*Signature*) Date

I acknowledge that the above information provided by my institution is true and correct and has been quality controlled.
**Follow-up Form**
Burkitt Lymphoma Genome Sequencing Project (BLGSP)

**Instructions:** The Clinical Data needed to complete this Follow-up Form should be collected for each qualified case in the Burkitt Lymphoma Genome Sequencing Project (BLGSP) at 12 and 24 months after the date of patient consent. The Tissue Source Site (TSS) should complete this Follow-up Form within 60 days after the 12 and 24 month patient consent anniversary for all qualified cases indicated by the Office of Cancer Genomics (OCG). Questions regarding this form should be sent to Nationwide Children’s Hospital or OCG.

Please note the following definitions for the "Unknown" and "Not Evaluated" answer options on this form.

**Unknown:** This answer option should only be selected if the TSS does not know this information after all efforts to obtain the data have been exhausted. If this answer option is selected for a question that is part of the BLGSP required data set, the TSS must complete a discrepancy note providing a reason why the answer is unknown.

**Not Evaluated:** This answer option should only be selected by the TSS if it is known that the information being requested cannot be obtained. If for example, a test was not performed the results of that test cannot be provided because it was "Not Evaluated."

**Tissue Source Site (TSS):** ____________________________ TSS Identifier: _____________ TSS Unique Patient Identifier: _____________________

Completed By (Interviewer Name in OpenClinica): ____________________________ Completed Date: ____________________________

<table>
<thead>
<tr>
<th>#</th>
<th>Data Element</th>
<th>Entry Alternatives</th>
<th>Working Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Vital Status (at date of last contact)</td>
<td>□ Living</td>
<td>Indicate whether the patient was living or deceased at the date of last contact, or has been lost to follow-up as defined by the ACoS Commission on Cancer. This only includes cases where updated follow-up information has not been collected within the past 15 months and all efforts to contact the patient have been exhausted (this includes reviewing death records). <em>If the patient is lost to follow-up, the remaining questions can be left unanswered.</em> <em>If the patient is deceased and a BLGSP follow-up form has not yet been completed, the remaining applicable questions should be completed.</em></td>
</tr>
<tr>
<td>2</td>
<td>Date of Last Contact</td>
<td>__________ / __________ / __________ (month) (day) (year)</td>
<td>If the patient is living, provide the date of last contact with the patient (as reported by the patient, medical provider, family member, or caregiver). <em>2897020 (month), 2897022 (day), 2897024 (year)</em> <strong>Do not answer if patient is deceased.</strong> <strong>Note: The day of Last Contact is not required.</strong></td>
</tr>
<tr>
<td>3</td>
<td>Date Last Known Alive</td>
<td>__________ / __________ / __________ (month) (day) (year)</td>
<td>Indicate the last date the patient was known to be alive, regardless of whether the patient, medical provider, family member or caregiver was contacted. <em>2975722 (month), 2975724 (day), 2975726 (year)</em> <strong>Note: The day of Last Known Alive is not required.</strong></td>
</tr>
<tr>
<td>4</td>
<td>Date of Death</td>
<td>__________ / __________ / __________ (month) (day) (year)</td>
<td>If the patient is deceased, provide the date of death. <em>2897026, (month) 2897028 (day), 2897030 (year)</em> <strong>Note: The day of Death is not required.</strong></td>
</tr>
</tbody>
</table>

**Patient Status (Regarding Submitted Tumor)**

| 5  | Tumor Status (at time of last contact or death)                               | □ Tumor free       | Indicate whether the patient was tumor/disease free (i.e. free of the malignancy that yielded the sample submitted for the BLGSP study) at the date of last contact or death. *2759550* |
|    |                                                                               | □ With tumor       |                                                                       |
|    |                                                                               | □ Unknown          |                                                                       |
| 6  | Adjuvant (Post-Operative) Radiation Therapy                                  | □ Yes              | Indicate whether the patient had adjuvant/ post-operative radiation therapy for the tumor submitted. *2005312* |
|    |                                                                               | □ No               |                                                                       |
|    |                                                                               | □ Unknown          |                                                                       |
| 7  | Adjuvant (Post-Operative) Pharmaceutical Therapy                             | □ Yes              | Indicate whether the patient had adjuvant/ post-operative pharmaceutical therapy for the tumor submitted. *3397567* |
|    |                                                                               | □ No               |                                                                       |
|    |                                                                               | □ Unknown          |                                                                       |
| 8  | Measure of Success of Outcome at the Completion of this Follow-up Submission (at time of last contact) | □ Progressive disease | Text term to describe the overall outcome of treatment up to the point of the current data submission. *3104050* |
|    |                                                                               | □ Persistent disease |                                                                       |
|    |                                                                               | □ Stable disease   |                                                                       |
|    |                                                                               | □ Partial Response |                                                                       |
|    |                                                                               | □ Complete Response|                                                                       |
|    |                                                                               | □ Unknown          |                                                                       |
|    |                                                                               | □ Not Applicable (Treatment Ongoing) |                                                                       |

**HIV Status**

| 9  | HIV antibody status                                                          | □ Positive         | Indicate whether the patient is HIV positive. *2180464* |
|    |                                                                               | □ Negative         |                                                                       |
|    |                                                                               | □ Unknown          |                                                                       |
### New Tumor Event Information

**Follow-up Form**  
Burkitt Lymphoma Genome Sequencing Project (BLGSP)

<table>
<thead>
<tr>
<th>Data Element</th>
<th>Entry Alternatives</th>
<th>Working Instructions</th>
</tr>
</thead>
</table>
| i* New Tumor Event After Initial Treatment? | ☐ Yes  
☐ No  
☐ Unknown | Indicate whether the patient had a new tumor event (e.g. metastatic, recurrent, or new primary tumor) after initial treatment. |
| ii† Date of New Tumor Event | _______/ _______/ _______ | If the patient had a new tumor event, provide the date of diagnosis for this new tumor event. |
| iii Type of New Tumor Event | ☐ Locoregional Recurrence  
☐ Distant Metastasis  
☐ New Primary Tumor | Indicate whether the patient’s new tumor event was a locoregional recurrence or a distant metastasis of the tissue submitted; or a new primary tumor. |
| iv Anatomic Site of New Tumor Event | ☐ Bone  
☐ Lung  
☐ Liver  
☐ Retroperitoneum  
☐ Lymph Node(s)  
☐ Other, specify | Indicate the site of this new tumor event. |
| v Other Site of New Tumor Event | ________________ | If the site of the new tumor event is not included in the provided list, describe the site of this new tumor event. |
| vi Diagnostic Evidence of Recurrence / Relapse (check all that apply) | ☐ Biopsy w/Histologic Confirmation  
☐ Convincing Imaging (i.e. CT, PET, MRI)  
☐ Positive Biomarker(s) | Indicate the procedure or testing method used to diagnose tumor recurrence or relapse. |
| vii Additional Surgery for New Tumor Event | ☐ Yes  
☐ No  
☐ Unknown | Using the patient’s medical records, indicate whether the patient had surgery for the new metastatic tumor event in question. |
| viii Additional Treatment of New Tumor Event Radiation Therapy | ☐ Yes  
☐ No  
☐ Unknown | Indicate whether the patient received radiation treatment for this new tumor event. |
| ix Additional Treatment of New Tumor Event Pharmaceutical Therapy | ☐ Yes  
☐ No  
☐ Unknown | Indicate whether the patient received pharmaceutical treatment for this new tumor event. |

---

**Principal Investigator (Printed Name)**

**Principal Investigator (Signature)**  
**Date**

*I acknowledge that the above information provided by my institution is true and correct and has been quality controlled.*
**Instructions:** The BLGSP treatment forms act as supplemental forms to the Follow-up form and are due at the time the Follow-up form is submitted to the BCR. However, if the patient has completed treatment or if the patient is deceased, these forms can be submitted to the BCR at the time the Enrollment form is submitted.

Questions regarding this form should be directed to Nationwide Children’s Hospital (NCH) or OCG.

Please note the following definitions for the “Unknown” and “Not Evaluated” answer options on this form.

**Unknown:** This answer option should only be selected if the TSS does not know this information after all efforts to obtain the data have been exhausted. If this answer option is selected for a question that is part of the TCGA required data set, the TSS must complete a discrepancy note providing a reason why the answer is unknown.

**Not Evaluated:** This answer option should only be selected by the TSS if it is known that the information being requested cannot be obtained. This could be because the test in question was never performed on the patient or the TSS knows that the information requested was never disclosed.

---

**Tissue Source Site (TSS):** ____________________________ **TSS Identifier:** _____________ **TSS Unique Patient Identifier:** _____________

**Completed By (Interviewer Name on OpenClinica):** ____________________________ **Completed Date:** ____________________________

<table>
<thead>
<tr>
<th>#</th>
<th>Data Element</th>
<th>Entry Alternatives</th>
<th>Working Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1*</td>
<td>Indication of Regimen</td>
<td>Initial, Adjuvant, Progression after initial, Recurrence, Palliative, Unknown</td>
<td>Text term to identify the reason for the administration of a treatment regimen. 2793511</td>
</tr>
<tr>
<td>2*</td>
<td>Lymphoma Treatment Type</td>
<td>Chemotherapy, Radiation, Stem Cell Transplant, Surgery, No Treatment, Other Treatment</td>
<td>Text term that describes the kind of treatment that was given for the primary lymphoma. 3284925</td>
</tr>
<tr>
<td>3†</td>
<td>If other, specify</td>
<td>____________________________</td>
<td>Indicate the other treatment type for the lymphoma. 2861111</td>
</tr>
<tr>
<td>4†</td>
<td>Other Treatment Start Date</td>
<td>_____ / _____ / _____, _____, _____</td>
<td>Provide the date that therapy was started. 3103072 (month), 3103070 (day), 3103074 (year)</td>
</tr>
<tr>
<td>5†</td>
<td>Other Treatment End Date</td>
<td>_____ / _____ / _____, _____, _____</td>
<td>Provide the date that therapy was completed/ended. 3103080 (month), 3103078 (day), 31030782 (year)</td>
</tr>
<tr>
<td>6†</td>
<td>Chemotherapy Start Date</td>
<td>_____ / _____ / _____, _____, _____</td>
<td>Date chemotherapy regimen started. 2897050 (month), 2897052 (day), 2897054 (year)</td>
</tr>
<tr>
<td>7†</td>
<td>Did chemotherapy end during this reporting period?</td>
<td>Yes, No</td>
<td>Indicate whether chemotherapy administration ended during this reporting period. 2188260</td>
</tr>
<tr>
<td>8†</td>
<td>Chemotherapy End Date</td>
<td>_____ / _____ / _____, _____, _____</td>
<td>Date chemotherapy regimen ended. 2897056 (month), 2897058 (day), 2897060 (year)</td>
</tr>
<tr>
<td>9†</td>
<td>Pharmaceutical Regimen</td>
<td>BACOP, C-MOPP, CAP-BOP, CHOP + Bleomycin, CHOP + Etoposide, CHOP-14, CHOP-14 + Rituximab, CHOP-21, CHOP-21 + Rituximab, CNOP</td>
<td>Text term or code to represent the name of a pharmaceutical regimen containing two or more agents which are given together or separately to treat a patient with malignant lymphoma. 3366758</td>
</tr>
</tbody>
</table>
# Data Element | Entry Alternatives | Working Instructions
--- | --- | ---
10 | If Other Pharmaceutical Regimen, specify | Text term or abbreviation to represent another name of a pharmaceutical regimen containing two or more agents which are given together or separately to treat a patient with malignant lymphoma that was not already mentioned or specified. 3366930
11 | If Single-Agent Therapy, specify | Text name for agent used without other agents in a treatment regimen or study. 3590022
12 | Number of Cycles | The total number of cycles administered to the patient of a protocol specified drug or therapy agent as of the current report. 62590
13 | Radiation Therapy Start Date | Date radiation therapy started. 2897100 (month), 2897102 (day), 2897104 (year)
14 | Did radiation therapy end during this reporting period? | Indicate whether radiation therapy ended during this reporting period. 4618471
15 | Radiation Therapy End Date | Date radiation therapy ended. 2897106 (month), 2897108 (day), 2897110 (year)
16 | Total Dose of Radiation Therapy | A numeric value for the total dose volume of radiation therapy given to a patient, in Gray. 36
17 | Radiation Field, extranodal | Text term to identify anatomically-specified areas or fields that are targeted for radiation therapy. 2416537

<table>
<thead>
<tr>
<th>Entry Alternatives</th>
<th>Working Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>CODOX + Rituximab</td>
<td></td>
</tr>
<tr>
<td>CVP</td>
<td></td>
</tr>
<tr>
<td>DA-EPOCH</td>
<td></td>
</tr>
<tr>
<td>DA-EPOCH + Rituxumab</td>
<td></td>
</tr>
<tr>
<td>F-MACHOP</td>
<td></td>
</tr>
<tr>
<td>High Dose Methotrexate w/Leucovorin</td>
<td></td>
</tr>
<tr>
<td>HyperCVAD-Mtx/AraC + Rituximab</td>
<td></td>
</tr>
<tr>
<td>ICE</td>
<td></td>
</tr>
<tr>
<td>ICE + Rituxumab</td>
<td></td>
</tr>
<tr>
<td>LNH-84</td>
<td></td>
</tr>
<tr>
<td>LNH-87</td>
<td></td>
</tr>
<tr>
<td>M-BACOP</td>
<td></td>
</tr>
<tr>
<td>MACOP-B</td>
<td></td>
</tr>
<tr>
<td>ProMace-CytaBOM</td>
<td></td>
</tr>
<tr>
<td>ProMace-MOPP</td>
<td></td>
</tr>
<tr>
<td>VACOP-B</td>
<td></td>
</tr>
<tr>
<td>Vanderbilt regimen + Rituximab</td>
<td></td>
</tr>
<tr>
<td>Single Agent Therapy (please specify)</td>
<td></td>
</tr>
<tr>
<td>Other Pharmaceutical Regimen (please specify)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
</tr>
</tbody>
</table>

Radiation Therapy (please answer following questions only if Radiation was selected in the treatment type question above)

36 | Abdomen, total | Leg |
37 | Arm | Lung |
38 | Body, Total | Lymph node, distant (specify site) |
39 | Bone, Non-spine | Lymph node, locoregional (specify site) |
40 | Brain, Focal | Lymph Nodes |
41 | Brain, Whole | Mediastinum |
42 | Breast | Mantle |
43 | Chest Wall | Pelvis |
44 | Eye | Shoulder |
45 | Gastrointestinal, Colon | Skin, lower extremity, local |
46 | Gastrointestinal, Gallbladder | Skin, trunk, local |
47 | Gastrointestinal, Intestine | Skin, upper extremity, local |
48 | Gastrointestinal, Liver | Spine |
49 | Gastrointestinal, NOS | Supraclavicular |
50 | Gastrointestinal, Pancreas | Thorax |
51 | Gastrointestinal, Stomach | Trunk |
52 | Genitourinary, Bladder | Other |
53 | Genitourinary, Kidney | |
54 | Genitourinary, NOS | |
55 | Head, Face, or Neck | |
<table>
<thead>
<tr>
<th>#</th>
<th>Data Element</th>
<th>Entry Alternatives</th>
<th>Working Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>Nodal Regions Targeted</td>
<td>Axillary, Cervical, Epitrochlear, Femoral, Hilair, Iliac-common, Iliac-external, Inguinal, Mediastinal, Mesenteric, Occipital, Paraaortic, Parotid, Popliteal, Retroperitoneal, Splanic, Submandibular, Supraclavicular</td>
<td>Identify lymph node sites targeted for radiation therapy. 3762198</td>
</tr>
<tr>
<td>19</td>
<td>Other, specify</td>
<td>Other, specify</td>
<td>Specify other field of radiation 62999</td>
</tr>
</tbody>
</table>

**Stem Cell Transplantation (please answer following questions only if Stem Cell Transplantation was selected in the treatment type question above)**

| 20 | Type of Stem Cell Transplantation | Autologous, Syngeneic/Allogeneic related donor, Allogeneic, unrelated donor | Indicate the hematopoietic stem cell source type. 2957417                             |
| 21 | Date of Stem Cell Transplantation | _____ _____ / _____ _____ / _____ _____ (month) (day) (year) | Indicate the date of the hematopoietic stem cell transplant. 3366911 (month), 3366912 (day), 3366913 (year) |

**Surgery (please answer following questions only if Surgery was selected in the treatment type question above)**

| 22 | Date of cancer debulking surgery | _____ _____ / _____ _____ / _____ _____ (month) (day) (year) | Indicate the date related to the procedure of surgically removing as much of the tumor as possible being executed. 4631583 (month), 4631581 (day), 4631584 (year) |
| 23 | Measure of Best Response of Treatment | Complete Response, Partial Response, Stable Disease, Progressive Disease, Not Applicable (Therapy Ongoing), Unknown | Indicate the patient's outcome (response) at the end of this treatment regimen. 2857291 |

Principal Investigator or Designee Signature  ________________________________ Print Name  ________________________________ Date  __/__/___
APPENDIX B: Checklist of Task Completion for Sample Submission

Date:
Institution:
Operator:

- Do you have an IRB-approved protocol?
- Have you sent your Institutional Certification to the Project Team and NCH?
- Have you consented the patient?
- Have you obtained the project-assigned ID and labels from the Project Team?
- Do you have at least one frozen tissue section (≤ 100 mg each) in individual cryovials? Are the cryovials labeled with only the freezer-resistant labels from the Project Team?
- Do you have frozen non-tumoral cells? Are they labeled with the freezer-resistant labels from the Project Team?
- Do you have a formalin-fixed paraffin embedded (FFPE) tissue block (or sixteen [16] unstained 4 µm sections from the formalin-fixed block mounted on adhesive (e.g. poly-L-lysine or APTS) coated glass slides)? Are they labeled with the freezer-resistant labels from the Project Team?
- Have you sent the FFPE tissue block or unstained sections for central pathology review? Have you received notification from OCG that the samples qualify for study inclusion?
- Have you ordered a cryoport?
- Do you have the clinical data elements required by the project? (Appendix A). Have you received notification from OCG to send the clinical data elements electronically to NCH following molecular QC of the samples?

You may ship samples ONLY once all of the questions above are answered “YES.”

Follow the flowchart on the next page for additional guidance.
Introduction

To assure the privacy of all human subjects that have consented to donate their tissues and clinical data to the Burkitt Lymphoma Genome Sequencing Project (BLGSP), all materials given to the project must be de-identified prior to shipment and study. This project-assigned ID must have a rational structure that permits tracking of which tissue source site (TSS) and case is labeled.

Adopted Standards

Samples contributed to the BLGSP must be labeled with a project-assigned ID obtained from the Data Coordinating Center (DCC, see BLGSP SOP #300) by the TSS prior to shipment. These codes must have the following form:

BLGSP – 71 - ## - ###### - ##X - ##Y

Where:

1. BLGSP stands for Burkitt Lymphoma Genome Sequencing Project
2. 71 is the tumor code for Non-Hodgkin’s lymphoma, Burkitt lymphoma
3. The next two digits identify the Tissue Source Site
4. The next five digits are the case identifier
5. The next three characters
   a. The two digits specify the tissue code (see table on next page)
   b. The letter identifies the aliquot/section of the sample
6. The final three characters denote the nucleic acid code if applicable (see list on next page)
7. Cases that have been cell sorted should have a “.1” between the tissue code and nucleic acid code (eg BLGSP-71 - ## - ###### - ##X.1 - ##Y). Contact OCG immediately if submitting samples that have been cell sorted.
<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Description</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Tumor</td>
<td>Primary Solid Tumor</td>
<td>01</td>
</tr>
<tr>
<td>Recurrent Tumor</td>
<td>Recurrent Solid Tumor</td>
<td>02</td>
</tr>
<tr>
<td>Primary Blood Cancer</td>
<td>Primary Blood Derived Cancer – Peripheral blood</td>
<td>03</td>
</tr>
<tr>
<td>Recurrent Blood Cancer</td>
<td>Recurrent Blood Derived Cancer - Bone Marrow</td>
<td>04</td>
</tr>
<tr>
<td>Addtl - New Primary</td>
<td>Additional - New Primary</td>
<td>05</td>
</tr>
<tr>
<td>Metastatic</td>
<td>Metastatic</td>
<td>06</td>
</tr>
<tr>
<td>Addtl Metastatic</td>
<td>Additional Metastatic</td>
<td>07</td>
</tr>
<tr>
<td>Post neo-adjuvant therapy</td>
<td>Tissue disease-specific post-adjuvant therapy</td>
<td>08</td>
</tr>
<tr>
<td>Primary Blood Cancer BM</td>
<td>Primary Blood Derived Cancer – Bone Marrow</td>
<td>09</td>
</tr>
<tr>
<td>Blood Derived Normal</td>
<td>Blood Derived Normal</td>
<td>10</td>
</tr>
<tr>
<td>Solid Tissue Normal</td>
<td>Solid Tissue Normal</td>
<td>11</td>
</tr>
<tr>
<td>Buccal Cell Normal</td>
<td>Buccal Cell Normal</td>
<td>12</td>
</tr>
<tr>
<td>EBV Normal</td>
<td>EBV Immortalized Normal</td>
<td>13</td>
</tr>
<tr>
<td>BM Normal</td>
<td>Bone Marrow Normal</td>
<td>14</td>
</tr>
<tr>
<td>Fibroblast Normal</td>
<td>Fibroblasts from Bone Marrow Normal</td>
<td>15</td>
</tr>
<tr>
<td>Mononuclear Cell Normal</td>
<td>Mononuclear Cells from Bone Marrow Normal</td>
<td>16</td>
</tr>
<tr>
<td>Lymphoid Normal</td>
<td>Lymphatic Tissue Normal (including centroblasts)</td>
<td>17</td>
</tr>
<tr>
<td>Cell Line Control</td>
<td>Cell Line Control (Control Analyte)</td>
<td>20</td>
</tr>
<tr>
<td>Recurrent Blood Cancer</td>
<td>Recurrent Blood Derived Cancer – Peripheral blood</td>
<td>40</td>
</tr>
<tr>
<td>Post treatment Blood Cancer</td>
<td>Blood Derived Cancer- Bone Marrow, Post-treatment</td>
<td>41</td>
</tr>
<tr>
<td>BM Marrow</td>
<td>Blood Derived Cancer- Peripheral Blood, Post-treatment</td>
<td>42</td>
</tr>
<tr>
<td>Cancer cell line</td>
<td>Cell line from patient tumor</td>
<td>50</td>
</tr>
<tr>
<td>Xenograft, primary</td>
<td>Xenograft from patient not grown as intermediate on plastic tissue culture</td>
<td>60</td>
</tr>
<tr>
<td>Xenograft, cell-line derived</td>
<td>Xenograft grown in mice from established cell lines</td>
<td>61</td>
</tr>
<tr>
<td>Granulocytes</td>
<td>Granulocytes after a Ficoll separation</td>
<td>99</td>
</tr>
</tbody>
</table>

Nucleic acid codes

- 01D = DNA, unamplified, from the first isolation of a tissue
- 01E = DNA, unamplified, from the first isolation of a tissue embedded in FFPE
- 01W = DNA, whole genome amplified by Qiagen (one independent reaction)
- 01X = DNA, whole genome amplified by Qiagen (a second, separate independent reaction)
- 01Y = DNA, whole genome amplified by Qiagen (pool of “W” and “X” aliquots)
- 01R = RNA, from the first isolation of a tissue
- 01S = RNA, from the first isolation of a tissue embedded in FFPE

Note: If additional isolations are needed from the same tissue aliquot, the # would change to 02D, etc.
Introduction

The National Cancer Institute’s Office of Cancer Genomics (OCG) has developed an initiative to generate a database of comprehensive molecular changes in Burkitt Lymphomas. The Burkitt Lymphoma Genome Sequencing Project (BLGSP) aims to generate large scale, high-quality data on the cancers’ genomes and transcriptomes using 2\textsuperscript{nd} and 3\textsuperscript{rd} generation sequencing technology. The data collected will allow scientists to identify genetic alterations in individuals with the various subtypes of Burkitt Lymphoma.

Scope and Purpose

1. To establish a procedure for tissue processing and storage at Tissue Source Sites (TSSs).
2. This protocol applies to all TSSs providing tissues prospectively.
3. Any deviation from this protocol should be noted in the lab notebook, indicating the nature of the deviation, times, and which samples were affected. This information should be given within 48 hours of the occurrence to the Project Team (PT) representative by sending an email (see BLGSP SOP #300) with the details.

Safety Precautions

1. Wear personal protective equipment (PPE) such as lab coats and gloves.
2. Liquid nitrogen is extremely cold and can cause ‘burns’. Wear gloves that are made to withstand liquid nitrogen, eye protection (preferably face shield) and a lab coat to protect skin from splashes and spills. Liquid nitrogen is an asphyxiant; use in a well-ventilated area.
3. Acute overexposure to formaldehyde solutions and/or vapors causes severe eye, skin, and respiratory tract irritation.

Equipment and Materials

Note: The vendors/part numbers listed below for each item are only suggestions and primarily intended to provide examples of the needed items. It is permissible to order another product with equivalent specifications. Contact the Project Team representative if you have questions.
1. Personal protective equipment (PPE) to include nitrile gloves, heavy duty gloves, eye protection (preferably face shield), lab coat, and closed-toe shoes
2. Plastic cassette mold(s) for formalin fixation
3. Cryovials (e.g. 2 mL vials from ChartBiomed, Part Number 10778828)
4. Freezer-resistant labels with project-assigned ID (obtained from Project Team representative, see BLGSP SOP #303 and #304)
   a. Set of eighteen (18) labels ending in -01 to be affixed to the FFPE block or sixteen (16) unstained FFPE sections of the BL tumor.
   b. Set of six (6) labels ending in -01X, where X is a letter from A to F, to be affixed to the cryovials containing frozen BL tissue.
   c. Set of ten (10) labels ending in the case ID to be affixed to the 15 mL conical tube used in formalin fixation.
5. Dewar thermo-flask, 1 L (e.g. Fisher Scientific Catalog Number 03-692-155)
6. Isopentane (2-methylbutane, certified) (e.g. Fisher Chemical Catalog Number O3551-4)
7. Liquid Nitrogen
8. Formalin (10% solution)
9. 15 mL conical tube (e.g. polypropylene tubes from BD Biosciences, Part Number 352097)
10. Fine point Cryomarker (e.g. Nalge Nunc Cryomarker Black #6313-0020)
11. Ice bucket
12. Dry ice
13. Three-prong beaker tongs, (e.g. Fisher Scientific Catalog Number 15-212)
14. Sterile forceps (e.g. Fisherbrand fine point forceps, Catalog Number 22-327-379)
15. Long forceps, 8-12” (e.g. Fisher Scientific Catalog Number 10-316B)
16. Metal beaker, 100 mL (e.g. Fisher Scientific Catalog Number 02-583A)
17. Sterile scalpel
18. Sterile dissection tray
19. Scale
20. Timer

Mark all containers with the freezer-resistant labels carrying the patient’s project-assigned ID obtained from the Project Team representative prior to surgery.

Procedure

A. Tissue diagnosed as Burkitt lymphoma should be processed as follows:
   1. Wearing sterile gloves, using a sterile scalpel, on a sterile dissection tray, cut the tissue into multiple 2 mm thin sections.
   2. Place tissue into various containers as follows:
      i. 24-hour formalin fixation: Fix at least two representative tissue pieces in a labeled 15 mL conical tube containing 10% formalin solution. Tissue in formalin should be no more than 2 mm in thickness for proper fixation. Prepare a formalin-fixed paraffin embedded (FFPE) tissue block from each fixed tissue piece. Submit 1 block to your Histology Lab for diagnosis. Submit the other block, or sixteen [16] unstained 4 µm sections on adhesive
(e.g. poly-L-lysine or APTS) coated glass slides, to the Pathology Coordinator (see BLGSP SOP #303) using the labels provided by the OCG.

ii. **Freezing tissue**: Select one to six representative pieces of tissue each measuring about 10 x 10 x 2 mm in dimension (approximately 100 mg). Do not freeze tissue pieces larger than this size or mass. Use a scale to ensure mass is 100 mg or less. If you have a larger tissue piece, cut it into smaller pieces and freeze them separately. Freeze as many pieces as possible. At least one piece is required. Do not freeze the tissue with Freon.

**Note:** Perform snap freezing of fresh tissue ASAP
- It is generally accepted that for the best tissue preservation snap freezing should take place within 20 minutes after tissue is excised from the patient.
- Do not perform snap freezing with bare hands. Wear gloves at all times and heavy duty gloves when working with liquid nitrogen, dry ice, or cooled isopentane.

a. **Set Up Freezing Station**
   1) Fill a small 100 mL metal beaker with about 40 mL isopentane.
   2) Fill the Dewar thermo-flask about 1/3 full with liquid nitrogen.

   Use extreme caution when dispensing liquid nitrogen.

b. **Label Cryovials** (as many as needed for the tissue quantity obtained from tumor)
   1) Use a cryovial for tissue snap freezing.
   2) Label cryovials with freezer-resistant labels obtained from the PT representative prior to surgery (see BLGSP SOP #303).

c. **Freezing Tissue in Cryovials**
   1) Put one piece of tissue (no more than 100 mg) into one labeled cryovial, using a pair of forceps washed in 70% ethanol.
   2) Screw on the cap tightly or else isopentane will seep into the vial.
   3) Store the tissue-containing cryovials awaiting freezing by placing them on dry ice in an ice bucket.
   4) Repeat steps 1 through 3 for additional tissue pieces.
   5) Use beaker tongs to very carefully lower the 100 mL metal beaker containing isopentane halfway into the liquid nitrogen for cooling. The liquid nitrogen will boil as the beaker is lowered, when the isopentane is reaching its freezing point the tone of the boiling will increase for 2-3 seconds.
   6) Use beaker tongs to lift the beaker out of the liquid nitrogen once you see beads of solid isopentane at the bottom of the beaker (about 2 minutes).
   7) Use long forceps to hold one to three cryovials down into the cooled isopentane. Hold for at least 1 minute.
   8) Use the long forceps to take out the cryovials containing frozen tissue.
   9) Store frozen cryovial(s) in liquid Nitrogen storage tanks.
   10) If there are more than three cryovials to be frozen, repeat steps 5-9.

B. **Complete the Sample Submission Form (SSF)** (see example below). **Patient information must be de-identified.**

C. Any questions regarding this protocol should be directed to the BLGSP Project Team representative (see BLGSP SOP #300).
Sample Submission Form
Burkitt Lymphoma Genome Sequencing Project (BLGSP)

Instructions: This form should be completed for all cases submitted for BLGSP, prior to the shipment of samples to Nationwide Children’s Hospital.

Questions regarding this form should be directed to the Office of Cancer Genomics (OCG).

Tissue Source Site (TSS) acknowledges that the Biospecimen Processing Core (BPC) will assess the tissue quality of the frozen biospecimen to determine whether it meets the metrics required by BLGSP. If the BPC identifies a possible discrepancy, the TSS authorizes the BPC to report these results to the TSS by means of a formal report in confidential email format for the quality assurance program of the TSS to address.

Tissue Source Site (TSS): ___________________________ TSS Identifier: ___________ TSS Unique Patient Identifier: ______________________

Completed by (interviewer name in OpenClinica): ________________ Completed Date: ___/___/______

Verification of BLGSP Requirements
Prior to the shipment of samples to the BPC, the TSS must answer the following questions to verify that BLGSP requirements are met. For a complete list of requirements, please contact the Office of Cancer Genomics.

<table>
<thead>
<tr>
<th>#</th>
<th>Question</th>
<th>Entry Alternatives</th>
<th>Working Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1*</td>
<td>BLGSP Patient Identifier</td>
<td>___________________________</td>
<td>The patient identifier is part of the BLGSP identifier is provided by the OCG project office and is defined below:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Example: BLGSP-71-05-12345-01-A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>BLGSP: The Burkitt Lymphoma Genome Sequencing Project</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>71: Disease Code for Non-Hodgkin’s Lymphoma, Burkitt lymphoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>05: Tissue Source Site Identifier</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>12345: Sample/Patient Identifier</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>01: This defines the type of sample submitted.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>A: This defines the aliquot/portion of the sample submitted.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Please provide only the patient identifier, not the entire BLGSP identifier.</td>
</tr>
<tr>
<td>2*</td>
<td>Tumor Type</td>
<td>☐ Primary Untreated Malignant Tumor Tissue</td>
<td>Indicate the tumor category of the tumor submitted for BLGSP. If tumor type is other than</td>
</tr>
<tr>
<td></td>
<td></td>
<td>☐ Metastatic Malignant Tumor Tissue</td>
<td>primary untreated malignant tumor tissue, contact OCG for assistance.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>☐ Recurrent Malignant Tumor Tissue</td>
<td>3288124</td>
</tr>
<tr>
<td></td>
<td></td>
<td>☐ Additional Primary Malignant Tumor Tissue</td>
<td></td>
</tr>
<tr>
<td>3*</td>
<td>Histological Subtype</td>
<td>☐ Burkitt Lymphoma</td>
<td>Indicate the histologic subtype for the tumor sample being submitted.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3081934</td>
</tr>
<tr>
<td>4*</td>
<td>Burkitt Lymphoma Clinical Variant</td>
<td>☐ Sporadic, Adult</td>
<td>Provide the clinical variant of the Burkitt Lymphoma case submitted for BLGSP.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>☐ Sporadic, Pediatric</td>
<td>3770421</td>
</tr>
<tr>
<td></td>
<td></td>
<td>☐ Endemic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>☐ Immunodeficiency-associated, Adult</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>☐ Immunodeficiency-associated, Pediatric</td>
<td></td>
</tr>
<tr>
<td>5*</td>
<td>History of Other Malignancy (Including ALL Prior and Synchronous Malignancies)</td>
<td>☐ Yes (exclusionary, see note at right)</td>
<td>Indicate whether the patient has a history of malignancies, including synchronous or</td>
</tr>
<tr>
<td></td>
<td></td>
<td>☐ No</td>
<td>bilateral malignancies. If the patient has a prior or synchronous malignancy, excluding</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>in situ cervical cancer or non-melanoma skin cancer, the case is not eligible for BLGSP.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3382736</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In situ cervical cancer and non-melanoma skin cancer are allowable.</td>
</tr>
<tr>
<td>6*</td>
<td>History of Neoadjuvant Treatment (prior to procurement) of Tumor Submitted for BLGSP</td>
<td>☐ Yes (exclusionary, see note at right)</td>
<td>Indicate whether the patient received therapy for the tumor submitted for BLGSP prior to</td>
</tr>
<tr>
<td></td>
<td></td>
<td>☐ No</td>
<td>the sample procurement. If the patient did receive treatment prior to procurement, the case</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>is not eligible for BLGSP. Any systemic or localized (those administered to the same site as</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>the BLGSP submitted tissue) therapies given prior to the procurement of the sample submitted</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>for BLGSP are exclusionary.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3382737</td>
</tr>
</tbody>
</table>
**Sample Submission Form**  
Burkitt Lymphoma Genome Sequencing Project (BLGSP)

<table>
<thead>
<tr>
<th>#</th>
<th>Question</th>
<th>Entry Alternatives</th>
<th>Working Instructions</th>
</tr>
</thead>
</table>
| 7*  | Consent Status                    | □ Formally Consented  
□ Consented by Death  
□ Exemption (see note at right)  
□ Waiver (see note at right) | Indicate whether the patient was formally consented, consented by death, or if the case  
has an exemption or waiver for consent.  
Exemptions and waivers for consent must be approved by OCG. 3288361 |
| 8†  | Date of Formal Consent            | ![Month, Day, Year](month, day, year)                                               | If the patient was formally consented, provide the month of consent.  
3081955 (month), 3081957 (day), 3081959 (year) |
| 9†  | Date of Death                     | ![Month, Day, Year](month, day, year)                                               | If the patient consented by death (i.e. they did not formally consent), provide the month  
of death.  
Do not complete if the patient formally consented.  
2897026 (month), 2897028 (day), 2897030 (year) |

**Tumor Information**

The following information must be completed for each vial submitted to the BPC.

The tumor sample ID is part of the BLGSP identifier is provided by the OCG project office and is defined below:

**BLGSP:** The Burkitt Lymphoma Genome Sequencing Project  
**71:** Disease Code for Non-Hodgkin’s Lymphoma, Burkitt lymphoma  
**05:** Tissue Source Site Identifier  
**12345:** Sample/Patient Identifier  
**01:** This defines the type of sample submitted (i.e. primary tumor = 01, normal blood =10). For a complete list see BLGSP SOP #007.

A: This defines the aliquot/portion of the sample submitted. If multiple portions of the same sample are submitted they would have multiple IDs with A, B, C, etc. added to the sample ID.

**The tumor sample ID is part of the BLGSP identifier is provided by the OCG project office and is defined below:**

### Sample Submission Form

<table>
<thead>
<tr>
<th>Tumor Sample ID</th>
<th>Vial ID</th>
<th>Tumor Sample Type</th>
<th>Preservation Method</th>
<th>Total Number of Cells Counted</th>
</tr>
</thead>
<tbody>
<tr>
<td>3288096</td>
<td>2186575</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vial ID</td>
<td>3812626</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preservation Method</td>
<td>5120693</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Number of Cells Counted</td>
<td>2006887</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Working Instructions**

- **Portion**
- **Block**
- **Scroll**
- **Unstained Slide**
- **Sorted Cells** *(please provide flow cytometry report, see #19)*

**Preservation Method**

- **FFPE**
- **Frozen**

---

*(please provide flow cytometry report, see #19)*
<table>
<thead>
<tr>
<th>#</th>
<th>Question</th>
<th>Entry Alternatives</th>
<th>Working Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>Method of Tumor Sample Procurement</td>
<td>☐ Bone Marrow Aspirate&lt;br&gt;☐ Excisional Biopsy&lt;br&gt;☐ Incisional Biopsy&lt;br&gt;☐ Needle Biopsy&lt;br&gt;☐ Surgical Resection&lt;br&gt;☐ Other (Please Specify)</td>
<td>Indicate the procedure performed to obtain the malignant tissue submitted for BLGSP.</td>
</tr>
<tr>
<td>16</td>
<td>Other Method of Tumor Sample Procurement</td>
<td>☐ Adrenal Gland&lt;br&gt;☐ Appendix&lt;br&gt;☐ Ascites&lt;br&gt;☐ Bladder&lt;br&gt;☐ Bone&lt;br&gt;☐ Bone Marrow&lt;br&gt;☐ Brain&lt;br&gt;☐ Breast&lt;br&gt;☐ Colon&lt;br&gt;☐ Epididymis&lt;br&gt;☐ Epidural Space&lt;br&gt;☐ Esophagus&lt;br&gt;☐ Eye&lt;br&gt;☐ Gallbladder&lt;br&gt;☐ Heart&lt;br&gt;☐ Kidney&lt;br&gt;☐ Larynx&lt;br&gt;☐ Leptomeninges&lt;br&gt;☐ Liver&lt;br&gt;☐ Lung&lt;br&gt;☐ Lymph Node(s), axillary&lt;br&gt;☐ Lymph Node(s), cervical&lt;br&gt;☐ Lymph Node(s), epitrochlear&lt;br&gt;☐ Lymph Node(s), femoral&lt;br&gt;☐ Lymph Node(s), hilar&lt;br&gt;☐ Lymph Node(s), iliac&lt;br&gt;☐ Lymph Node(s), iliac-common&lt;br&gt;☐ Lymph Node(s), iliac-external&lt;br&gt;☐ Lymph Node(s), mediastinal&lt;br&gt;☐ Lymph Node(s), mesenteric&lt;br&gt;☐ Lymph Node(s), occipital&lt;br&gt;☐ Lymph Node(s), paraaortic&lt;br&gt;☐ Lymph Node(s), parotid&lt;br&gt;☐ Lymph Node(s), popliteal&lt;br&gt;☐ Lymph Node(s), retroperitoneal</td>
<td>If the procedure performed to obtain the malignant tissue is not included in the provided list, indicate the procedure performed.</td>
</tr>
<tr>
<td>17</td>
<td>Anatomic Site of Frozen Biospecimen</td>
<td>☐ Lymph Node(s), splenic&lt;br&gt;☐ Lymph Node(s), submandibular&lt;br&gt;☐ Lymph Node(s), supraclavicular&lt;br&gt;☐ Mandible&lt;br&gt;☐ Maxilla&lt;br&gt;☐ Mediastinal Soft Tissue&lt;br&gt;☐ Nasal Soft Tissue&lt;br&gt;☐ Nasopharynx&lt;br&gt;☐ Ocular orbits&lt;br&gt;☐ Oral Cavity&lt;br&gt;☐ Oropharynx&lt;br&gt;☐ Ovary&lt;br&gt;☐ Pancreas&lt;br&gt;☐ Parotid Gland&lt;br&gt;☐ Pericardium&lt;br&gt;☐ Peri-orbital Soft Tissue&lt;br&gt;☐ Peripheral Blood&lt;br&gt;☐ Pleura&lt;br&gt;☐ Prostate&lt;br&gt;☐ Rectum&lt;br&gt;☐ Salivary Gland&lt;br&gt;☐ Sinus(es)&lt;br&gt;☐ Skin&lt;br&gt;☐ Small Intestine&lt;br&gt;☐ Soft Tissue <em>(muscle, ligaments, subcutaneous)</em>&lt;br&gt;☐ Stomach&lt;br&gt;☐ Testicle&lt;br&gt;☐ Thymus&lt;br&gt;☐ Thyroid gland&lt;br&gt;☐ Uterus&lt;br&gt;☐ Other, please specify</td>
<td>Indicate the anatomic site of the frozen biospecimen tumor tissue sample.</td>
</tr>
<tr>
<td>18</td>
<td>Other Anatomic Site of Frozen Biospecimen</td>
<td>☐ Lymph Node(s), axillary&lt;br&gt;☐ Lymph Node(s), cervical&lt;br&gt;☐ Lymph Node(s), epitrochlear&lt;br&gt;☐ Lymph Node(s), femoral&lt;br&gt;☐ Lymph Node(s), hilar&lt;br&gt;☐ Lymph Node(s), iliac&lt;br&gt;☐ Lymph Node(s), iliac-common&lt;br&gt;☐ Lymph Node(s), iliac-external&lt;br&gt;☐ Lymph Node(s), mediastinal&lt;br&gt;☐ Lymph Node(s), mesenteric&lt;br&gt;☐ Lymph Node(s), occipital&lt;br&gt;☐ Lymph Node(s), paraaortic&lt;br&gt;☐ Lymph Node(s), parotid&lt;br&gt;☐ Lymph Node(s), popliteal&lt;br&gt;☐ Lymph Node(s), retroperitoneal</td>
<td>Name of the anatomic site of a frozen biospecimen that is different from those already specified.</td>
</tr>
<tr>
<td>19</td>
<td>Date of Tumor Sample Procurement</td>
<td>☐ Month ☐ Day ☐ Year</td>
<td>Provide the date of the procedure performed to obtain the malignant tissue submitted for BLGSP.</td>
</tr>
</tbody>
</table>
Normal Control Information
The following information must be completed for the normal control sample submitted for BLGSP and should be answered specifically about the submitted control(s). If multiple normal control types are submitted, ALL QUESTIONS should be completed for each sample. If multiple vials of the same normal control are submitted, the “Normal Control Sample Information” must be completed for each vial submitted to the BPC.

<table>
<thead>
<tr>
<th>Normal Control ID</th>
<th>Vial ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>3288138</td>
<td>2186575</td>
</tr>
</tbody>
</table>

Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID.

Provide the vial ID. If multiple vials are submitted, each normal sample needs a unique ID.

# Question | Entry Alternatives | Working Instructions |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>23</td>
<td>Type(s) of Normal Control(s) Check all that apply</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Whole Blood*</td>
<td>Indicate the type(s) of normal control(s) submitted for this case.</td>
</tr>
<tr>
<td></td>
<td>Buccal Cells</td>
<td>*These normal controls are only allowable if there is NO evidence of Burkitt Lymphoma in the peripheral blood.</td>
</tr>
<tr>
<td></td>
<td>Granulocytes</td>
<td>3081936</td>
</tr>
<tr>
<td></td>
<td>Lymphocytes (buffy coat)*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Extracted DNA from Blood*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Extracted DNA from Buccal Cells</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mononuclear Cells from Bone Marrow Normal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Normal Tissue</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sorted Cells (please provide flow cytometry report, see #33)</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Method of Normal Control Procurement</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Blood Draw</td>
<td>Indicate the procedure performed to obtain the normal control sample submitted for BLGSP.</td>
</tr>
<tr>
<td></td>
<td>Buccal Swab</td>
<td>3288147</td>
</tr>
<tr>
<td></td>
<td>Mouthwash</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bone Marrow Aspirate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Surgical Resection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Other Method of Normal Control Procurement</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Date of Normal Control Procurement</td>
<td></td>
</tr>
<tr>
<td></td>
<td>_______ _______ _______ _______ _______ _______</td>
<td>Provide the date of the procedure performed to obtain the normal control submitted for BLGSP.</td>
</tr>
<tr>
<td></td>
<td>Month Day Year</td>
<td>3288195 (month), 3288196 (day), 3288197 (year)</td>
</tr>
<tr>
<td>27</td>
<td>Extracted DNA Quantity of Normal Control</td>
<td></td>
</tr>
<tr>
<td></td>
<td>___________________________ (µg)</td>
<td>If the normal control type is extracted DNA, provide the quantity (µg) of the normal control sample sent to the BPC for BLGSP.</td>
</tr>
<tr>
<td>28</td>
<td>Extracted DNA Quantification Method of Normal Control</td>
<td></td>
</tr>
<tr>
<td></td>
<td>___________________________</td>
<td>If the normal control type is extracted DNA, provide the quantification method of the normal control sample sent to the BPC for BLGSP.</td>
</tr>
<tr>
<td>29</td>
<td>Extracted DNA Concentration of Normal Control</td>
<td></td>
</tr>
<tr>
<td></td>
<td>___________________________ (µg/µL)</td>
<td>If the normal control type is extracted DNA, provide the concentration (µg/µL) of the normal control sample sent to the BPC for BLGSP.</td>
</tr>
</tbody>
</table>
### Sample Submission Form
Burkitt Lymphoma Genome Sequencing Project (BLGSP)

<table>
<thead>
<tr>
<th>Question</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>30† Extracted DNA Volume of Normal Control</strong></td>
<td>If the normal control type is extracted DNA, provide the volume (µL) of the normal control sample sent to the BPC for BLGSP.</td>
</tr>
<tr>
<td><strong>31† Anatomic Site of Normal Sample</strong></td>
<td>If the normal control type is normal tissue or sorted cells, indicate the anatomic site of the non-neoplastic control tissue submitted for BLGSP.</td>
</tr>
<tr>
<td><strong>32† Other Anatomic Site of Normal Sample</strong></td>
<td>Text to describe another anatomic site of the normal tissue not previously mentioned or specified.</td>
</tr>
<tr>
<td><strong>33† Distance of Normal Tissue from Tumor</strong></td>
<td>If the normal control type is normal tissue or sorted cells, confirm that the submitted tissue was at least 2cm away from the primary tumor.</td>
</tr>
<tr>
<td><strong>34† Total Number of Cells Counted for the Normal Sample</strong></td>
<td>If the normal control type is sorted cells, provide the number of cells counted.</td>
</tr>
<tr>
<td><strong>35 De-Identified Reports Associated with Normal Sample</strong></td>
<td>Associated reports may include: flow cytometry report, pathology report, immunohistochemistry reports, etc. All reports should be de-identified prior to sending to the BPC.</td>
</tr>
</tbody>
</table>

*Questions required for submission
†Questions conditionally required for submission (i.e. required based on the answer provided for a prior question)

I acknowledge that the above information provided by my institution is true and correct and has been quality controlled.
BLGSP SOP #315: 
Processing FFPE Samples for the Burkitt Lymphoma Genome Sequencing Project: Collecting FFPE tissue scrolls

Introduction

The National Cancer Institute’s Office of Cancer Genomics (OCG) has developed an initiative to generate a database of comprehensive molecular changes in Burkitt Lymphomas. The Burkitt Lymphoma Genome Sequencing Project (BLGSP) aims to generate large scale, high-quality data on the cancers’ genomes and transcriptomes using 2nd and 3rd generation sequencing technology. Case-matched normal control tissue is required to exclude DNA alterations that are not tumor-specific. For BLGSP, the preferred normal control tissue is granulocytes isolated from whole blood.

Tissues that have been formalin-fixed and paraffin-embedded (FFPE) present a challenge to molecular biology. Formalin fixation causes a wide variety of chemical modifications and damage to nucleic acid, including crosslinking and strand breaks. Paraffin embedding renders tissues insoluble in common molecular biology buffers and aggregates nucleic acid in a manner that lowers quality further complicates efficient extraction.

Shipping a whole FFPE block is the preferred method for the processing site to perform necessary molecular QC analysis followed by tissue extraction. If this is not feasible, creation and shipment of tissue scrolls is permissible. This protocol uses a simple calculator to determine the number of tissue scrolls needed to be cut to yield a sufficient amount of DNA and RNA for whole genome and whole transcriptome purposes, respectively.

Scope and Purpose

1. To establish a common procedure for collecting a sufficient amount of tissue from FFPE tissue.
2. This protocol applies to all TSSs providing tissues that were not rapidly frozen tumor tissues that were stored properly.
3. Any deviation from this protocol should be noted in the lab notebook, indicating the nature of the deviation, times, and which samples were affected. This information should be given within 48 hours of the deviation to the Project Team (PT) representative by sending an email (see BLGSP SOP #300) with the details.

Safety Precautions

1. Wear personal protective equipment (PPE) such as lab coats and gloves.
Quality Control

1. Freezer-resistant labels with project-assigned ID (from PT representative, see BLGSP SOP #303 and #304). Set of three (3) labels ending in -01X, where X is a letter from A to S, to be affixed to the cryovials DNA and RNA from processed FFPEs.

Equipment and Materials

Fix assigned labels for all containers with the patient project-assigned ID labels obtained prior to the start of the procedure.

Procedure

1. Prior the processing and shipment of FFPE material for purposes of genomic sequencing, the BLGSP case must have passed central pathology review and the site must receive notification from the program office that the case is approved for shipment to the Biospecimen processing core (BPC).

2. In the absence of frozen tumor tissue, an FFPE block may be shipped to the BPC following notification from the program office. If an FFPE block cannot be shipped, the following tissue scroll procedure can be used.

3. Contact the BCR to obtain a shipping label for the tissue material to be sent. The BCR will provide you with a scroll calculator to determine the number of scrolls to cut to create 12 mm$^3$ of tissue. The scroll calculator protocol can be downloaded from the CGCI webpage (URL).

4. If collecting tissue scrolls, please use the following steps:
   a. **Cut a 4 µm slice and stain the slide with H&E stain as a top stain for pathology review**
   b. Measure length and width (in mm) of tissue specimen surface within paraffin block (see figure below)
   c. Double click on excel table provided by the BCR (example shown below) to open editing function. (URL)
   d. Enter tumor length and width values measured in step b and cut the number of 10 micrometer scrolls required to create 12mm$^3$ is shown in yellow
   e. Put scrolls in tube for shipping (Eppendorf or cryovial)
   f. **Cut a 4 µm top slide and stain with H&E stain as a bottom slide for pathology review**
   g. Ship tube of scrolls and the two H&E stained slides immediately to the BCR at ambient temperature within 24 hours (with cold pack April-September)
### Scroll Calculator

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enter tissue area width:</td>
<td>12 mm</td>
</tr>
<tr>
<td>Enter tissue area length:</td>
<td>12 mm</td>
</tr>
<tr>
<td>Enter scroll thickness:</td>
<td>10 microns</td>
</tr>
<tr>
<td>(please submit 10 micron scrolls)</td>
<td></td>
</tr>
<tr>
<td>How much volume of tissue do you need?</td>
<td>12 mm³</td>
</tr>
<tr>
<td>Cut this many scrolls &gt;&gt;&gt;</td>
<td>8</td>
</tr>
</tbody>
</table>

### Example #1

Length = 12 mm
Width = 4 mm

To calculate the number of 10μM thick scrolls: 

\[
\text{Number of Scrolls} = \frac{12}{(0.01 \times L \times W)}
\]

**Example #1 Answer**

\[
\text{Example #1 Answer} = \frac{12}{(0.01 \times 12 \times 4)} = 25 \text{ Scrolls}
\]

### Example #2

Length = 8 mm
Width = 8 mm

**Example #2 Answer**

\[
\text{Example #2 Answer} = \frac{12}{(0.01 \times 8 \times 8)} = 19 \text{ Scrolls}
\]
BLGSP SOP #316:
Use of a Single FFPE block for the Dual Purpose of Central Pathology and Molecular Characterization

Introduction

The National Cancer Institute’s Office of Cancer Genomics (OCG) has developed an initiative to generate a database of comprehensive molecular changes in Burkitt Lymphomas. The Burkitt Lymphoma Genome Sequencing Project (BLGSP) aims to generate large scale, high-quality data on the cancers’ genomes and transcriptomes using sequencing by synthesis technology.

Accrual of frozen tissue can be a challenge for any tissue source site. Thus, BLGSP allows the use of FFPE tissue in place of frozen tissue if the latter is unavailable. In rare circumstances (e.g. if only one FFPE block is available for a case), that FFPE block can be used for both central pathology review and sequencing. Please note that there is a higher failure rate of entry into the project since there may not be enough tissue left for extraction of nucleic acids.

This protocol dictates how an FFPE block should be submitted for the dual purposes of central pathology services and molecular characterization.

Scope and Purpose

1. To establish a standard procedure for using a single FFPE block for the dual purpose of central pathology and molecular characterization.
2. This protocol applies to all TSSs providing tissues in the absence of frozen tumor tissue, scrolls or a 2nd FFPE block.
3. Any deviation from this protocol should be noted in the lab notebook, indicating the nature of the deviation, times, and which samples were affected. This information should be given within 48 hours of the occurrence to the Project Team (PT) representative by sending an email (see BLGSP SOP #300) with the details.

Safety Precautions

1. Wear personal protective equipment (PPE) such as lab coats and gloves.

Quality Control

1. Freezer-resistant labels with project-assigned ID (from PT representative, see BLGSP SOP #303 and #304).
Equipment and Materials

Mark FFPE block(s) with the patient project-assigned ID labels obtained prior to the start of the procedure.

Procedure

1. TSS will inform the OCG program manager that only a single FFPE block for specified cases is available for the Project when they receive the project-specific case labels.
2. The program manager will communicate with the lead central pathologist indicating that the FFPE blocks with the specified project IDs will be used for both central pathology and molecular characterization.
3. BLGSP central pathology will proceed according to BLGSP SOP#309 resulting in IHC and FISH stained slides, and/or TMA construction.
4. The slides along with the original FFPE block will be shipped to Nationwide Children’s Hospital (NCH) unless there is a high chance that additional slides would be needed at a future date as determined by the lead central pathologist based on the preliminary evaluation of the slides.
5. If the FFPE block is not shipped at the same time as the slides, it will be shipped to NCH at a later date, though not later than one month, to be coordinated with the lead central pathologist and OCG program manager.
**BLGSP SOP #306:**
Processing Non-Tumor Samples for the Burkitt Lymphoma Genome Sequencing Project: Blood and Buccal Cells

**Introduction**

The National Cancer Institute’s Office of Cancer Genomics (OCG) has developed an initiative to generate a database of comprehensive molecular changes in Burkitt Lymphomas. The Burkitt Lymphoma Genome Sequencing Project (BLGSP) aims to generate large scale, high-quality data on the cancers’ genomes and transcriptomes using 2nd and 3rd generation sequencing technology. Case-matched normal control tissue is required to exclude DNA alterations that are not tumor-specific. For BLGSP, the preferred normal control tissue is granulocytes isolated from whole blood.

**Scope and Purpose**

1. To establish a common procedure for case-matched normal tissue processing, such as blood or buccal cells, prior to shipment to The Research Institute at Nationwide Children’s Hospital (NCH) by tissue source sites (TSS).
2. This protocol applies to all TSSs providing tissues prospectively.
3. Any deviation from this protocol should be noted in the lab notebook, indicating the nature of the deviation, times, and which samples were affected. This information should be given within 48 hours of the occurrence to the Project Team (PT) representative by sending an email (see BLGSP SOP #300) with the details.

**Safety Precautions**

1. Wear personal protective equipment (PPE) such as lab coats and gloves.
2. Liquid nitrogen is extremely cold and can cause ‘burns’. Wear gloves that are specially made to withstand liquid nitrogen, eye protection (preferably Face Shield), and a lab coat to protect skin from splashes and spills. Liquid nitrogen is an asphyxiant; be sure to use in a well-ventilated area.

**Equipment and Materials**

*Note:* The vendors/part numbers listed below for each item are only suggestions and primarily intended to provide examples of the needed items. It is permissible to order from another vendor...
as long as the product specifications are equivalent. Contact the Project Team representative if you have questions.

1. Common Equipment and Materials
   a. Personal protective equipment (PPE) to include latex or nitrile gloves, heavy duty gloves, eye protection (preferably Face Shield), lab coat, and closed-toe shoes
   b. Micropipettor, 1000 µL, with sterile tips
   c. 50 mL conical polypropylene tubes (e.g. BD Biosciences Part Number 352098)
   d. Clinical Centrifuge with swinging bucket rotor
   e. 250 mL flask containing 50 mL bleach for waste disposal
   f. Cryovials (e.g. 2 mL screw-cap vials, ChartBiomed Part Number 10778828)
   g. Freezer-resistant labels with project-assigned ID (from PT representative, see BLGSP SOP #303 and #304)
      - Set of three (3) labels ending in -10X, where X is a letter from A to C, to be affixed to the cryovials containing white blood cells (buffy coat) processed from patient peripheral blood, if applicable.
      - Set of three (3) labels ending in -99X, where X is a letter from A to C, to be affixed to the cryovials containing granulocytes processed from patient peripheral blood, if applicable.
      - Set of three (3) labels ending in -12X, where X is a letter from A to C, to be affixed to the cryovials containing buccal cells obtained from the patient, if applicable.
   h. Freezing Medium (10% DMSO, 20% FCS, RPMI 1640), 0.2 µm filtered
   i. Phosphate-Buffered Saline (PBS), sterile (e.g. Sigma Aldrich Product D8662)
   j. Dewar thermo-flask, 1 L (e.g. Fisher Scientific Catalog Number 03-692-155)
   k. Liquid nitrogen
   l. Isopentane (2-methylbutane, certified grade) (e.g. Fisher Cat Number O3551-4)
   m. Three-prong beaker tongs (e.g. Fisher Scientific Catalog Number 15-212)
   n. Long forceps, 8-12” (e.g. Fisher Scientific Catalog Number 10-316B)
   o. Metal beaker, 100 mL (e.g. Fisher Scientific Catalog Number 02-583A)
   p. Timer
   q. Fine point Cryomarker (e.g. Nalge Nunc Cryomarker Black #6313-0020)
   r. Disposable, sterile plastic transfer pipets (e.g. Falcon Cat #357524) or sterilized glass Pasteur pipets (e.g. Fisher Scientific Catalog Number 13-678-20A)
   s. 10 mL serological pipets, sterile (e.g. Fisher Scientific Catalog Number 568228D)
   t. Ice bucket
   u. Dry ice

2. For Blood Sample Processing with Blood Fractionation (Part II A 5, below)
   a. Wright-Giemsa Stain (e.g. Sigma Aldrich Product Number WG128)
   b. Two 1” x 3” glass microscope slides
   c. Deionized water, pH 6.8 – 7.2
   d. Red Blood Cell (RBC) Lysis Buffer (0.15 M NH₄Cl, 10 mM KHCO₃, 0.1 mM EDTA in dH₂O, 0.2 µm filtered)
e. Ficoll-Paque PLUS (GE Healthcare Life Sciences, Product Code 17-1440-02)
f. 15 mL Conical polypropylene tubes (e.g. BD Biosciences Part Number 352097)

3. For Blood Sample Processing without Blood Fractionation (Part II A 6, below)
   a. Wright-Giemsa Stain (e.g. Sigma Aldrich Product Number WG128)
   b. Two 1” x 3” glass microscope slides
   c. Deionized water, pH 6.8 – 7.2
   d. Red Blood Cell (RBC) Lysis Buffer (0.15 M NH₄Cl, 10 mM KHCO₃, 0.1 mM EDTA in dH₂O, 0.2 µm filtered)

4. For Buccal Cell Collection with Mouthwash (Part II B 1, below)
   a. Mouthwash (e.g. Scope or Listerine)
   b. Sterilized funnel (optional)

5. For Buccal Cell Collection with Swabs or Brushes (Part II B 2, below)
   a. Microcentrifuge
   b. Buccal swabs or brushes (e.g. Catch-All Sample Swabs, Epicentre Catalog Number QEC89100)
   c. 1.5 mL centrifuge tubes
   d. Vortex
   e. Sterile forceps (e.g. Fisherbrand fine point forceps, Catalog Number 22-327-379)
   f. Scissors
   g. TE buffer (10 mM Tris-HCl, 1mM EDTA-Na₂, pH 8.0, 0.2 µm filtered)

Mark all containers with the patient project-assigned ID labels obtained prior to surgery.

Procedure

A. Blood Sample Processing

1. Collect 10 mL of blood in a tube containing either EDTA or acid citrate dextrose (ACD) anticoagulant labeled with the BLGSP project-assigned ID.

2. Prepare a peripheral blood smear.
   a. Label a 1” x 3” glass microscope slide at one end with the BLGSP project-assigned ID.
   b. Place a 2-3 mm drop of blood on the slide, about 1 cm from the labeled end.
   c. Hold the slide by the narrow sides between the thumb and forefinger of one hand to keep it from sliding on the work surface. The labeled end should be closest to your body.
   d. Hold the second glass microscope slide near one end, between the thumb and forefinger of your other hand.
   e. Place the short edge of the second slide on the labeled slide, about 1 cm farther away from you than the drop of blood.
   f. Pull the second slide back slowly toward the blood drop and allow capillary action to spread the blood until it almost reaches the edges of the second slide.
   g. Tilt the second slide down toward you until it is at a 30 degree angle from the labeled slide, and push it forward (away from you) in a rapid, even motion.
   h. Dispose of the second slide.
i. Allow the smear to dry for about 10 minutes.

3. Stain the peripheral blood smear with Wright-Giemsa stain.
   a. Flood the blood smear slide with 1-2 mL Wright-Giemsa stain. Allow the slide to sit for 1 minute.
   b. Add an equal volume of deionized water to the slide and mix thoroughly by gently blowing on the slide. Allow the slide to sit for 1-3 minutes.
   c. Rinse the slide thoroughly with deionized water and allow to air dry.

4. Examine the peripheral blood smear under a microscope.
   a. Perform a white blood cell differential count.
   b. Record the presence of lymphoid cells that meet morphological criteria for Burkitt Lymphoma:
      • Uniform, medium-sized
      • Round nuclei and one or more basophilic nucleoli
      • Moderately abundant cytoplasm that is deep blue in color and contains multiple vacuoles
   c. If tumor cells are present in the blood, fractionate the blood as soon as possible after collection. Proceed to section II A 5, “Blood Sample Processing with Blood Fractionation”.
   d. If tumor cells are not present in the blood, red blood cell lysis of whole blood and collection of all the nucleated cells is sufficient. Proceed to section II A 6, “Blood Sample Processing without Blood Fractionation”.

5. Blood Sample Processing with Blood Fractionation
   a. In a test-tube rack, label four 50 mL conical tubes with the BLGSP project-assigned ID and (“whole blood”, “Ficoll 1”, “Ficoll 2”, “RBC lysis”) and one 15 mL conical tube with the BLGSP case ID and “granulocytes”.
   b. Prepare an ice bucket with dry ice. Chill two 2 mL cryovials. One vial must be identified with the BLGSP case ID freezer-resistant label from the Project Team (PT) to collect the white blood cells (WBCs) and the second 2 mL cryovial must be identified with the BLGSP case ID freezer-resistant label from the PT to collect the granulocytes. The labels from the PT are obtained prior to surgery (see BLGSP SOP #303).
   c. In the 50 mL conical tube labeled “whole blood”, dilute 10 mL of the whole blood with 40 mL of PBS.
   d. To the 50 mL conical tubes labeled “Ficoll 1” and “Ficoll 2”, add 15 mL of Ficoll-Paque PLUS. Using a 10 mL serological pipet, slowly and carefully layer 25 mL of the diluted blood over the Ficoll-Paque PLUS in each tube by allowing the blood to slowly run down one side of the 50 mL tube. Do not allow the Ficoll and blood to mix.
   e. Centrifuge the two 50 mL tubes containing Ficoll and blood at 400 X g for 30 min at room temperature with the brake off. **NOTE:** Check the user manual for your centrifuge to determine the speed (rpm) necessary to achieve a force of 400 X g.
      • After centrifugation, the blood will be separated into three distinguishable layers: an upper plasma layer, a middle Ficoll layer, and a lower red blood cell
At the interface between the plasma and Ficoll layers there will be a thin layer containing the WBCs, also called the buffy coat. At the interface between the Ficoll and RBC layers there will be a thin layer containing the granulocytes (see Figure).

f. Use a disposable plastic transfer pipet or Pasteur pipet to slowly and carefully aspirate the plasma (upper layer) down to ~1 mm above the buffy coat. Do not disturb the buffy coat. Discard the plasma into a 250 mL flask containing bleach. Repeat this step for the second 50 mL conical tube.

g. Gently recover the buffy coat with a 1000 µL micropipettor with a sterile tip. Try not to uptake the Ficoll (the layer below the buffy coat), as it is toxic to cells.

h. Place the recovered buffy coat into the WBC labeled cryovial cooled on ice from step b.

i. Repeat steps g and h for the second 50 mL conical tube containing Ficoll, pooling the two WBC samples into the same cryovial.

j. Screw on the cryovial cap tightly to prevent isopentane from seeping into the vial.

k. Visually estimate the volume of WBCs recovered using the volume lines on the cryovial and write the information into the datasheet. Buffy coat volume is greater in samples with high WBC counts. Usually you can expect ≤ 1.0 mL total.

l. Use a new plastic transfer pipet or Pasteur pipet to carefully aspirate the Ficoll layer, down to ~0.5 cm from the interface with the RBC layer, into the 250 mL flask containing bleach, taking care not to disturb the granulocyte layer beneath the Ficoll layer. The granulocytes sit on the surface of the RBCs and may be visible as a white haze. Repeat this step for the second 50 mL conical tube containing Ficoll.

m. Use a 1000 µL micropipettor with a sterile tip to recover the bottom of the Ficoll layer, the granulocyte layer, and ~0.5 cm of the top of the RBC layer. The volume will usually be between 0.5 and 2 mL. Place cells into the 50 mL conical tube labeled “RBC lysis”.

n. Repeat step m for the second 50 mL “Ficoll” conical tube, pooling the two granulocyte samples into the same 50 mL conical tube labeled “RBC lysis”.

o. Add 30 mL of RBC Lysis Buffer to the 50 mL “RBC lysis” tube and screw the cap on tightly. Invert gently and incubate at room temperature for 20 minutes, inverting occasionally.

p. Check the color of the contents of the “RBC lysis” tube.
   - If the sample is transparent and red, proceed to step q.
   - If the sample is opaque and red, or visible red blood cells are present, incubate the tubes for an additional 5 minutes, then proceed to step q.

q. Centrifuge the 50 mL “RBC lysis” tube at 300 X g for 10 min at room temperature with
the brake on. **NOTE: Check the user manual for your centrifuge to determine the speed (rpm) necessary to achieve a force of 300 X g.**

r. Gently decant the supernatant, down to 0.5 - 1 cm from the cell pellet, into the 250 mL flask containing bleach. Be careful not to disturb the cell pellet!

s. Check the color of the cell pellet in the 50 ml “RBC lysis” tube.
   - If the pellet is white or pink in color (contains granulocytes and some RBC debris), proceed to step t.
   - If the pellet is red in color (contains many RBCs), repeat steps o – r, then proceed to step t.

t. Wash the granulocyte cell pellet with 10 mL PBS and transfer to the 15 mL tube labeled “granulocytes”.

u. Centrifuge the 15 mL tube containing the granulocytes at 300 X g for 10 minutes with the brake on. **NOTE: Check the user manual for your centrifuge to determine the speed (rpm) necessary to achieve a force of 300 X g.**

v. Gently decant the supernatant, down to ~0.5 cm from the granulocyte cell pellet, into the 250 mL flask containing bleach. Be careful not to disturb the cell pellet.

w. Wash the cell pellet by resuspending it another 10 mL PBS. Centrifuge as in step u and decant the supernatant as in step v.

x. Use the 1000 µL micropipettor with a sterile tip to add 500 µL Freezing Medium to the granulocyte cell pellet. Gently pipet up and down to resuspend the cells.

y. Place the recovered granulocytes into the prepared cooled freezer-resistant labeled cryovial. Screw on the cap tightly to prevent isopentane from seeping into the vial during freezing. Keep the vial on dry ice in an ice bucket.

z. Proceed to section C, “Freezing Collected Cells.”

### 6. Blood Sample Processing without Blood Fractionation

a. In a tube rack, label four 50 mL tubes with the BLGSP project-assigned ID.

b. Prepare an ice bucket with dry ice. Chill one 2 mL cryovial. The vial must be identified with the BLGSP case ID freezer-resistant label from the Project Team (PT) to collect the white blood cells (WBCs). The labels from the PT are obtained prior to surgery (BLGSP SOP #303).

c. Use a sterile serological pipet to add 2.5 mL blood to each of the 50 mL tubes.

d. Add 30 mL RBC Lysis Buffer to each of the 50 mL tubes and screw the caps on tightly.

e. Gently invert the tubes, then incubate at room temperature for 10 minutes, inverting the tubes occasionally.

f. Check the color of the contents of the tubes.
   - If the sample is red in color and transparent, proceed to step g.
   - If the sample is opaque or visible red blood cells are present, incubate the tubes for an additional 5 minutes, then proceed to step g.

g. Centrifuge the four 50 mL tubes at 300 X g for 10 minutes with the brake on. **NOTE: Check the user manual for your centrifuge to determine the speed (rpm) necessary to achieve a force of 300 X g.**

h. Use a plastic transfer pipet, Pasteur pipet, or serological pipet to carefully aspirate the
supernatant, down to 0.5-1 cm from the cell pellet, into the 250 mL flask containing bleach. Be careful not to disturb the cell pellet!

i. Check the color of the cell pellet in the 50 ml tubes.
   • If the pellet is white in color (contains WBCs only), proceed to step j.
   • If the pellet is red in color (contains RBCs), repeat steps d – h, then proceed to step j.

j. Wash the WBC cell pellet in each tube with 10 mL PBS. Pool the cell suspensions into one 50 mL tube.

k. Centrifuge the 50 mL tube containing the pooled cell suspensions at 300 X \( g \) for 10 minutes with the brake on.
   NOTE: Check the user manual for your centrifuge to determine the speed (rpm) necessary to achieve a force of 300 X \( g \).

l. Use a plastic transfer pipet, Pasteur pipet, or serological pipet to carefully aspirate the supernatant, down to ~0.5 cm from the WBC pellet, into the 250 mL flask containing bleach. Be careful not to disturb the cell pellet.

m. Use the 1000 µL micropipettor with a sterile tip to add 1000 µL Freezing Medium to the WBC pellet. Gently pipet up and down to resuspend the pellet.

n. Place the recovered WBCs into the prepared cooled freezer-resistant labeled cryovial. Screw on the cap tightly to prevent isopentane from seeping into the vial during freezing. Keep the vial on dry ice in an ice bucket.

o. Proceed to section C, “Freezing Collected Cells.”

B. Buccal Cell Processing

1. Buccal Cell Collection with Mouthwash
   a. Label a 50 mL conical tube with the BLGSP case ID using the cryomarker.
   b. Attach the BLGSP case ID freezer-resistant label for Buccal Cells obtained from the PT to a 2 mL cryovial. Place the vial on dry ice in an ice bucket to chill.
   c. Pour 20 mL mouthwash into the 50 mL conical tube.
   d. Ask the patient to rinse his/her mouth with tap water for 10 seconds, then swallow or spit it out.
   e. Ask the patient to rub his/her cheeks against his/her teeth for 15 seconds.
   f. Ask the patient to empty the mouthwash from the 50 mL conical tube into his/her mouth and swish vigorously for 60 seconds. The patient should then carefully spit the mouthwash back into the 50 mL tube. A funnel may be used to ensure that the entire sample is captured.
   g. Centrifuge the 50 mL conical tube containing buccal cells at 300 X \( g \) for 10 minutes with the brake on.
   NOTE: Check the user manual for your centrifuge to determine the speed (rpm) necessary to achieve a force of 300 X \( g \).
   h. Use a plastic transfer pipet or Pasteur pipet to slowly and carefully aspirate the supernatant and discard it into the 250 mL flask containing bleach.
   i. Wash the buccal cells by resuspending the pellet in 20 mL PBS and vortexing for 10 seconds.
   j. Centrifuge the 50 mL tube containing the buccal cells at 300 X \( g \) for 10 minutes with the brake on.
   NOTE: Check the user manual for your centrifuge to determine the speed (rpm) necessary to achieve a force of 300 X \( g \).
k. Use a plastic transfer pipet, Pasteur pipet, or serological pipet to slowly and carefully aspirate the supernatant and discard it into the 250 mL flask containing bleach.
l. Resuspend the buccal cell pellet in 500 μL freezing medium.
m. Place suspension into the labeled cryovial from step b.
n. Proceed to section C, “Freezing Collected Cells.”

2. **Buccal Cell Collection with Swabs or Brushes**
   a. Attach the BLGSP case ID freezer-resistant labels for buccal cells obtained from the Project Team to three 2 mL cryovials. Place the vials on dry ice in an ice bucket to chill.
   b. To ensure adequate DNA collection, we recommend that a technician rubs the inside of both of the patient’s cheeks firmly with a minimum of three swabs or brushes. Each swab or brush should be rubbed for a minimum of 15 seconds on a different location on the cheeks.
   c. Immediately after each swab or brush has been used, use scissors to cut the tip of the swab or brush and place it into one of the labeled 2 mL cryovials.
   d. Once all three swab or brush tips have been collected into the cryovials, add 1 mL TE buffer to each vial and screw the caps on tightly and carefully.
   e. The swab or brush tips in buffer should then be frozen as described in section C, “Freezing Collected Cells”.

C. **Freezing Collected Cells**

1. **Set Up Freezing Station**
   - Do not perform snap freezing with bare hands. Wear gloves at all times and heavy duty gloves when working with liquid nitrogen or cooled isopentane.
   - Use extreme caution when dispensing liquid nitrogen.
   a. Fill a small 100 mL metal beaker about 1/4 full with isopentane.
   b. Fill the Dewar thermo-flask about 1/3 full with liquid nitrogen.

2. **Freezing Cells in Cryovials**
   a. Using beaker tongs lower the 100 mL metal beaker containing isopentane half-way into the liquid nitrogen for cooling. The liquid nitrogen will boil as the beaker is lowered. When the isopentane is reaching its freezing point the tone of the boiling will increase for 2-3 seconds.
   b. Using beaker tongs, lift the beaker out of the liquid nitrogen once you see beads of solid isopentane at the bottom of the beaker (about 2 minutes). Place the beaker on the workbench.
   c. Use long forceps to hold one to three cryovial(s) down into the cooled isopentane. Submerge cryovial(s) for at least 1 minute.
   d. Take out the cryovial(s) containing frozen tissue.
   e. Store frozen cryovial(s) in liquid nitrogen storage tanks or -80°C freezers.
The frozen specimens should be kept frozen ON DRY ICE AT ALL TIMES during transport to and from storage tanks.

<table>
<thead>
<tr>
<th>To use this normal...</th>
<th>These requirements must be met...</th>
<th>Collect using protocol...</th>
</tr>
</thead>
</table>
| Granulocytes          | - Safely draw 10 mL blood from patient  
                        - Collect blood into an EDTA or ACD tube  
                        - Fractionate blood using Ficoll-Paque and a clinical centrifuge  
                        - Lyse red blood cells (RBCs) using RBC buffer | Part II A 5: Blood Sample Processing with Blood Fractionation |
| White blood cells (WBC) | - Safely draw 10 mL blood from patient  
                          - Collect blood into an EDTA or ACD tube  
                          - Perform a blood smear and differential WBC count  
                          - Verify no BL cells are present in the blood  
                          - Lyse red blood cells (RBCs) using RBC buffer | Part II A 6: Blood Sample Processing without Blood Fractionation |
| Buccal cells (rinse)  | - BL tumor cannot be in head or neck  
                        - Patient must be able to use mouthwash without swallowing | Part II B 1: Buccal Cell Collection with Mouthwash |
| Buccal cells (swab)   | - BL tumor cannot be in head or neck  
                        - Patient’s mouth must be swabbed | Part II B 2: Buccal Cell Collection with Swabs or Brushes |
Introduction

Tumor samples from Burkitt Lymphoma patients are rare and they may be accrued at specific tumor source sites (TSS) at a rate of 3-5 per calendar year. Some tumor samples may also be HIV-infected. Shipping costs for infectious labeled material in vapor phase liquid nitrogen containers (cryoports) are expensive.

Scope and Purpose

1. To establish a sample shipping guideline standard to be applied to all samples contributed to the Burkitt Lymphoma Genome Sequencing Project (BLGSP) that balances the need for expeditious transport while maintaining cost efficiency.
2. This procedure applies to all TSSs.

Adopted Standard

- Immediate requests for a cryoport will be made to The Research Institute at Nationwide Children’s Hospital (NCH) coordinator (see BLGSP SOP #300) when the contributing TSS has in its possession three (3) or more matched tumor-normal tissues.
- However, if fewer than three cases are accrued, and the date of oldest sample resection is more than four (4) months, shipment of this/these sample(s) is warranted.

Questions regarding this protocol should be directed to the Project Team manager (see BLGSP SOP #300).
BLGSP SOP #308:  
Shipping Cryoports Containing Frozen Biosamples for Processing and Extraction of Nucleic Acids

Introduction

Cryoports are shipped from The Research Institute at Nationwide Children’s Hospital (NCH) to the Tissue Source Site (TSS). TSSs are instructed to use this SOP when shipping samples to NCH.

Scope and Purpose

1. To establish a procedure for personnel to use when shipping cryoports.
2. This procedure applies to all laboratory personnel.
3. Any deviation from this protocol should be noted in the lab notebook, indicating the nature of the deviation, times, and which samples were affected. This information should be given within 48 hours of the occurrence to the Project Team (PT) manager by sending an email (see BLGSP SOP #300) with the details.

Safety Precautions

1. Wear personal protective equipment (PPE) such as lab coats and gloves.
2. Liquid nitrogen is extremely cold and can cause ‘burns’. Wear gloves that are specially made to withstand liquid nitrogen, eye protection, and a lab coat to protect skin from splashes and spills. Liquid nitrogen is an asphyxiant; be sure to use in a well-ventilated area.
3. Always keep the cryoport in the upright position.

Equipment and Materials

1. Cryoport, obtained in 3 or 4 days in advance from the NCH Coordinator (see BLGSP SOP #300)
2. Personal protective equipment (PPE) to include heavy duty gloves, eye protection (preferably Face Shield), lab coat, and closed-toe shoes
3. Shipping documents

Procedure

A. Request cryoport from NCH coordinator (see BLGSP SOP #300) according to the guidelines in BLGSP SOP #307.
B. Complete the appropriate shipping forms needed for the sample(s).
C. Complete the sample shipping document with the project-assigned ID obtained prior to surgery (see BLGSP SOP #303 and #304), the sample type information, and any comments. Sign and date the form and have a second individual verify the contents of the shipment and sign and date the form.
D. Don personal protection equipment.
E. Open the cryoport shipping vessel and remove the temperature probe that has been wrapped in bubble wrap and placed between the cryoport and the outside shipping vessel. Lift the cryoport out of the shipping vessel to access the data logger which has also been wrapped in bubble wrap and placed between the cryoport and the shipping vessel.
F. Open cryoport lid carefully.
G. Take the temperature of the cryoport prior to placing the samples in the cryoport.
   1. Turn the On/Off switch on the digital thermometer to the “On” position.
   2. Press the Celsius/Fahrenheit to read “C” in the upper right corner of the screen.
   3. Place the temperature probe into the cryoport for a minimum of five minutes.
   4. After five minutes, record the temperature of the cryoport on the Cryoport Temperature Log that is enclosed in the plastic tie envelope.
   5. If the temperature is -170°C or colder, it can be used to ship the samples to NCH. **ALERT:** If the temperature is warmer than -170°C, please contact the NCH coordinator for instructions.
   6. Wrap the data logger and temperature probe and return all items to the shipping vessel in reverse order as listed above.
H. Place your samples in the cryoport. Carefully close the lid. Affix a plastic zip tie through the loop of the lid and the loop on the cryoport (see images on next page).
I. Place all shipping documents, including the Sample Shipping Document and the Cryoport Temperature Log, into the plastic sleeve.
J. Notify the shipping carrier for pick-up. Under normal conditions, shipments should only be sent to NCH on Monday through Wednesday. If an exception is needed, the NCH coordinator must be contacted for further instructions and to alert the appropriate NCH personnel of any schedule changes.
K. Attach the enclosed shipping label to the handle of the outside shipping vessel and use the other enclosed plastic tie to secure the outside lock before shipping the cryoport (see image on next page).
L. TSS personnel will notify the NCH Coordinator by email stating the cryoport is being returned with tissue samples back to NCH.
M. The NCH Coordinator will track the cryoport in transit.
N. If there are any exceptions to the normal shipping schedule or in the event of an anticipated shipment delay, the NCH coordinator will notify the NCH on-call personnel of the potential arrival of samples after normal working hours or on the weekend.
O. Upon receiving the cryoport, the temperature will be recorded and quality control verified by a second individual.
P. Any questions regarding shipments to NCH should be directed to the NCH Coordinator (see BLGSP SOP #300).
Correct (Below): Zip tie used to secure Fed-Ex bill

Correct (Below): Zip tie used to close lid

Incorrect (Below): Zip tie is not connected to cryoport hood

Correct (Below): Zip tie is connected to cryoport hood to prevent cryoport from opening
**Introduction**

Pathological diagnosis of tumors can be impacted by the subjective nature of the process as well as the subjective definition of the criteria used in the assessment. To ensure that samples meet the tissue requirements for the Burkitt Lymphoma Genome Sequencing Project (BLGSP) and are Burkitt Lymphoma, atypical Burkitt Lymphoma or dual translocation Burkitt Lymphoma (BL), a Pathology Review Committee (PRC) of three board-certified pathologists is established. The review of tissues by a group minimizes the subjectivity that is unavoidable in pathology reviews and allows an efficient resolution of discrepancies.

**Scope and Purpose**

To establish a standard procedure for the centralized pathology review of tissue submitted to the BLGSP.

**Equipment and Materials**

1. A formalin-fixed paraffin-embedded (FFPE) diagnostic block (preferred) OR a minimum of sixteen (16) unstained 4 µm thick sections from the formalin-fixed paraffin-embedded (FFPE) diagnostic block mounted on adhesive (e.g. poly-L-lysine or APTS) coated glass slides. These blocks/sections will be provided by the tissue source site (TSS) contributing the case and should be labeled with freezer-resistant labels containing the project-assigned ID (obtained from the Project Team; see BLGSP SOP #303 and #304).

**General Procedure**

1. FFPE blocks or slides arrive to the pathology review lab from the tissue source site. Slides are sent to histology service for the BL appropriate stains (see below).
2. Stained slides are shipped to Nationwide Children’s Hospital to be scanned and have the slide images uploaded to the pathology viewing software VIPER.
3. The pathology review committee views the slide images using VIPER and renders a diagnosis based on the image data.
**Procedure**

**Preparation for review:**

1. All members of a centralized pathology board will schedule a date and time to receive training to use the Nationwide Children’s Hospital (NCH) slide viewing software program VIPER, by contacting the NCH program manager Jay Bowen (Jay.Bowen@nationwidechildrens.org).
2. Immediately upon arrival to the Pathology Review Lab (PRL), the Pathology Coordinator will verify that all blocks/slides submitted are labeled with the same project-assigned ID for each case.
   (1) If slides are received, the Pathology Coordinator will send the appropriate number of slides for Hematoxylin and Eosin (H&E) staining (BLGSP SOP #311). An initial evaluation will be performed for Burkitt Lymphoma hallmarks (“starry sky” morphology). Sections that pass this initial evaluation will be cleared as candidates and be further processed for immunohistochemical (IHC) studies (BLGSP SOP #312), and fluorescence in situ hybridization (FISH; BLGSP SOP #313). The processing should take no longer than 5 days.
   (2) If a paraffin block is received, an H&E stained section will be prepared for an initial evaluation for Burkitt Lymphoma hallmarks as well to identify the distribution of the tumor in the block. Sections that pass this initial evaluation will be cleared as candidates and be further processed. The Pathology Coordinator will select an appropriate area in the block for the tissue microarray (TMA), circle such area on the H&E stained slide, and submit the block to the core laboratory for preparation of the TMA (BLGSP SOP #310). A TMA will be constructed once blocks from 10 cases have been received, or every 3 months, whichever comes first.

**H&E**

- Tissue will be evaluated for the following: presence of the “starry sky” morphology associated with Burkitt Lymphoma; percent tumor nuclei in the tissue (qualifying tissue will have > 70% tumor nuclei); and percent necrosis in the tissue.

**Immunohistochemical analysis**

- IHC to be performed are: **CD3, CD10, CD20, BCL2, BCL6, and Ki67**

**FISH analysis**

- FISH analysis will be performed on TMAs (or individual slides when TMAs do not exist) for all cases to determine the presence of **MYC** to immunoglobulin locus translocation.

- **Note:** Initial sample processing, H&E, and IHC analysis should take no longer than 5 days, using either submitted unstained slides or a paraffin block (which will be cut by the reference laboratory and mounted on adhesive (e.g. poly-L-lysine or APTS) coated glass slides). FISH analysis, when performed on individual slides or after a
sufficient number of cases have accrued for TMA construction, will take
approximately 7-14 days to complete.

3. Once all processing is completed, the Pathology Coordinator will coordinate the shipment of all slides to NCH via FedEx.
4. Once the slides are received at NCH, the NCH Program Manager will contact the Pathology Review Committee informing them that the slides have been scanned and uploaded to the online VIPER viewing program for pathology review. This communication must specify the number and name of files, as well as the project-assigned ID(s) for the case(s) under review.

B. Review:
1. Within three days of receipt of the e-mail from the NCH Program Manager, all members of the Pathology Review Committee will log-in to the VIPER software and render their diagnosis of the available slide images.
2. The tumors will be classified using the WHO classification.
3. If a consensus is reached and the case passes the specified criteria, the NCH Program Manager will alert the Pathology Coordinator and provide a spreadsheet of the Pathology Review Committee’s reviews. The Pathology Coordinator will then complete the spreadsheet to create the consensus pathology spreadsheet. Steps 1-3 will take 2 weeks total.
4. Cases for which the diagnosis is not Burkitt Lymphoma will be labeled as such and taken out of the study.
5. Cases for which the members of the Pathology Review Committee do not agree on a diagnosis will undergo an additional review by the Pathology Review Committee to reach a consensus. This consensus review will be convened by Pathology Coordinator. The schedule of such consensus reviews will be dictated by the following:
   - When six or more discordant cases have been accrued, a consensus review panel must be convened.
   - If there are fewer than six discordant cases, but the oldest accrued case is more than three months old, a consensus review panel must be convened.

Note: Some cases may forgo central pathology processing of slides at the University of Nebraska Medical Center, and instead, be processed at the NCI. Pathology slides processed at the NCI will still undergo the same procedures as outlined above. Please complete the following NCI pathology consulting form before submitting any tissue blocks for BLGSP central pathology. Permission must be granted by the OCG office before submitting tissue blocks to the NCI pathology consulting service.
<table>
<thead>
<tr>
<th>SPECIMEN SUBMITTED BY</th>
<th>ADDRESS</th>
<th>DATE SUBMITTED</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAME (Last, First, Middle Initial)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHONE/ FAX/EMAIL/</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRINCIPAL INVESTIGATOR</th>
<th>ADDRESS / EMAIL CONTACT INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAME (Last, First, Middle Initial)</td>
<td></td>
</tr>
</tbody>
</table>

| CLINICAL DIAGNOSIS | |
|-------------------| |

| BRIEF CLINICAL HISTORY | |
|------------------------| |

<table>
<thead>
<tr>
<th>Gross Description, Number of histology slides and blocks submitted and original pathology ID number</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>BLGSP ID</th>
<th>AGE</th>
<th>SEX</th>
<th>RACE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| PATHOLOGIST | |
|-------------| |

<table>
<thead>
<tr>
<th>SPECIAL REQUESTS:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Please include copy of the local pathology report of the submitted tissue with this form</td>
</tr>
<tr>
<td>- Please note, submitting tissue source site will be responsible for clinical data input for tissues submitted to BLGSP. Alternatively, please contact the BLGSP program manager, Nicholas Griner (<a href="mailto:nicholas.griner@nih.gov">nicholas.griner@nih.gov</a>), who can assist in this matter.</td>
</tr>
<tr>
<td>- Please see attached BLGSP flowchart for additional information</td>
</tr>
</tbody>
</table>
BLGSP SOP #310: 
Production of Tissue Microarrays (TMA)

Introduction

Standard protocols for pathological diagnosis have been established to enable uniform assessment of samples submitted to the Burkitt Lymphoma Genome Sequencing Project.

Scope and Purpose

1. To establish standard procedures for pathology review of tissue submitted to BLGSP to confirm the cases accurately diagnosed as Burkitt lymphoma. TMAs allow for simultaneous processing of multiple cases thereby ensuring better technical uniformity and reduction in cost of the materials used on a case basis.

Safety Precautions

1. Wear personal protective equipment (PPE) including chemical splash goggles, gloves, and protective clothing (e.g. lab coat, closed-toed footwear).
2. Read all applicable Material Safety Data Sheets (MSDS) for safety and health information.
3. Read all applicable equipment user manuals for safety information.

Equipment and Materials

1. Empty paraffin block
2. Tools to create tissue microarray:
   a. 1-2” needle with 0.6 mm core diameter (23-gauge) (e.g. Fisher Scientific Catalog # 14-815-611), or
   b. Tissue Microarrayer, manual (e.g. Manual Tissue Arrayer, Estigen Product # MTA-1) or automated (e.g. TMA Master Tissue Microarrayer, Perkin-Elmer Product #133115)
3. Ten (10) formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks from a BLGSP Tissue Source Site (TSS) labeled with case ID (BLGSP SOP #304)
4. Microtome (manual, semi-automated, or fully-automated)
5. Adhesive (e.g. poly-L-lysine) coated glass slides (e.g. Thermo Scientific Polysine Adhesion Slides, Part # 10143265)

Procedure

A. Design the TMA
1. Remove and dispose of cores from the empty paraffin block (hereafter called the “recipient block”) manually or with a tissue microarrayer.
   a) Manually: use a 23-gauge needle to remove thirty (30) cores, in a grid of five cores by six cores, from the empty paraffin block. Cores should be taken at least 3 mm from the block’s edge. Spacing between cores should be 0.5 mm.
   b) With a tissue microarrayer: follow the manufacturer’s instructions to remove thirty (30) cores with a diameter of 0.6 mm, in a grid of five cores by six cores, from the empty paraffin block. Cores should be taken at least 3 mm from the block’s edge. Spacing between cores should be 0.5 mm or less.

2. Create a chart to diagram the placement of the cores of tumor tissue from the BLGSP FFPE blocks (hereafter called the “donor blocks”) into the recipient block. This is easily done using a spreadsheet program like Microsoft Excel.
   a) The 30-core TMA should be designed to contain three tumor tissue cores from 10 BLGSP FFPE tumor tissue blocks.
   b) Arrange tumor tissue cores from the donor blocks into the recipient block in an asymmetrical and irregular pattern to decrease the risks of interpretation bias between cores from the same case and staining artifacts related to the location of the core on the slide. See example in Appendix A.

B. Identify tissue cores to collect from the candidate BLGSP cases
   1. Use a microtome to cut a 4 µm thick section from each of the 10 donor blocks.
   2. Mount each tissue section to an adhesive-coated glass slide.
   3. Stain the tissue sections with Hematoxylin and Eosin (H&E) (see SOP #311).
   4. Evaluate the H&E stained tissue sections under a light microscope using a 20x or 40x objective to identify areas of high-quality tumor tissue.

C. Build the TMA
   1. Use the H&E stained tissue section as a guide to identify three areas of high quality tumor tissue from the first donor block. Cores of tumor tissue will be collected from these areas and placed into the holes in the recipient block.
   2. Collect a 0.6 mm core from the first area of high quality tumor tissue from the first donor block with a 23-gauge needle or tissue microarrayer.
   3. Insert the core into recipient paraffin block according to the chart created in step A2 manually or with an automated tissue microarrayer.
   4. Repeat steps 2 and 3 twice more, choosing cores from different areas of high quality tumor tissue in the first donor block. This will place three different cores from the first donor block into the recipient block.
   5. Repeat steps 1-4 with the nine remaining donor blocks. The recipient block now contains 30 total cores- three cores from each of the 10 donor blocks- and is a complete TMA.

D. Temper the TMA
   1. Incubate the TMA block at 37°C overnight.
   2. Chill the TMA block at 0 to -20°C for one hour.
   3. Incubate the TMA block at 37°C for one hour.
   4. Repeat steps 2 and 3 twice.

E. Store the TMA block at room temperature until further processing.
Example of TMA sample layout chart:

In this example, there are 10 donor FFPE blocks, labeled 1 through 10, and three cores from each block, labeled A through C.

<table>
<thead>
<tr>
<th>Column 1</th>
<th>Column 2</th>
<th>Column 3</th>
<th>Column 4</th>
<th>Column 5</th>
<th>Column 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Row 1</td>
<td>1A</td>
<td>10B</td>
<td>6C</td>
<td>9C</td>
<td>2A</td>
</tr>
<tr>
<td>Row 2</td>
<td>8A</td>
<td>9B</td>
<td>5C</td>
<td>4C</td>
<td>10A</td>
</tr>
<tr>
<td>Row 3</td>
<td>4A</td>
<td>7C</td>
<td>2B</td>
<td>1B</td>
<td>8C</td>
</tr>
<tr>
<td>Row 4</td>
<td>2C</td>
<td>3C</td>
<td>10C</td>
<td>6B</td>
<td>1C</td>
</tr>
<tr>
<td>Row 5</td>
<td>6A</td>
<td>5B</td>
<td>8B</td>
<td>7B</td>
<td>3A</td>
</tr>
</tbody>
</table>

Note that the cores from the same block are distributed in an asymmetrical and irregular pattern, and at least one core from each block is not on the edge.

Please note: Tissue controls for TMA construction should be situated in the top left corner of the above map so that orientation of the TMA is consistent.
Introduction

Accurate pathological diagnosis of Burkitt lymphoma (BL) is essential to determine which samples qualify for the Burkitt Lymphoma Genome Sequencing Project (BLGSP). Each putative case will undergo staining with hematoxylin and eosin (H&E) to visualize gross tissue morphology.

Burkitt lymphoma cells have high rates of cell proliferation and death. In response, macrophages infiltrate the tumors to ingest the dead cells, leaving non-cellular spaces in the tumor tissue. When sections of BL tumor tissue are stained with H&E, only the cellular regions of the tissue are colored by the dyes, giving them a dark purple color. The non-cellular spaces appear as white spots on a dark background. This results in the classical “starry sky” appearance of Burkitt Lymphoma tissue visualized under low-power microscopy.

Scope and Purpose

1. To establish standard procedures for H&E staining of tissue submitted to BLGSP to confirm the cases accurately diagnosed as Burkitt lymphoma. The slides will be evaluated by expert pathology lymphoma panel.

Safety Precautions

1. Wear personal protective equipment (PPE) including chemical splash goggles, gloves, and protective clothing (e.g. lab coat, closed-toed footwear).
2. Gloves are not suitable for immersion protection, only splash protection.
3. Read all applicable Material Safety Data Sheets (MSDS) for reagent safety and health information.
4. Read all applicable equipment user manuals for safety information.

Equipment and Materials

A. General

1. Formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks or slides from a BLGSP Tissue Source Site (TSS) or tissue microarray (TMA; BLGSP SOP #310) blocks produced from the TSS tumor tissue blocks, labeled with the BLGSP project-assigned ID (BLGSP SOP #304)
2. Microtome (manual, semi-automated, or fully-automated)
3. Adhesive (e.g. poly-L-lysine) coated glass slides (e.g. Thermo Scientific Polysine Adhesion Slides, Part # 10143265)
4. Glass coverslips (e.g. Fisherbrand Cover Glasses, Part # 12-544E)
5. Xylene (e.g. Sigma-Aldrich histological grade, Part # 534056)
6. Ethanol, anhydrous (e.g. Sigma-Aldrich Part # 676829)
7. Deionized water
8. Shandon Consul-Mount histology formation mounting medium (Fisher Scientific Catalog # 99-904-40) or Permount Mounting medium (e.g. Fisher Permount, Catalog # S70104)
9. Standard light microscope (e.g. Olympus IX71 Inverted Microscope)

B. For manual staining
   1. 10 glass staining dishes (e.g. Fisherbrand Glass Staining Dish, Part Number 08-810)
   2. 2 slide racks (e.g. Wheaton Science Products, Part Number 900204)
   3. Laboratory wipes (e.g. Kimwipes, Part Number 34155)
   4. Sterile forceps (e.g. Fisherbrand fine point forceps, Catalog Number 22-327-379)
   5. Hematoxylin solution, Mayer’s (e.g. Sigma-Aldrich Part # MHS16)
   6. Eosin Y aqueous solution (e.g. Sigma-Aldrich Part # HT110216)

C. For automated staining
   1. Hematoxylin solution (e.g. Surgipath SelecTech 560MX, Leica Product # 3801575)
   2. Eosin Y alcoholic solution (e.g. Surgipath SelecTech Alcoholic Eosin Y 515, Leica Product # 3801615)
   3. Tissue-Tek® Prisma® Automated Slide Stainer (Sakura Product #6130)
   4. Tissue-Tek® Glas™ g2 Automated Coverslipper (Sakura Product #6500)

Procedure

A. Use a microtome to cut one 4 µm thick tissue section from each FFPE block (TMA blocks preferred, but individual case blocks if necessary) and mount each section to an adhesive-coated glass slide.

B. Perform manual or automated H&E staining
   1. Manual H&E
      a) Prepare 100 mL each of 95% and 80% ethanol solutions using deionized water and anhydrous ethanol.
      b) Set out the glass staining dishes in a row and label them in this order:
         (1) Xylene
         (2) Xylene
         (3) 100% ethanol
         (4) 100% ethanol
         (5) 95% ethanol
         (6) 80% ethanol
         (7) Deionized water
         (8) Hematoxylin
         (9) Deionized water
         (10) Eosin
c) Fill the glass staining dishes with approximately 100 mL of the reagent for which they are labeled.
   (1) Ethanol solutions, xylene, and deionized water must be fresh.
   (2) Hematoxylin can be reused for about 1 week but must be stored in the dark. Eosin can be reused for about 1 week.

d) Place slides containing tissue sections into slide rack.

e) Deparaffinize sections by submerging slides in slide rack into first staining dish containing xylene for 3 minutes. Repeat this step with the second staining dish containing xylene.

f) Use a laboratory wipe to gently blot excess xylene from slide rack before submerging slides (in slide rack) in ethanol to rehydrate according to the following:
   (1) 3 minutes in the first staining dish containing 100% ethanol.
   Repeat this step with the second staining dish containing 100% ethanol.
   (2) 3 minutes in the staining dish containing 95% ethanol.
   (3) 3 minutes in the staining dish containing 80% ethanol.
   (4) 5 minutes in the staining dish containing deionized water.

g) Blot excess water from the slide rack before submerging slides (in slide rack) to stain with Mayer’s hematoxylin according to the following:
   (1) 1 minute in the staining dish containing Mayer’s hematoxylin
   (2) 1 minute in the staining dish containing deionized water
   (3) Change the deionized water in the staining dish to fresh water and submerge slides for 5 minutes.

h) Blot excess water from the slide rack before submerging slides (in slide rack) to stain with eosin according to the following:
   (1) 30-45 seconds in Eosin Y
   (2) 95% ethanol for 1 minute.
   (3) 100% ethanol for 1 minute. Repeat this step in the second staining dish containing 100% ethanol.

i) Blot excess ethanol from the slide rack before submerging slides (in slide rack) into a staining dish containing xylene for 2 minutes. Repeat this step in the second staining dish containing xylene.

j) Remove slides from slide rack, blot excess xylene from slides using a laboratory wipe, and then overlay the tissue on the slides with 2-3 drops of mounting medium, taking care to avoid bubbles.

k) Angle a coverslip about 30 degrees above the tissue section and let it fall gently onto the slide. Allow the mounting medium to spread beneath the coverslip, covering all of the tissue.
   
   NOTE: If air bubbles do occur, squeeze them out by applying light pressure with forceps to the coverslip from the center outward to draw the bubbles to the edge of the slide so they can escape from between the slide and coverslip.

l) Allow slides to cure and dry.
2. Automated H&E using Sakura Prisma Autostainer (all steps completed within machine)
   a) Deparaffinize and hydrate tissue
      (1) Immerse sections in xylene for 90 seconds. Repeat this step once.
      (2) Immerse sections in 100% ethanol for 20 seconds. Repeat this step once.
      (3) Immerse sections in 95% ethanol in deionized water for 15 seconds.
      (4) Immerse sections in 70% ethanol in deionized water for 15 seconds.
      (5) Immerse sections in deionized water for 5 minutes.
   b) Stain with Leica Hematoxylin 560MX, incubate 90 seconds.
   c) Stain with Leica Eosin Y 515, incubate 30 seconds.
   d) Dehydrate and clear sections
      (1) Rinse slides 3 times using deionized water.
      (2) Immerse sections in 95% ethanol in deionized water for 15 seconds.
      (3) Immerse sections in 100% ethanol for 20 seconds. Repeat this step twice.
      (4) Immerse sections in xylene for 90 seconds. Repeat this step once.
   e) Mount and coverslip slides using the Sakura Tissue-Tek Glas automated coverslipper
      (1) Mount sections using Shandon Consul-Mount Histology formation.
      (2) Add glass coverslips and allow the slides to cure and dry.

C. Scan slides using the Roche/Ventana iScan Coreo Au scanner and a 40x objective. Store color images in JPEG2000 (lossless) file format.
Introduction

Accurate pathological diagnosis of Burkitt lymphoma (BL) is essential to determine which samples qualify for the Burkitt Lymphoma Genome Sequencing Project (BLGSP). Each putative case will undergo immunohistochemical detection of molecular markers of BL. Burkitt lymphoma tumors are expected to stain positively for Ki67, CD10, BCL6, and CD20, and negatively for BCL2 (with some exceptions) and CD3.

Scope and Purpose

1. To establish standard procedures for immunohistochemistry of tissue submitted to BLGSP to confirm the cases accurately diagnosed as Burkitt lymphoma. After completion of the protocol, the slides need to be “read” by a lymphoma-qualified expert pathologist.

Safety Precautions

1. Wear personal protective equipment (PPE) including chemical splash goggles, gloves, and protective clothing (e.g. lab coat, closed-toed footwear).
2. Gloves are not suitable for immersion protection, only splash protection.
3. Read all applicable Material Safety Data Sheets (MSDS) for reagent safety and health information.
4. Read all applicable equipment user manuals for safety information.

Equipment and Materials

A. General

1. Formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks or slides from a BLGSP Tissue Source Site (TSS) or tissue microarray (TMA; BLGSP SOP #310) blocks produced from the TSS tumor tissue blocks labeled with BLGSP project-assigned IDs (BLGSP SOP #304)
2. Microtome (manual, semi-automated, or fully-automated)
3. Adhesive (e.g. poly-L-lysine) coated glass slides (e.g. Thermo Scientific Polysine Adhesion Slides, Part # 10143265)
4. Glass coverslips (e.g. Fisherbrand Cover Glasses, Part # 12-544E)
5. Xylene (e.g. Sigma-Aldrich histological grade, Part # 534056)
6. Ethanol, anhydrous (e.g. Sigma-Aldrich Part # 676829)
7. Deionized water
8. 3% hydrogen peroxide in deionized water, prepared fresh from stock (e.g. 30% hydrogen peroxide, Sigma Product #H-1009)
9. Ki67 RTU (Ready to Use) primary antibody, Clone MIB1, Mouse anti-human (Dako Product # IR62661-2)
10. CD10 RTU primary antibody, Clone 56C6, Mouse anti-human (Dako Product # IR64861-2)
11. BCL2 RTU primary antibody, Clone 124, Mouse anti-human (Dako Product # IR61461-2)
12. BCL6 RTU primary antibody, Clone PG-B6p, Mouse anti-human (Dako Product # IR62561-2)
13. CD20cy RTU primary antibody, Clone L26, Mouse anti-human (Dako Product # IR60461-2)
14. CD3 RTU primary antibody, Polyclonal (epsilon variant), Rabbit anti-human (Dako Product # IR50361-2)
15. Shandon Consul-Mount histology formation mounting medium (Fisher Scientific Catalog # 99-904-40) or Permount Mounting medium (e.g. Fisher Permount, Catalog # S70104)
16. iScan Coreo Au scanner (Roche/Ventana)
17. Standard light microscope (e.g. Olympus IX71 Inverted Microscope)

B. For manual staining
1. 9 glass staining dishes (e.g. Fisherbrand Glass Staining Dish, Part Number 08-810)
2. Steamer or water bath that can be heated to 98°C
3. Tris-EDTA buffer, pH 9.0, with 0.05% Tween-20 (10 mM Tris base, 1 mM EDTA)
4. 2 slide racks (e.g. Wheaton Science Products, Part Number 900204)
5. Laboratory wipes (e.g. Kimwipes, Part Number 34155)
6. Tris-buffered saline (TBS) (50 mM Tris, 0.9% NaCl, pH 8.4) prepared from 20X stock solution (1 M Tris base, 18% NaCl) and deionized water
7. Squeeze wash bottle containing TBS
8. Squeeze wash bottle containing deionized water
9. Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody, 1 mg/mL in sterile 50% glycerol in deionized water (e.g. Millipore # 12-349)
10. HRP-conjugated goat anti-rabbit IgG antibody, 1 mg/mL in sterile 50% glycerol in deionized water (e.g. Millipore # 12-348)
11. Substrate chromogen 3,3’-Diaminobenzidine (DAB) and urea hydrogen peroxide tablet dissolved in 1 mL deionized water (e.g. Sigma-Aldrich SIGMAFAST DAB tablets Part # D4168)
12. Hematoxylin solution, Mayer’s (e.g. Sigma-Aldrich Part # MHS16)
13. Sterile forceps (e.g. Fisherbrand fine point forceps, Catalog Number 22-327-379)
14. 200 µL micropipettor (e.g. Gilson P200 Pipetman, Fisher Catalog # F123601G)

C. For automated staining
1. Leica Biosystems BOND-MAX (Leica)
2. Novacastra Bond Epitope Retrieval Solution 2, 10mM, pH 9.0 (Leica Catalog # AR9640)
3. **BOND Wash Solution** prepared with deionized water from 10X concentrate (Leica Catalog # AR9590)

4. **Novocastra BOND Polymer Refine Detection system** (Leica Catalog # DS9800)
   a) Post Primary Rabbit anti-mouse IgG (<10ug/mL) in 10% (v/v) animal serum in tris-buffered saline (TBS)/0.09% ProClin 950
   b) Polymer Anti-rabbit Poly-HP IgG (<25ug/mL) in 10% (v/v) animal serum in TBS/0.09% ProClin 950
   c) Substrate chromogen 3,3’-Diaminobenzidine (DAB) <0.1% (v/v) hydrogen peroxide in a stabilizer solution

5. **Hematoxylin solution** (*e.g.* Surgipath SelecTech 560MX, Leica Product # 3801575)

6. **Tissue-Tek® Prisma® Automated Slide Stainer** (Sakura Product #6130)

7. **Tissue-Tek® Glas™ g2 Automated Coverslipper** (Sakura Product #6500)

---

**Procedure**

**A. Use a microtome to cut six 4 µm thick tissue sections from each FFPE block (TMA blocks preferred, but individual case blocks if necessary) and mount each section to an adhesive-coated glass slide.**

**B. Perform manual or automated IHC**

1. **Manual IHC**
   a) Prepare 100 mL each of 95% and 80% ethanol solutions using deionized water and anhydrous ethanol.
   b) Set out the glass staining dishes in a row and label them in this order:
      1) Xylene
      2) Xylene
      3) 100% ethanol
      4) 100% ethanol
      5) 95% ethanol
      6) 80% ethanol
      7) Hematoxylin
      8) Deionized water
      9) Tris-EDTA + Tween-20
   c) Fill the glass staining dishes with approximately 100 mL of the reagent for which they are labeled.
      1) Ethanol solutions, xylene, and deionized water must be fresh.
      2) Hematoxylin can be reused for about 1 week but must be stored in the dark.
   d) Pre-heat steamer or water bath with staining dish containing Tris-EDTA + Tween-20 until temperature reaches 98°C.
   e) Heat slides containing tissue sections with 56-60°C oven or heat block for 15 minutes.
   f) Place slides into slide rack.
g) Deparaffinize sections by submerging slides in slide rack into the first staining dish containing xylene for 3 minutes. Repeat this step with the second staining dish containing xylene.

h) Use a laboratory wipe to gently blot excess xylene from slide rack before submerging slides (in slide rack) in ethanol to rehydrate according to the following:
   1) 3 minutes in the first staining dish containing 100% ethanol.
   2) Repeat this step with the second staining dish containing 100% ethanol.
   3) 3 minutes in the staining dish containing 95% ethanol.
   4) 3 minutes in the staining dish containing 80% ethanol.
   5) 5 minutes in the staining dish containing deionized water.

i) Perform heat-induced epitope retrieval by immersing slide rack in the preheated staining dish containing Tris-EDTA pH 9.0 with 0.05% Tween-20 and incubating at 98°C for 20 minutes.

j) Rinse slides 3 times using the wash bottle of TBS. Do not spray directly on tissue.

k) Block endogenous peroxidase activity by incubating sections in 3% hydrogen peroxide for 10 minutes.

l) Rinse slides 3 times using the wash bottle of TBS. Do not spray directly on tissue.

m) Dry the back of the slides with a laboratory wipe. Carefully dry the front of the slides, never wiping closer than 0.5 cm from the tissue.

n) Incubate the tissue sections in primary antibody by dripping approximately 100 µL onto the tissue with a micropipettor and allowing the antibody to sit on the tissue for 30-90 minutes at room temperature. From the set of six slides cut from the same FFPE block, one of each should be incubated in one of the following primary antibodies:
   1) Ki67, Clone MIB1, Mouse anti-human
   2) CD10, Clone 56C6, Mouse anti-human
   3) BCL2, Clone 124, Mouse anti-human
   4) BCL6, Clone PG-B6p, Mouse anti-human
   5) CD20cy, Clone L26, Mouse anti-human
   6) CD3, Polyclonal (epsilon variant), Rabbit anti-human

   Antibodies can be re-used by carefully collecting the antibody with a micropipettor and storing at 4°C.

o) Rinse slides 3 times using the wash bottle of TBS. Do not spray directly on tissue.

p) Dry the back of the slides with a laboratory wipe. Carefully dry the front of the slides, never wiping closer than 0.5 cm from the tissue.

q) In the same manner as the primary antibodies, incubate the tissue sections for 30 minutes at room temperature in the following secondary antibodies:
   1) For slides treated with mouse anti-human antibodies, use goat anti-mouse-HRP antibody diluted 1:500 to 1:2000 in TBS.
(2) For slides treated with rabbit anti-human antibodies, use goat anti-
rabbit-HRP antibody diluted 1:500 to 1:3000 in TBS.

r) Rinse slides 3 times using the wash bottle of TBS. Do not spray directly on

tissue.

s) Rinse slides 3 times using the wash bottle of deionized water. Do not spray
directly on tissue.

t) Dry the back of the slides with a laboratory wipe. Carefully dry the front of
the slides, never wiping closer than 0.5 cm from the tissue.

u) Add enough drops of substrate chromogen 3,3'-Diaminobenzidine (DAB) in
hydrogen peroxide to cover the tissue section and incubate for 10 minutes.
The HRP causes precipitation of the chromogen at the location of the
antibody.

v) Rinse slides 3 times using the wash bottle of deionized water. Do not spray
directly on tissue.

w) Place slides containing tissue sections into slide rack.

x) Submerge slides (in slide rack) to counterstain with hematoxylin according
to the following:
   (1) 1 minute in the staining dish containing Mayer’s hematoxylin
   (2) 1 minute in the staining dish containing deionized water
   (3) Change the deionized water in the staining dish to fresh water and
       submerge slides for 5 minutes.

y) Blot excess water from the slide rack before submerging slides (in slide rack)
to dehydrate tissue:
   (1) 95% ethanol for 1 minute.
   (2) 100% ethanol for 1 minute. Repeat this step in the second staining
dish containing 100% ethanol.

z) Blot excess ethanol from the slide rack before submerging slides (in slide
rack) into a staining dish containing xylene for 2 minutes. Repeat this step in
the second staining dish containing xylene.

aa) Remove slides from slide rack, blot excess xylene from slides using a
laboratory wipe, and then overlay the tissue on the slides with 2-3 drops of
mounting medium, taking care to avoid bubbles.

bb) Angle a coverslip about 30 degrees above the tissue section and let it fall
gently onto the slide. Allow the mounting medium to spread beneath the
coverslip, covering all of the tissue.
   NOTE: If air bubbles do occur, squeeze them out by applying light pressure
   with forceps to the coverslip from the center outward to draw the bubbles
to the edge of the slide so they can escape from between the slide and
coverslip.

cc) Allow slides to cure and dry.
2. Automated IHC using the Leica Biosystems BOND-MAX system
   a) Deparaffinize and perform heat-induced epitope retrieval (HIER) by incubating sections in 10mM Bond Epitope Retrieval Solution 2, pH 9.0, for 20 minutes at 98°C.
   b) Rinse slides 3 times using BOND Wash Solution.
   c) Block endogenous peroxidase activity by incubating sections in 3% hydrogen peroxide for 10 minutes.
   d) Rinse slides 3 times using BOND Wash Solution.
   e) Incubate each of the six tissue sections from the same FFPE block in one of the following primary antibodies for 45 minutes.
      (1) Ki67, Clone MIB1, Mouse anti-human
      (2) CD10, Clone 56C6, Mouse anti-human
      (3) BCL2, Clone 124, Mouse anti-human
      (4) BCL6, Clone PG-B6p, Mouse anti-human
      (5) CD20cy, Clone L26, Mouse anti-human
      (6) CD3, Polyclonal (epsilon variant), Rabbit anti-human
   f) Rinse slides 3 times using BOND Wash Solution.
   g) Visualize using Novocastra BOND Polymer Refine Detection system
      (1) Incubate in post-primary rabbit anti-mouse IgG in 10% animal serum in Tris-buffered saline (TBS)/0.09% ProClin 950 for 12 minutes.
      (2) Rinse slides 3 times using BOND Wash Solution.
      (3) Incubate in polymer anti-rabbit Poly-HRP IgG in 10% animal serum in TBS/0.09% ProClin 950 for 12 minutes.
      (4) Rinse slides 3 times using BOND Wash Solution.
      (5) Incubate in substrate chromogen 3,3’-Diaminobenzidine (DAB) in hydrogen peroxide for 10 minutes.
      (6) Rinse slides 3 times using BOND Wash Solution.
   h) Counterstain, dehydrate, and clear sections using Sakura Tissue-Tek Prisma autostainer
      (1) Counterstain with Leica hematoxylin 560 MX for 5 minutes.
      (2) Rinse slides 3 times using deionized water.
      (3) Immerse sections in 95% ethanol in deionized water for 15 seconds.
      (4) Immerse sections in 100% ethanol for 20 seconds. Repeat this step twice.
      (5) Immerse sections in xylene for 90 seconds. Repeat this step once.
   i) Mount and coverslip slides using the Sakura Tissue-Tek Glas automated coverslipper
      (1) Mount sections using Shandon Consul-Mount Histology formation.
      (2) Add glass coverslips and allow to cure and dry.

C. Scan slides using the Roche/Ventana iScan Coreo Au scanner and a 40x objective. Store color images in JPEG2000 (lossless) file format.
D. Store slides at room temperature in a dark and dry location.
Introduction

Accurate pathological diagnosis of Burkitt lymphoma (BL) is essential to determine which samples qualify for the Burkitt Lymphoma Genome Sequencing Project (BLGSP). Each putative case submitted for pathology review will undergo central pathology review, which includes fluorescence in situ hybridization (FISH) to determine if a MYC translocation is present. The MYC gene is translocated to an immunoglobulin locus in nearly all cases of BL: to the immunoglobulin heavy chain locus in about 80%, and the kappa or lambda light chain loci in the remainder. MYC translocations are detected by FISH using a “break-apart” probe for the 8q24 chromosomal region. In an intact 8q24 region the green and orange fluorophores co-localize in a fusion pattern, but in the event of a translocation they appear as distinct signals.

Scope and Purpose

1. To establish standard procedures for fluorescence in situ hybridization of tissue submitted to BLGSP to confirm the cases accurately diagnosed as Burkitt lymphoma. The slides will be read by pathologists certified as lymphoma experts.

Safety Precautions

1. Wear personal protective equipment (PPE) including chemical splash goggles, gloves, and protective clothing (e.g. lab coat, closed-toed footwear).
2. Gloves are not suitable for immersion protection, only splash protection.
3. Read all applicable Material Safety Data Sheets (MSDS) for safety and health information.
4. Read all applicable equipment user manuals for safety information.

Equipment and Materials

A. General
   1. Formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks or slides from a BLGSP Tissue Source Site (TSS) or tissue microarray (TMA; BLGSP SOP #310) blocks produced from the TSS tumor tissue blocks, labeled with BLGSP project-assigned ID (BLGSP SOP #304)
   2. Microtome (manual, semi-automated, or fully-automated)
3. Adhesive (e.g. poly-L-lysine) coated glass slides (e.g. Thermo Scientific Polysine Adhesion Slides, Part # 10143265)
4. Glass coverslips (e.g. Fisherbrand Cover Glasses, Part # 12-544E)
5. Xylene (e.g. Sigma-Aldrich histological grade, Part # 534056)
6. Ethanol, anhydrous (e.g. Sigma-Aldrich Part # 676829)
7. Deionized water
8. 10% buffered formalin
9. 2x saline-sodium citrate (or standard sodium citrate, SSC) [300mM NaCl, 30 mM Na$_3$C$_6$H$_5$O$_7$, pH 7.0] buffer in deionized water, prepared fresh from 20X stock with 0.1% Nonidet P-40 (NP-40) (e.g. IGEPAL CA-630, Sigma Product # I3021)
10. Denaturation solution: 70% formamide (Sigma-Aldrich Product # F7508)/2x SSC
11. 4’,6-Diamidino-2-phenylindole (DAPI) (e.g. Invitrogen Catalog # D1306)
12. Fluorescence-protecting mounting medium (e.g. VECTASHIELD HardSet Mounting Medium, Vector Labs Catalog # H-1400)
13. Cytovision® Image Analysis System (Leica)
14. Standard fluorescence microscope with filters to simultaneously visualize DAPI, SpectrumOrange, and SpectrumGreen (e.g. DAPI/Green/Orange Triple Bandpass Filter Set, Abbott Molecular)

B. For manual FISH
1. 12 glass staining dishes (e.g. Fisherbrand Glass Staining Dish, Part Number 08-810)
2. 2 slide racks (e.g. Wheaton Science Products, Part Number 900204)
3. Laboratory wipes (e.g. Kimwipes, Part Number 34155)
4. Hybridization solution: 50% formamide (Sigma-Aldrich Product # F7508), 10% dextran sulfate (Sigma-Aldrich Product # D8906), 0.1% SDS (Sigma-Aldrich Product # L4390), 0.5-1.5 ng/µl labeled probe and 300 ng/ml Salmon Sperm DNA (Sigma-Aldrich Product # D7656) in 2x SSC.
5. Wash buffer: 20% formamide (Sigma-Aldrich Product # F7508) in 0.1x SSC.
6. Sterile forceps (e.g. Fisherbrand fine point forceps, Catalog Number 22-327-379)
7. Pepsin (Sigma-Aldrich Product # P6887) 40 units/ml in 10 mM HCl.

C. For automated FISH
1. Surgipath SelecTech Hematoxylin 560MX (Leica Product # 3801575)
2. Surgipath SelecTech Alcoholic Eosin Y 515 (Leica Product # 3801615)
3. VP2000™ Automated Tissue Processor (Abbott Molecular Order # 02J11-060)
4. Vysis LSI MYC (8q24) Dual Color (SpectrumOrange and SpectrumGreen), Break Apart Rearrangement Probe (Abbott Molecular Order # 05J91-001)
5. Hemo-De (Abbott Molecular Order # 05N14-001)
6. 0.2 N HCl in deionized water, prepared fresh from stock (e.g. 37% hydrochloric acid, Sigma Product # 320331)
7. Vysis Paraffin Pretreatment IV & Post-Hybridization Wash Buffer Kit (Abbott Molecular Order # 01N31-005)
   a) Pretreatment Buffer
   b) Protease Buffer IV
   c) Vysis Wash Buffer
8. ThermoBrite StatSpin® (Abbott Molecular Order # 07J91-010)
A. Use a microtome to cut one 4 µm thick tissue section from each FFPE block (TMA blocks preferred, but individual case blocks if necessary) and mount each section to an adhesive-coated glass slide.

B. Perform manual or automated FISH
   1. Manual FISH
      a) Prepare 200 mL of 95% ethanol solution and 100 mL of 80% ethanol solution using deionized water and anhydrous ethanol.
      b) Set out the glass staining dishes in a row and label them in this order:
         (1) Xylene
         (2) Xylene
         (3) 100% ethanol
         (4) 100% ethanol
         (5) 95% ethanol
         (6) 95% ethanol
         (7) 80% ethanol
         (8) 0.2 N HCl
         (9) Deionized water
         (10) Wash buffer
         (11) 10% buffered formalin
         (12) 2X SSC
      c) Fill the glass staining dishes with approximately 100 mL of the reagent for which they are labeled. Ethanol solutions, xylene, and deionized water must be fresh.
      d) Place slides containing tissue sections into slide rack.
      e) Deparaffinize sections by submerging slides in slide rack into staining dish containing xylene for 3 minutes. Repeat this step using the second staining dish containing xylene.
      f) Use a laboratory wipe to gently blot excess xylene from slide rack before submerging slides (in slide rack) in ethanol to rehydrate according to the following:
         (1) 3 minutes in 100% ethanol. Repeat this step with the second staining dish containing 100% ethanol.
         (2) 3 minutes in 95% ethanol. Repeat this step with the second staining dish containing 95% ethanol.
      g) Use a laboratory wipe to gently blot excess ethanol from slide rack before submerging slides (in slide rack) in the following to pretreat the tissue:
         (1) 5 minutes in deionized water
         (2) 20 minutes in 0.2 N HCl
         (3) 3 minutes in deionized water
      h) Incubate with 200 µl pepsin for 10 minutes at 37 °C.
      i) Submerge slides (in slide rack) in wash buffer and incubate at room temperature for 5 minutes. Repeat with fresh wash buffer.
j) Submerge slides (in slide rack) in 10% buffered formalin for 10 minutes.
k) Submerge slides (in slide rack) in wash buffer and incubate at room temperature for 5 minutes. Repeat with fresh wash buffer.
l) Blot excess buffer from the slide rack before submerging slides (in slide rack) to dehydrate tissue:
   (1) 2 minutes in 80% ethanol
   (2) 1 minute in 95% ethanol. Repeat this step in the second staining dish containing 95% ethanol.
   (3) 1 minute in 100% ethanol. Repeat this step in the second staining dish containing 100% ethanol.
m) Air dry slides for 2-5 minutes.

n) Denature the probe and tissue
   (1) Prepare 30 µl hybridization solution per slide. Heat to 70°C for 10 minutes, then place on ice.
   (2) Add the MYC (8q24) Dual Color, Break Apart Rearrangement probe.
   (3) Place 30 µl of hybridization solution with probe on each slide and cover with a cover slip.
   (4) Co-denature slide and probe at 65-70°C for 5 minutes on a heat block. Adjustments may be made to the probe concentration, temperature, and duration of the denaturation in order to achieve optimal quality of the hybridization and preservation of the tissue.
   (5) Gradually decrease temperature to 37 °C.

o) Hybridize at 37 °C overnight in humidity chamber.
p) Remove cover slips and wash slides
   (1) Immerse section in 2x SSC/0.1% NP-40 at 74°C for 2 minutes.
   (2) Immerse section in 2x SSC at room temperature for 1 minute.

q) Dry the back of the slides with a laboratory wipe. Carefully dry the front of the slides, never wiping closer than 0.5 cm from the tissue.
r) Counterstain the nuclei by covering tissue with DAPI (~30 ul per slide) for 10 minutes.
s) Mount sections using fluorescence-protecting mounting medium and coverslip.

2. Automated FISH using the VP2000™ Automated Tissue Processor
   a) Deparaffinize, dehydrate, and pretreat tissue
      (1) Immerse section in Hemo-De for 10 minutes. Repeat this step twice using fresh Hemo-De each time.
      (2) Dehydrate section by immersing in 95% ethanol in deionized water for 5 minutes. Repeat this step.
      (3) Dry slides for 2-5 minutes.
      (4) Immerse section in 0.2 N HCl for 20 minutes.
      (5) Immerse section in deionized water for 3 minutes.
      (6) Immerse section in Vysis wash buffer for 3 minutes.
(7) Incubate section in Vysis Pretreatment Buffer at 80°C for 30 minutes.
(8) Immerse section in deionized water for 1 minute.
(9) Immerse section in Vysis wash buffer for 5 minutes. Repeat this step using fresh buffer.
(10) Incubate section in Vysis protease buffer IV at 37°C for 10 minutes.
(11) Immerse section in Vysis wash buffer for 5 minutes. Repeat this step using fresh buffer.
(12) Dry slides for 2-5 minutes.
(13) Incubate section in 10% buffered formalin for 10 minutes.
(14) Immerse section in Vysis wash buffer for 5 minutes. Repeat this step using fresh buffer.
(15) Dry slides for 2-5 minutes.
(16) Dehydrate in 75% ethanol in deionized water for 1 minute.
(17) Dehydrate in 85% ethanol in deionized water for 1 minute.
(18) Dehydrate in 95% ethanol in deionized water for 1 minute.

b) Automated denaturation and hybridization using the ThermoBrite StatSpin®
   (1) Co-denature the tissue and MYC (8q24) Dual Color, Break Apart Rearrangement probe in denaturation solution at 76°C for 7 minutes. Adjustments may be made to the probe concentration, temperature, and duration of the denaturation in order to achieve optimal quality of the hybridization and preservation of the tissue.
   (2) Hybridize by incubating overnight at 39°C.

c) Wash slides
   (1) Immerse section in 2x SSC/0.1% NP-40 at 74°C for 2 minutes.
   (2) Immerse section in 2x SSC at room temperature for 1 minute.

d) Counterstain with DAPI for 10 minutes.

e) Mount sections using fluorescence-protecting mounting medium and coverslip.

C. Analyze hybridization signals in 50-100 interphase nuclei on a fluorescent microscope with filters for SpectrumOrange, SpectrumGreen, and DAPI. Acquire images using the Cytovision® Image Analysis System.

D. Store hybridized slides in the dark at -20°C.